The  ||| S:33 E:37 ||| DT
Antihypertensive  ||| S:37 E:54 ||| NNP
and  ||| S:54 E:58 ||| CC
Lipid  ||| S:58 E:64 ||| NNP
Lowering  ||| S:64 E:73 ||| NNP
Treatment  ||| S:73 E:83 ||| NNP
to  ||| S:83 E:94 ||| TO
Prevent  ||| S:94 E:102 ||| VB
Heart  ||| S:102 E:108 ||| NNP
Attack  ||| S:108 E:115 ||| NNP
Trial  ||| S:115 E:121 ||| NNP
( ||| S:121 E:122 ||| -LRB-
ALLHAT ||| S:122 E:128 ||| NNP
)  ||| S:128 E:130 ||| -RRB-
is  ||| S:130 E:133 ||| VBZ
a  ||| S:133 E:135 ||| DT
randomized ||| S:135 E:145 ||| NN
,  ||| S:145 E:155 ||| ,
two-component  ||| S:155 E:169 ||| JJ
clinical  ||| S:169 E:178 ||| JJ
trial  ||| S:178 E:184 ||| NN
sponsored  ||| S:184 E:194 ||| VBN
by  ||| S:194 E:197 ||| IN
the  ||| S:197 E:201 ||| DT
National  ||| S:201 E:218 ||| NNP
Heart ||| S:218 E:223 ||| NNP
,  ||| S:223 E:225 ||| ,
Lung ||| S:225 E:229 ||| NNP
,  ||| S:229 E:231 ||| ,
and  ||| S:231 E:235 ||| CC
Blood  ||| S:235 E:241 ||| NNP
Institute  ||| S:241 E:251 ||| NNP
( ||| S:251 E:252 ||| -LRB-
NHLBI ||| S:252 E:257 ||| NNP
) ||| S:257 E:258 ||| -RRB-
.  ||| S:258 E:260 ||| .
A  ||| S:260 E:262 ||| DT
double-blind ||| S:262 E:274 ||| JJ
,  ||| S:274 E:284 ||| ,
active-controlled  ||| S:284 E:302 ||| JJ
hypertension  ||| S:302 E:315 ||| NN
component  ||| S:315 E:325 ||| NN
is  ||| S:325 E:328 ||| VBZ
designed  ||| S:328 E:337 ||| VBN
to  ||| S:337 E:348 ||| TO
compare  ||| S:348 E:356 ||| VB
the  ||| S:356 E:360 ||| DT
rate  ||| S:360 E:365 ||| NN
of  ||| S:365 E:368 ||| IN
fatal  ||| S:368 E:374 ||| JJ
coronary  ||| S:374 E:383 ||| JJ
heart  ||| S:383 E:389 ||| NN
disease  ||| S:389 E:397 ||| NN
( ||| S:397 E:398 ||| -LRB-
CHD ||| S:398 E:401 ||| NNP
)  ||| S:401 E:403 ||| -RRB-
or  ||| S:403 E:414 ||| CC
nonfatal  ||| S:414 E:423 ||| FW
myocardial  ||| S:423 E:434 ||| FW
infarction  ||| S:434 E:445 ||| FW
( ||| S:445 E:446 ||| -LRB-
MI ||| S:446 E:448 ||| NNP
)  ||| S:448 E:450 ||| -RRB-
( ||| S:450 E:451 ||| -LRB-
the  ||| S:451 E:455 ||| DT
primary  ||| S:455 E:463 ||| JJ
endpoint ||| S:463 E:471 ||| NN
)  ||| S:471 E:481 ||| -RRB-
in  ||| S:481 E:484 ||| IN
high-risk  ||| S:484 E:494 ||| JJ
hypertensive  ||| S:494 E:507 ||| JJ
participants ||| S:507 E:519 ||| NNS
,  ||| S:519 E:521 ||| ,
aged  ||| S:521 E:526 ||| VBN
55  ||| S:526 E:529 ||| CD
years  ||| S:529 E:535 ||| NNS
or  ||| S:535 E:546 ||| CC
older ||| S:546 E:551 ||| JJR
,  ||| S:551 E:553 ||| ,
between  ||| S:553 E:561 ||| IN
those  ||| S:561 E:567 ||| DT
randomized  ||| S:567 E:578 ||| NN
to  ||| S:578 E:581 ||| TO
treatment  ||| S:581 E:591 ||| VB
initiated  ||| S:591 E:601 ||| VBN
with  ||| S:601 E:614 ||| IN
a  ||| S:614 E:616 ||| DT
diuretic  ||| S:616 E:625 ||| NN
( ||| S:625 E:626 ||| -LRB-
chlorthalidone ||| S:626 E:640 ||| LS
)  ||| S:640 E:642 ||| -RRB-
and  ||| S:642 E:646 ||| CC
treatment  ||| S:646 E:656 ||| NN
initiated  ||| S:656 E:666 ||| VBN
with  ||| S:666 E:679 ||| IN
each  ||| S:679 E:684 ||| DT
of  ||| S:684 E:687 ||| IN
three  ||| S:687 E:693 ||| CD
alternative  ||| S:693 E:705 ||| NN
antihypertensive  ||| S:705 E:722 ||| NN
drugs ||| S:722 E:727 ||| NNS
:  ||| S:727 E:729 ||| :
a  ||| S:729 E:739 ||| DT
calcium-channel  ||| S:739 E:755 ||| JJ
blocker  ||| S:755 E:763 ||| NN
( ||| S:763 E:764 ||| -LRB-
amlodipine ||| S:764 E:774 ||| LS
) ||| S:774 E:775 ||| -RRB-
,  ||| S:775 E:777 ||| ,
an  ||| S:777 E:788 ||| DT
angiotensin-converting  ||| S:788 E:811 ||| JJ
enzyme  ||| S:811 E:818 ||| NNS
( ||| S:818 E:819 ||| -LRB-
ACE ||| S:819 E:822 ||| NNP
) ||| S:822 E:823 ||| -RRB-
-inhibitor  ||| S:823 E:834 ||| NNP
( ||| S:834 E:835 ||| -LRB-
lisinopril ||| S:835 E:845 ||| LS
) ||| S:845 E:846 ||| -RRB-
,  ||| S:846 E:856 ||| ,
or  ||| S:856 E:859 ||| CC
an  ||| S:859 E:862 ||| DT
alpha-adrenergic  ||| S:862 E:879 ||| JJ
blocker  ||| S:879 E:887 ||| NN
( ||| S:887 E:888 ||| -LRB-
doxazosin ||| S:888 E:897 ||| LS
) ||| S:897 E:898 ||| -RRB-
.  ||| S:898 E:900 ||| .
An  ||| S:900 E:903 ||| DT
open-label  ||| S:903 E:922 ||| JJ
lipid-lowering  ||| S:922 E:937 ||| JJ
component  ||| S:937 E:947 ||| NN
is  ||| S:947 E:950 ||| VBZ
designed  ||| S:950 E:959 ||| VBN
to  ||| S:959 E:962 ||| TO
determine  ||| S:962 E:972 ||| VB
if  ||| S:972 E:983 ||| IN
lowering  ||| S:983 E:992 ||| VBG
LDL  ||| S:992 E:996 ||| NNP
cholesterol  ||| S:996 E:1008 ||| NN
with  ||| S:1008 E:1013 ||| IN
pravastatin  ||| S:1013 E:1025 ||| VBG
compared  ||| S:1025 E:1034 ||| VBN
to  ||| S:1034 E:1045 ||| TO
"usual  ||| S:1045 E:1052 ||| CD
care ||| S:1052 E:1056 ||| NN
"  ||| S:1056 E:1058 ||| ''
reduces  ||| S:1058 E:1066 ||| VBZ
all-cause  ||| S:1066 E:1076 ||| JJ
mortality  ||| S:1076 E:1086 ||| NN
in  ||| S:1086 E:1089 ||| IN
a  ||| S:1089 E:1091 ||| DT
subset  ||| S:1091 E:1098 ||| NN
of  ||| S:1098 E:1109 ||| IN
moderately  ||| S:1109 E:1120 ||| RB
hypercholesterolemic  ||| S:1120 E:1141 ||| JJ
patients ||| S:1141 E:1149 ||| NNS
.  ||| S:1149 E:1151 ||| .
Randomization  ||| S:1151 E:1165 ||| JJ
to  ||| S:1165 E:1176 ||| TO
the  ||| S:1176 E:1180 ||| DT
hypertension  ||| S:1180 E:1193 ||| JJ
component  ||| S:1193 E:1203 ||| NN
began  ||| S:1203 E:1209 ||| VBD
in  ||| S:1209 E:1212 ||| IN
February ||| S:1212 E:1220 ||| NNP
,  ||| S:1220 E:1222 ||| ,
1994 ||| S:1222 E:1226 ||| CD
,  ||| S:1226 E:1228 ||| ,
and  ||| S:1228 E:1240 ||| CC
continued  ||| S:1240 E:1250 ||| VBD
through  ||| S:1250 E:1258 ||| IN
January ||| S:1258 E:1265 ||| NNP
,  ||| S:1265 E:1267 ||| ,
1998 ||| S:1267 E:1271 ||| CD
,  ||| S:1271 E:1273 ||| ,
with  ||| S:1273 E:1278 ||| IN
42,418  ||| S:1278 E:1285 ||| CD
participants  ||| S:1285 E:1306 ||| NNS
recruited  ||| S:1306 E:1316 ||| VBN
at  ||| S:1316 E:1319 ||| IN
623  ||| S:1319 E:1323 ||| CD
clinical  ||| S:1323 E:1332 ||| JJ
centers  ||| S:1332 E:1340 ||| NNS
in  ||| S:1340 E:1343 ||| IN
the  ||| S:1343 E:1347 ||| DT
United  ||| S:1347 E:1354 ||| NNP
States ||| S:1354 E:1360 ||| NNPS
,  ||| S:1360 E:1370 ||| ,
Canada ||| S:1370 E:1376 ||| NNP
,  ||| S:1376 E:1378 ||| ,
Puerto  ||| S:1378 E:1385 ||| NNP
Rico  ||| S:1385 E:1390 ||| NNP
and  ||| S:1390 E:1394 ||| CC
the  ||| S:1394 E:1398 ||| DT
US  ||| S:1398 E:1401 ||| NNP
Virgin  ||| S:1401 E:1408 ||| NNP
Islands ||| S:1408 E:1415 ||| NNPS
.  ||| S:1415 E:1425 ||| .
Randomization  ||| S:1425 E:1439 ||| NNP
of  ||| S:1439 E:1442 ||| IN
10,355  ||| S:1442 E:1449 ||| CD
participants  ||| S:1449 E:1462 ||| NNS
into  ||| S:1462 E:1467 ||| IN
the  ||| S:1467 E:1471 ||| DT
lipid  ||| S:1471 E:1477 ||| JJ
trial  ||| S:1477 E:1491 ||| NN
ended  ||| S:1491 E:1497 ||| VBD
May  ||| S:1497 E:1501 ||| NNP
31 ||| S:1501 E:1503 ||| CD
,  ||| S:1503 E:1505 ||| ,
1998 ||| S:1505 E:1509 ||| CD
.  ||| S:1509 E:1511 ||| .
Follow-up  ||| S:1511 E:1521 ||| JJ
on  ||| S:1521 E:1524 ||| IN
all  ||| S:1524 E:1528 ||| DT
participants  ||| S:1528 E:1541 ||| NNS
continued  ||| S:1541 E:1559 ||| VBD
through  ||| S:1559 E:1567 ||| IN
March ||| S:1567 E:1572 ||| NNP
,  ||| S:1572 E:1574 ||| ,
2002  ||| S:1574 E:1579 ||| CD
[  ||| S:1579 E:1581 ||| -LRB-
1  ||| S:1581 E:1583 ||| LS
]  ||| S:1583 E:1585 ||| -RRB-
.  ||| S:1585 E:1595 ||| .
Following  ||| S:1595 E:1605 ||| VBG
independent  ||| S:1605 E:1617 ||| JJ
reviews  ||| S:1617 E:1625 ||| NNS
by  ||| S:1625 E:1628 ||| IN
the  ||| S:1628 E:1632 ||| DT
Data  ||| S:1632 E:1637 ||| NNP
and  ||| S:1637 E:1641 ||| CC
Safety  ||| S:1641 E:1656 ||| NNP
Monitoring  ||| S:1656 E:1667 ||| NNP
Board  ||| S:1667 E:1673 ||| NNP
( ||| S:1673 E:1674 ||| -LRB-
DSMB ||| S:1674 E:1678 ||| NNP
)  ||| S:1678 E:1680 ||| -RRB-
on  ||| S:1680 E:1683 ||| IN
January  ||| S:1683 E:1691 ||| NNP
6 ||| S:1691 E:1692 ||| CD
,  ||| S:1692 E:1694 ||| ,
2000 ||| S:1694 E:1698 ||| CD
,  ||| S:1698 E:1700 ||| ,
and  ||| S:1700 E:1704 ||| CC
by  ||| S:1704 E:1707 ||| IN
an  ||| S:1707 E:1710 ||| DT
Ad  ||| S:1710 E:1721 ||| NNP
Hoc  ||| S:1721 E:1725 ||| NNP
Committee  ||| S:1725 E:1735 ||| NNP
on  ||| S:1735 E:1738 ||| IN
January  ||| S:1738 E:1746 ||| NNP
21 ||| S:1746 E:1748 ||| CD
,  ||| S:1748 E:1750 ||| ,
2000 ||| S:1750 E:1754 ||| CD
,  ||| S:1754 E:1756 ||| ,
the  ||| S:1756 E:1760 ||| DT
Director  ||| S:1760 E:1769 ||| NNP
of  ||| S:1769 E:1772 ||| IN
the  ||| S:1772 E:1784 ||| DT
National  ||| S:1784 E:1793 ||| NNP
Heart ||| S:1793 E:1798 ||| NNP
,  ||| S:1798 E:1800 ||| ,
Lung ||| S:1800 E:1804 ||| NNP
,  ||| S:1804 E:1806 ||| ,
and  ||| S:1806 E:1810 ||| CC
Blood  ||| S:1810 E:1816 ||| NNP
Institute  ||| S:1816 E:1826 ||| NNP
accepted  ||| S:1826 E:1835 ||| VBD
a  ||| S:1835 E:1845 ||| DT
recommendation  ||| S:1845 E:1860 ||| NN
to  ||| S:1860 E:1863 ||| TO
discontinue  ||| S:1863 E:1875 ||| VB
the  ||| S:1875 E:1879 ||| DT
doxazosin  ||| S:1879 E:1889 ||| JJ
treatment  ||| S:1889 E:1899 ||| NN
arm  ||| S:1899 E:1911 ||| NN
of  ||| S:1911 E:1914 ||| IN
the  ||| S:1914 E:1918 ||| DT
antihypertensive  ||| S:1918 E:1935 ||| JJ
trial ||| S:1935 E:1940 ||| NN
.  ||| S:1940 E:1942 ||| .
This  ||| S:1942 E:1947 ||| DT
recommendation  ||| S:1947 E:1962 ||| NN
was  ||| S:1962 E:1974 ||| VBD
based  ||| S:1974 E:1980 ||| VBN
on  ||| S:1980 E:1983 ||| IN
the  ||| S:1983 E:1987 ||| DT
low  ||| S:1987 E:1991 ||| JJ
probability  ||| S:1991 E:2003 ||| NN
of  ||| S:2003 E:2006 ||| IN
doxazosin  ||| S:2006 E:2016 ||| JJ
showing  ||| S:2016 E:2024 ||| NN
benefit  ||| S:2024 E:2040 ||| NN
over  ||| S:2040 E:2045 ||| IN
chlorthalidone  ||| S:2045 E:2060 ||| NN
for  ||| S:2060 E:2064 ||| IN
the  ||| S:2064 E:2068 ||| DT
primary  ||| S:2068 E:2076 ||| JJ
endpoint ||| S:2076 E:2084 ||| NN
,  ||| S:2084 E:2086 ||| ,
as  ||| S:2086 E:2089 ||| RB
well  ||| S:2089 E:2094 ||| RB
as  ||| S:2094 E:2105 ||| IN
the  ||| S:2105 E:2109 ||| DT
significantly  ||| S:2109 E:2123 ||| RB
increased  ||| S:2123 E:2133 ||| VBD
occurrence  ||| S:2133 E:2144 ||| VBN
of  ||| S:2144 E:2147 ||| IN
the  ||| S:2147 E:2151 ||| DT
secondary  ||| S:2151 E:2169 ||| JJ
endpoint ||| S:2169 E:2177 ||| NN
,  ||| S:2177 E:2179 ||| ,
combined  ||| S:2179 E:2188 ||| VBN
cardiovascular  ||| S:2188 E:2203 ||| JJ
disease  ||| S:2203 E:2211 ||| NN
( ||| S:2211 E:2212 ||| -LRB-
CVD ||| S:2212 E:2215 ||| NNP
)  ||| S:2215 E:2225 ||| -RRB-
( ||| S:2225 E:2226 ||| -LRB-
encompassing  ||| S:2226 E:2239 ||| FW
CHD  ||| S:2239 E:2243 ||| FW
deaths ||| S:2243 E:2249 ||| NNS
,  ||| S:2249 E:2251 ||| ,
nonfatal  ||| S:2251 E:2260 ||| VBG
MI ||| S:2260 E:2262 ||| NNP
,  ||| S:2262 E:2264 ||| ,
stroke ||| S:2264 E:2270 ||| NN
,  ||| S:2270 E:2272 ||| ,
coronary  ||| S:2272 E:2289 ||| JJ
revascularization  ||| S:2289 E:2307 ||| JJ
procedures  ||| S:2307 E:2318 ||| NNS
[ ||| S:2318 E:2319 ||| -LRB-
coronary  ||| S:2319 E:2328 ||| FW
artery  ||| S:2328 E:2335 ||| FW
bypass  ||| S:2335 E:2342 ||| FW
graft  ||| S:2342 E:2356 ||| FW
or  ||| S:2356 E:2359 ||| CC
CABG ||| S:2359 E:2363 ||| NNP
,  ||| S:2363 E:2365 ||| ,
percutaneous  ||| S:2365 E:2378 ||| FW
transluminal  ||| S:2378 E:2391 ||| FW
coronary  ||| S:2391 E:2400 ||| FW
angioplasty  ||| S:2400 E:2412 ||| FW
or  ||| S:2412 E:2423 ||| FW
PTCA ||| S:2423 E:2427 ||| FW
/ ||| S:2427 E:2428 ||| FW
stent ||| S:2428 E:2433 ||| FW
] ||| S:2433 E:2434 ||| -RRB-
,  ||| S:2434 E:2436 ||| ,
angina  ||| S:2436 E:2443 ||| NNS
[ ||| S:2443 E:2444 ||| -LRB-
hospitalized  ||| S:2444 E:2457 ||| VBN
or  ||| S:2457 E:2460 ||| CC
treated  ||| S:2460 E:2468 ||| VBN
as  ||| S:2468 E:2471 ||| IN
an  ||| S:2471 E:2482 ||| DT
outpatient ||| S:2482 E:2492 ||| NN
] ||| S:2492 E:2493 ||| -RRB-
,  ||| S:2493 E:2495 ||| ,
heart  ||| S:2495 E:2501 ||| NN
failure  ||| S:2501 E:2509 ||| NN
[ ||| S:2509 E:2510 ||| -LRB-
HF ||| S:2510 E:2512 ||| NNP
/ ||| S:2512 E:2513 ||| NNP
treated  ||| S:2513 E:2521 ||| VBD
in  ||| S:2521 E:2524 ||| IN
the  ||| S:2524 E:2528 ||| DT
hospital  ||| S:2528 E:2537 ||| NN
or  ||| S:2537 E:2548 ||| CC
as  ||| S:2548 E:2551 ||| IN
an  ||| S:2551 E:2554 ||| DT
outpatient ||| S:2554 E:2564 ||| NN
] ||| S:2564 E:2565 ||| -RRB-
,  ||| S:2565 E:2567 ||| ,
and  ||| S:2567 E:2571 ||| CC
peripheral  ||| S:2571 E:2582 ||| JJ
arterial  ||| S:2582 E:2591 ||| JJ
disease  ||| S:2591 E:2607 ||| NN
[ ||| S:2607 E:2608 ||| -LRB-
in-hospital  ||| S:2608 E:2620 ||| NNP
or  ||| S:2620 E:2623 ||| CC
outpatient  ||| S:2623 E:2634 ||| JJ
revascularization ||| S:2634 E:2651 ||| NN
] ||| S:2651 E:2652 ||| -RRB-
)  ||| S:2652 E:2654 ||| -RRB-
in  ||| S:2654 E:2657 ||| IN
the  ||| S:2657 E:2669 ||| DT
doxazosin  ||| S:2669 E:2679 ||| JJ
arm  ||| S:2679 E:2683 ||| NN
( ||| S:2683 E:2684 ||| -LRB-
RR  ||| S:2684 E:2687 ||| NNP
1.25 ||| S:2687 E:2691 ||| CD
;  ||| S:2691 E:2693 ||| :
95 ||| S:2693 E:2695 ||| CD
%  ||| S:2695 E:2697 ||| NN
CI ||| S:2697 E:2699 ||| NNP
,  ||| S:2699 E:2701 ||| ,
1.17-1.33 ||| S:2701 E:2710 ||| NNP
;  ||| S:2710 E:2721 ||| :
P  ||| S:2721 E:2723 ||| NNP
< ||| S:2723 E:2725 ||| SYM
.001 ||| S:2725 E:2729 ||| NNP
) ||| S:2729 E:2730 ||| -RRB-
,  ||| S:2730 E:2732 ||| ,
with  ||| S:2732 E:2737 ||| IN
a  ||| S:2737 E:2739 ||| DT
doubling  ||| S:2739 E:2748 ||| NN
of  ||| S:2748 E:2751 ||| IN
risk  ||| S:2751 E:2764 ||| NN
of  ||| S:2764 E:2767 ||| IN
HF  ||| S:2767 E:2770 ||| NNP
( ||| S:2770 E:2771 ||| -LRB-
fatal ||| S:2771 E:2776 ||| JJ
,  ||| S:2776 E:2778 ||| ,
hospitalized  ||| S:2778 E:2791 ||| VBN
and  ||| S:2791 E:2795 ||| CC
treated  ||| S:2795 E:2803 ||| VBN
but  ||| S:2803 E:2807 ||| CC
nonhospitalized ||| S:2807 E:2822 ||| CD
)  ||| S:2822 E:2832 ||| -RRB-
( ||| S:2832 E:2833 ||| -LRB-
RR  ||| S:2833 E:2836 ||| NNP
2.04 ||| S:2836 E:2840 ||| CD
;  ||| S:2840 E:2842 ||| :
95 ||| S:2842 E:2844 ||| CD
%  ||| S:2844 E:2846 ||| NN
CI ||| S:2846 E:2848 ||| NNP
,  ||| S:2848 E:2850 ||| ,
1.79-2.32 ||| S:2850 E:2859 ||| NNP
;  ||| S:2859 E:2870 ||| :
P  ||| S:2870 E:2872 ||| NNP
< ||| S:2872 E:2874 ||| SYM
.001 ||| S:2874 E:2878 ||| NNP
) ||| S:2878 E:2879 ||| -RRB-
.  ||| S:2879 E:2881 ||| .
When  ||| S:2881 E:2886 ||| WRB
only  ||| S:2886 E:2891 ||| RB
fatal  ||| S:2891 E:2897 ||| JJ
and  ||| S:2897 E:2909 ||| CC
hospitalized  ||| S:2909 E:2922 ||| VBN
HF  ||| S:2922 E:2925 ||| NNP
were  ||| S:2925 E:2930 ||| VBD
analyzed ||| S:2930 E:2938 ||| VBN
,  ||| S:2938 E:2940 ||| ,
the  ||| S:2940 E:2944 ||| DT
large  ||| S:2944 E:2950 ||| JJ
difference  ||| S:2950 E:2969 ||| NN
remained  ||| S:2969 E:2978 ||| VBD
( ||| S:2978 E:2979 ||| -LRB-
RR  ||| S:2979 E:2982 ||| NNP
1.83 ||| S:2982 E:2986 ||| CD
;  ||| S:2986 E:2988 ||| :
95 ||| S:2988 E:2990 ||| CD
%  ||| S:2990 E:2992 ||| NN
CI ||| S:2992 E:2994 ||| NNP
,  ||| S:2994 E:2996 ||| ,
1.58-2.13 ||| S:2996 E:3005 ||| NNP
;  ||| S:3005 E:3016 ||| :
P  ||| S:3016 E:3018 ||| NNP
< ||| S:3018 E:3020 ||| SYM
.001 ||| S:3020 E:3024 ||| NNP
) ||| S:3024 E:3025 ||| -RRB-
.  ||| S:3025 E:3027 ||| .
The  ||| S:3027 E:3031 ||| DT
findings  ||| S:3031 E:3040 ||| NNS
and  ||| S:3040 E:3052 ||| CC
operational  ||| S:3052 E:3064 ||| JJ
aspects  ||| S:3064 E:3072 ||| NNS
of  ||| S:3072 E:3075 ||| IN
stopping  ||| S:3075 E:3084 ||| VBG
the  ||| S:3084 E:3088 ||| DT
doxazosin  ||| S:3088 E:3098 ||| JJ
arm  ||| S:3098 E:3102 ||| NN
of  ||| S:3102 E:3105 ||| IN
the  ||| S:3105 E:3117 ||| DT
study  ||| S:3117 E:3123 ||| NN
have  ||| S:3123 E:3128 ||| VBP
been  ||| S:3128 E:3133 ||| VBN
previously  ||| S:3133 E:3144 ||| RB
described  ||| S:3144 E:3154 ||| VBN
[  ||| S:3154 E:3156 ||| -LRB-
2  ||| S:3156 E:3158 ||| CD
3  ||| S:3158 E:3160 ||| CD
4  ||| S:3160 E:3162 ||| CD
]  ||| S:3162 E:3164 ||| -RRB-
.  ||| S:3164 E:3174 ||| .
The  ||| S:3174 E:3178 ||| DT
observed  ||| S:3178 E:3187 ||| JJ
increase  ||| S:3187 E:3196 ||| NN
in  ||| S:3196 E:3199 ||| IN
HF  ||| S:3199 E:3202 ||| NNP
in  ||| S:3202 E:3205 ||| IN
the  ||| S:3205 E:3209 ||| DT
doxazosin  ||| S:3209 E:3219 ||| JJ
group  ||| S:3219 E:3225 ||| NN
as  ||| S:3225 E:3236 ||| IN
compared  ||| S:3236 E:3245 ||| VBN
to  ||| S:3245 E:3248 ||| TO
the  ||| S:3248 E:3252 ||| DT
chlorthalidone  ||| S:3252 E:3267 ||| JJ
group  ||| S:3267 E:3273 ||| NN
led  ||| S:3273 E:3277 ||| VBD
to  ||| S:3277 E:3280 ||| TO
several  ||| S:3280 E:3296 ||| JJ
additional  ||| S:3296 E:3307 ||| JJ
analyses  ||| S:3307 E:3316 ||| NNS
aimed  ||| S:3316 E:3322 ||| VBN
toward  ||| S:3322 E:3329 ||| IN
validation  ||| S:3329 E:3340 ||| NN
of  ||| S:3340 E:3343 ||| IN
the  ||| S:3343 E:3355 ||| DT
diagnoses ||| S:3355 E:3364 ||| NN
,  ||| S:3364 E:3366 ||| ,
with  ||| S:3366 E:3371 ||| IN
a  ||| S:3371 E:3373 ||| DT
focus  ||| S:3373 E:3379 ||| NN
on  ||| S:3379 E:3382 ||| IN
hospitalized  ||| S:3382 E:3395 ||| NN
and  ||| S:3395 E:3399 ||| CC
fatal  ||| S:3399 E:3405 ||| JJ
HF ||| S:3405 E:3407 ||| NNP
.  ||| S:3407 E:3409 ||| .
The  ||| S:3409 E:3421 ||| DT
purposes  ||| S:3421 E:3430 ||| NNS
of  ||| S:3430 E:3433 ||| IN
these  ||| S:3433 E:3439 ||| DT
analyses  ||| S:3439 E:3448 ||| NNS
were ||| S:3448 E:3452 ||| VBD
:  ||| S:3452 E:3454 ||| :
1 ||| S:3454 E:3455 ||| LS
)  ||| S:3455 E:3457 ||| -RRB-
to  ||| S:3457 E:3460 ||| TO
evaluate  ||| S:3460 E:3469 ||| VB
the  ||| S:3469 E:3473 ||| DT
reality  ||| S:3473 E:3489 ||| NN
of  ||| S:3489 E:3492 ||| IN
HF  ||| S:3492 E:3495 ||| NNP
cases ||| S:3495 E:3500 ||| NNS
,  ||| S:3500 E:3502 ||| ,
i.e.  ||| S:3502 E:3507 ||| FW
whether  ||| S:3507 E:3515 ||| IN
diagnosis ||| S:3515 E:3524 ||| NN
,  ||| S:3524 E:3526 ||| ,
management ||| S:3526 E:3536 ||| NN
,  ||| S:3536 E:3538 ||| ,
and  ||| S:3538 E:3550 ||| CC
clinical  ||| S:3550 E:3559 ||| JJ
course  ||| S:3559 E:3566 ||| NN
were  ||| S:3566 E:3571 ||| VBD
what  ||| S:3571 E:3576 ||| WP
might  ||| S:3576 E:3582 ||| MD
be  ||| S:3582 E:3585 ||| VB
expected ||| S:3585 E:3593 ||| VBN
,  ||| S:3593 E:3595 ||| ,
and  ||| S:3595 E:3599 ||| CC
2 ||| S:3599 E:3600 ||| LS
)  ||| S:3600 E:3602 ||| -RRB-
to  ||| S:3602 E:3613 ||| TO
compare  ||| S:3613 E:3621 ||| VB
these  ||| S:3621 E:3627 ||| DT
features  ||| S:3627 E:3636 ||| NNS
between  ||| S:3636 E:3644 ||| IN
the  ||| S:3644 E:3648 ||| DT
two  ||| S:3648 E:3652 ||| CD
treatment  ||| S:3652 E:3670 ||| NN
groups ||| S:3670 E:3676 ||| NNS
.  ||| S:3676 E:3700 ||| .
Methods  ||| S:3700 E:3727 ||| NNP
Study  ||| S:3727 E:3733 ||| NNP
Design  ||| S:3733 E:3750 ||| NNP
The  ||| S:3750 E:3754 ||| DT
rationale  ||| S:3754 E:3764 ||| NN
and  ||| S:3764 E:3768 ||| CC
design  ||| S:3768 E:3775 ||| NN
of  ||| S:3775 E:3778 ||| IN
ALLHAT  ||| S:3778 E:3785 ||| NNP
are  ||| S:3785 E:3789 ||| VBP
described  ||| S:3789 E:3799 ||| VBN
in  ||| S:3799 E:3812 ||| IN
detail  ||| S:3812 E:3819 ||| NN
elsewhere  ||| S:3819 E:3829 ||| RB
[  ||| S:3829 E:3831 ||| -LRB-
1  ||| S:3831 E:3833 ||| LS
]  ||| S:3833 E:3835 ||| -RRB-
.  ||| S:3835 E:3837 ||| .
Briefly ||| S:3837 E:3844 ||| RB
,  ||| S:3844 E:3846 ||| ,
those  ||| S:3846 E:3852 ||| DT
eligible  ||| S:3852 E:3861 ||| NN
for  ||| S:3861 E:3875 ||| IN
randomization  ||| S:3875 E:3889 ||| NN
had  ||| S:3889 E:3893 ||| VBD
systolic  ||| S:3893 E:3902 ||| JJ
blood  ||| S:3902 E:3908 ||| NN
pressure  ||| S:3908 E:3917 ||| NN
( ||| S:3917 E:3918 ||| -LRB-
SBP ||| S:3918 E:3921 ||| NNP
)  ||| S:3921 E:3923 ||| -RRB-
of  ||| S:3923 E:3926 ||| IN
at  ||| S:3926 E:3939 ||| IN
least  ||| S:3939 E:3945 ||| JJS
140  ||| S:3945 E:3949 ||| CD
mm  ||| S:3949 E:3952 ||| JJ
Hg  ||| S:3952 E:3955 ||| NNP
and ||| S:3955 E:3958 ||| CC
/ ||| S:3958 E:3959 ||| NNP
or  ||| S:3959 E:3962 ||| CC
diastolic  ||| S:3962 E:3972 ||| JJ
blood  ||| S:3972 E:3978 ||| NN
pressure  ||| S:3978 E:3987 ||| NN
of  ||| S:3987 E:3990 ||| IN
at  ||| S:3990 E:4003 ||| IN
least  ||| S:4003 E:4009 ||| JJS
90  ||| S:4009 E:4012 ||| CD
mm  ||| S:4012 E:4015 ||| JJ
Hg ||| S:4015 E:4017 ||| NNP
,  ||| S:4017 E:4019 ||| ,
or  ||| S:4019 E:4022 ||| CC
took  ||| S:4022 E:4027 ||| VBD
medication  ||| S:4027 E:4038 ||| NN
for  ||| S:4038 E:4042 ||| IN
hypertension ||| S:4042 E:4054 ||| NN
,  ||| S:4054 E:4056 ||| ,
and  ||| S:4056 E:4070 ||| CC
had  ||| S:4070 E:4074 ||| VBD
at  ||| S:4074 E:4077 ||| IN
least  ||| S:4077 E:4083 ||| JJS
one  ||| S:4083 E:4087 ||| CD
other  ||| S:4087 E:4093 ||| JJ
risk  ||| S:4093 E:4098 ||| NN
factor  ||| S:4098 E:4105 ||| NN
for  ||| S:4105 E:4109 ||| IN
CHD  ||| S:4109 E:4113 ||| NNP
events ||| S:4113 E:4119 ||| NNS
.  ||| S:4119 E:4121 ||| .
Risk  ||| S:4121 E:4136 ||| NN
factors  ||| S:4136 E:4144 ||| NNS
included  ||| S:4144 E:4153 ||| VBD
previous  ||| S:4153 E:4162 ||| JJ
MI  ||| S:4162 E:4165 ||| NNP
or  ||| S:4165 E:4168 ||| CC
stroke ||| S:4168 E:4174 ||| NN
,  ||| S:4174 E:4176 ||| ,
left  ||| S:4176 E:4181 ||| VBD
ventricular  ||| S:4181 E:4203 ||| JJ
hypertrophy  ||| S:4203 E:4215 ||| NN
by  ||| S:4215 E:4218 ||| IN
electrocardiogram  ||| S:4218 E:4236 ||| NN
or  ||| S:4236 E:4239 ||| CC
echocardiogram ||| S:4239 E:4253 ||| NN
,  ||| S:4253 E:4265 ||| ,
history  ||| S:4265 E:4273 ||| NN
of  ||| S:4273 E:4276 ||| IN
type  ||| S:4276 E:4281 ||| NN
2  ||| S:4281 E:4283 ||| CD
diabetes ||| S:4283 E:4291 ||| NN
,  ||| S:4291 E:4293 ||| ,
current  ||| S:4293 E:4301 ||| JJ
cigarette  ||| S:4301 E:4311 ||| NN
smoking ||| S:4311 E:4318 ||| NN
,  ||| S:4318 E:4330 ||| ,
and  ||| S:4330 E:4334 ||| CC
low  ||| S:4334 E:4338 ||| JJ
high-density  ||| S:4338 E:4351 ||| JJ
lipoprotein  ||| S:4351 E:4363 ||| NNS
( ||| S:4363 E:4364 ||| -LRB-
HDL ||| S:4364 E:4367 ||| NNP
)  ||| S:4367 E:4369 ||| -RRB-
level ||| S:4369 E:4374 ||| NN
.  ||| S:4374 E:4386 ||| .
The  ||| S:4386 E:4390 ||| DT
primary  ||| S:4390 E:4398 ||| JJ
endpoint  ||| S:4398 E:4407 ||| NN
of  ||| S:4407 E:4410 ||| IN
the  ||| S:4410 E:4414 ||| DT
blood  ||| S:4414 E:4420 ||| NN
pressure  ||| S:4420 E:4429 ||| NN
( ||| S:4429 E:4430 ||| -LRB-
BP ||| S:4430 E:4432 ||| NNP
)  ||| S:4432 E:4434 ||| -RRB-
trial  ||| S:4434 E:4450 ||| NN
is  ||| S:4450 E:4453 ||| VBZ
the  ||| S:4453 E:4457 ||| DT
composite  ||| S:4457 E:4467 ||| JJ
of  ||| S:4467 E:4470 ||| IN
nonfatal  ||| S:4470 E:4479 ||| JJ
MI  ||| S:4479 E:4482 ||| NNP
and  ||| S:4482 E:4486 ||| CC
fatal  ||| S:4486 E:4492 ||| JJ
CHD ||| S:4492 E:4495 ||| NNP
.  ||| S:4495 E:4497 ||| .
The  ||| S:4497 E:4501 ||| DT
four  ||| S:4501 E:4516 ||| CD
protocol-defined  ||| S:4516 E:4533 ||| JJ
secondary  ||| S:4533 E:4543 ||| JJ
clinical  ||| S:4543 E:4552 ||| JJ
outcomes  ||| S:4552 E:4561 ||| NNS
are  ||| S:4561 E:4575 ||| VBP
all-cause  ||| S:4575 E:4585 ||| JJ
mortality ||| S:4585 E:4594 ||| NN
,  ||| S:4594 E:4596 ||| ,
combined  ||| S:4596 E:4605 ||| VBN
CHD  ||| S:4605 E:4609 ||| NNP
( ||| S:4609 E:4610 ||| -LRB-
including  ||| S:4610 E:4620 ||| VBG
CHD  ||| S:4620 E:4624 ||| NNP
death ||| S:4624 E:4629 ||| NN
,  ||| S:4629 E:4641 ||| ,
nonfatal  ||| S:4641 E:4650 ||| VBG
MI ||| S:4650 E:4652 ||| NNP
,  ||| S:4652 E:4654 ||| ,
coronary  ||| S:4654 E:4663 ||| JJ
revascularization  ||| S:4663 E:4681 ||| JJ
procedures  ||| S:4681 E:4692 ||| NNS
and  ||| S:4692 E:4706 ||| CC
hospitalized  ||| S:4706 E:4719 ||| JJ
angina ||| S:4719 E:4725 ||| NN
) ||| S:4725 E:4726 ||| -RRB-
,  ||| S:4726 E:4728 ||| ,
stroke ||| S:4728 E:4734 ||| NN
,  ||| S:4734 E:4736 ||| ,
and  ||| S:4736 E:4740 ||| CC
combined  ||| S:4740 E:4749 ||| JJ
CVD  ||| S:4749 E:4753 ||| NNP
( ||| S:4753 E:4754 ||| -LRB-
including  ||| S:4754 E:4774 ||| VBG
CHD  ||| S:4774 E:4778 ||| NNP
death ||| S:4778 E:4783 ||| NN
,  ||| S:4783 E:4785 ||| ,
nonfatal  ||| S:4785 E:4794 ||| VBG
MI ||| S:4794 E:4796 ||| NNP
,  ||| S:4796 E:4798 ||| ,
stroke ||| S:4798 E:4804 ||| NN
,  ||| S:4804 E:4806 ||| ,
coronary  ||| S:4806 E:4825 ||| JJ
revascularization  ||| S:4825 E:4843 ||| JJ
procedures ||| S:4843 E:4853 ||| NNS
,  ||| S:4853 E:4855 ||| ,
angina  ||| S:4855 E:4862 ||| VBD
treated  ||| S:4862 E:4870 ||| VBN
in  ||| S:4870 E:4873 ||| IN
the  ||| S:4873 E:4887 ||| DT
hospital  ||| S:4887 E:4896 ||| NN
or  ||| S:4896 E:4899 ||| CC
as  ||| S:4899 E:4902 ||| IN
an  ||| S:4902 E:4905 ||| DT
outpatient ||| S:4905 E:4915 ||| NN
,  ||| S:4915 E:4917 ||| ,
lower  ||| S:4917 E:4923 ||| JJR
extremity  ||| S:4923 E:4933 ||| JJ
peripheral  ||| S:4933 E:4954 ||| JJ
arterial  ||| S:4954 E:4963 ||| JJ
disease  ||| S:4963 E:4971 ||| NN
treated  ||| S:4971 E:4979 ||| VBN
in  ||| S:4979 E:4982 ||| IN
the  ||| S:4982 E:4986 ||| DT
hospital  ||| S:4986 E:4995 ||| NN
or  ||| S:4995 E:4998 ||| CC
with  ||| S:4998 E:5013 ||| IN
outpatient  ||| S:5013 E:5024 ||| JJ
revascularization ||| S:5024 E:5041 ||| NN
,  ||| S:5041 E:5043 ||| ,
and  ||| S:5043 E:5047 ||| CC
HF ||| S:5047 E:5049 ||| NNP
,  ||| S:5049 E:5051 ||| ,
fatal  ||| S:5051 E:5057 ||| JJ
or  ||| S:5057 E:5060 ||| CC
treated  ||| S:5060 E:5068 ||| VBN
in  ||| S:5068 E:5081 ||| IN
the  ||| S:5081 E:5085 ||| DT
hospital  ||| S:5085 E:5094 ||| NN
or  ||| S:5094 E:5097 ||| CC
as  ||| S:5097 E:5100 ||| IN
an  ||| S:5100 E:5103 ||| DT
outpatient ||| S:5103 E:5113 ||| NN
) ||| S:5113 E:5114 ||| -RRB-
.  ||| S:5114 E:5126 ||| .
The  ||| S:5126 E:5130 ||| DT
validation  ||| S:5130 E:5141 ||| NN
of  ||| S:5141 E:5144 ||| IN
HF  ||| S:5144 E:5147 ||| NNP
diagnosis  ||| S:5147 E:5157 ||| VBD
entailed  ||| S:5157 E:5166 ||| VBN
answering  ||| S:5166 E:5186 ||| VBG
several  ||| S:5186 E:5194 ||| JJ
questions ||| S:5194 E:5203 ||| NNS
:  ||| S:5203 E:5215 ||| :
1 ||| S:5215 E:5216 ||| LS
.  ||| S:5216 E:5218 ||| .
Did  ||| S:5218 E:5222 ||| VBD
HF  ||| S:5222 E:5225 ||| NNP
cases  ||| S:5225 E:5231 ||| NNS
meet  ||| S:5231 E:5236 ||| VBP
ALLHAT  ||| S:5236 E:5243 ||| JJ
diagnostic  ||| S:5243 E:5254 ||| JJ
criteria ||| S:5254 E:5262 ||| NNS
?  ||| S:5262 E:5274 ||| .
2 ||| S:5274 E:5275 ||| LS
.  ||| S:5275 E:5277 ||| .
Were  ||| S:5277 E:5282 ||| VBD
baseline  ||| S:5282 E:5291 ||| JJ
characteristics  ||| S:5291 E:5307 ||| NNS
and  ||| S:5307 E:5311 ||| CC
medical  ||| S:5311 E:5329 ||| JJ
management  ||| S:5329 E:5340 ||| NN
for  ||| S:5340 E:5344 ||| IN
HF  ||| S:5344 E:5347 ||| NNP
cases  ||| S:5347 E:5353 ||| NNS
as  ||| S:5353 E:5356 ||| RB
expected  ||| S:5356 E:5365 ||| VBN
and  ||| S:5365 E:5369 ||| CC
similar  ||| S:5369 E:5377 ||| JJ
across  ||| S:5377 E:5394 ||| IN
the  ||| S:5394 E:5398 ||| DT
drug  ||| S:5398 E:5403 ||| NN
groups ||| S:5403 E:5409 ||| NNS
?  ||| S:5409 E:5421 ||| .
3 ||| S:5421 E:5422 ||| LS
.  ||| S:5422 E:5424 ||| .
Were  ||| S:5424 E:5429 ||| VBD
prevalence  ||| S:5429 E:5440 ||| JJ
and  ||| S:5440 E:5444 ||| CC
severity  ||| S:5444 E:5453 ||| NN
of  ||| S:5453 E:5456 ||| IN
systolic  ||| S:5456 E:5475 ||| JJ
dysfunction  ||| S:5475 E:5487 ||| NN
as  ||| S:5487 E:5490 ||| IN
expected  ||| S:5490 E:5499 ||| VBN
and  ||| S:5499 E:5503 ||| CC
similar  ||| S:5503 E:5511 ||| JJ
across  ||| S:5511 E:5518 ||| IN
drug  ||| S:5518 E:5533 ||| NN
groups ||| S:5533 E:5539 ||| NNS
?  ||| S:5539 E:5551 ||| .
4 ||| S:5551 E:5552 ||| LS
.  ||| S:5552 E:5554 ||| .
Were  ||| S:5554 E:5559 ||| VBD
case-fatality  ||| S:5559 E:5573 ||| JJ
rates  ||| S:5573 E:5579 ||| NNS
as  ||| S:5579 E:5582 ||| RB
expected  ||| S:5582 E:5591 ||| VBN
and  ||| S:5591 E:5595 ||| CC
similar  ||| S:5595 E:5613 ||| JJ
across  ||| S:5613 E:5620 ||| IN
drug  ||| S:5620 E:5625 ||| NN
groups ||| S:5625 E:5631 ||| NNS
?  ||| S:5631 E:5643 ||| .
Unless  ||| S:5643 E:5650 ||| IN
otherwise  ||| S:5650 E:5660 ||| RB
specified ||| S:5660 E:5669 ||| VBN
,  ||| S:5669 E:5671 ||| ,
all  ||| S:5671 E:5675 ||| DT
data  ||| S:5675 E:5680 ||| NNS
for  ||| S:5680 E:5684 ||| IN
these  ||| S:5684 E:5700 ||| DT
analyses  ||| S:5700 E:5709 ||| NNS
were  ||| S:5709 E:5714 ||| VBD
collected  ||| S:5714 E:5724 ||| VBN
as  ||| S:5724 E:5727 ||| IN
of  ||| S:5727 E:5730 ||| IN
December ||| S:5730 E:5738 ||| NNP
,  ||| S:5738 E:5740 ||| ,
1999 ||| S:5740 E:5744 ||| CD
.  ||| S:5744 E:5774 ||| .
Heart  ||| S:5774 E:5780 ||| NNP
Failure  ||| S:5780 E:5788 ||| NNP
Diagnosis  ||| S:5788 E:5808 ||| NNP
At  ||| S:5808 E:5811 ||| IN
each  ||| S:5811 E:5816 ||| DT
follow-up  ||| S:5816 E:5826 ||| JJ
clinic  ||| S:5826 E:5833 ||| NN
visit  ||| S:5833 E:5839 ||| NN
the  ||| S:5839 E:5843 ||| DT
occurrence  ||| S:5843 E:5854 ||| NN
of  ||| S:5854 E:5857 ||| IN
study  ||| S:5857 E:5873 ||| NN
clinical  ||| S:5873 E:5882 ||| JJ
events  ||| S:5882 E:5889 ||| NNS
was  ||| S:5889 E:5893 ||| VBD
assessed ||| S:5893 E:5901 ||| VBN
,  ||| S:5901 E:5903 ||| ,
and ||| S:5903 E:5906 ||| CC
,  ||| S:5906 E:5908 ||| ,
if  ||| S:5908 E:5911 ||| IN
identified  ||| S:5911 E:5922 ||| VBN
by  ||| S:5922 E:5925 ||| IN
the  ||| S:5925 E:5939 ||| DT
clinical  ||| S:5939 E:5948 ||| JJ
investigator ||| S:5948 E:5960 ||| NN
,  ||| S:5960 E:5962 ||| ,
reported  ||| S:5962 E:5971 ||| VBD
on  ||| S:5971 E:5974 ||| IN
an  ||| S:5974 E:5977 ||| DT
endpoint  ||| S:5977 E:5986 ||| JJ
form ||| S:5986 E:5990 ||| NN
.  ||| S:5990 E:5992 ||| .
For  ||| S:5992 E:6006 ||| IN
each  ||| S:6006 E:6011 ||| DT
event  ||| S:6011 E:6017 ||| NN
involving  ||| S:6017 E:6027 ||| VBG
hospitalization ||| S:6027 E:6042 ||| NN
,  ||| S:6042 E:6044 ||| ,
a  ||| S:6044 E:6046 ||| DT
hospital  ||| S:6046 E:6065 ||| NN
discharge  ||| S:6065 E:6075 ||| NN
summary  ||| S:6075 E:6083 ||| NN
or  ||| S:6083 E:6086 ||| CC
expiration  ||| S:6086 E:6097 ||| NN
summary  ||| S:6097 E:6105 ||| NN
was  ||| S:6105 E:6109 ||| VBD
to  ||| S:6109 E:6112 ||| TO
be  ||| S:6112 E:6125 ||| VB
submitted ||| S:6125 E:6134 ||| VBN
,  ||| S:6134 E:6136 ||| ,
and  ||| S:6136 E:6140 ||| CC
for  ||| S:6140 E:6144 ||| IN
each  ||| S:6144 E:6149 ||| DT
death  ||| S:6149 E:6155 ||| NN
a  ||| S:6155 E:6157 ||| DT
death  ||| S:6157 E:6163 ||| NN
certificate  ||| S:6163 E:6175 ||| NN
was  ||| S:6175 E:6189 ||| VBD
required ||| S:6189 E:6197 ||| VBN
.  ||| S:6197 E:6199 ||| .
Endpoint  ||| S:6199 E:6208 ||| JJ
forms  ||| S:6208 E:6214 ||| NNS
and  ||| S:6214 E:6218 ||| CC
supporting  ||| S:6218 E:6229 ||| VBG
documentation  ||| S:6229 E:6253 ||| NNS
were  ||| S:6253 E:6258 ||| VBD
reviewed  ||| S:6258 E:6267 ||| VBN
at  ||| S:6267 E:6270 ||| IN
the  ||| S:6270 E:6274 ||| DT
ALLHAT  ||| S:6274 E:6281 ||| NNP
Clinical  ||| S:6281 E:6290 ||| NNP
Trials  ||| S:6290 E:6297 ||| NNP
Center  ||| S:6297 E:6304 ||| NNP
( ||| S:6304 E:6305 ||| -LRB-
CTC ||| S:6305 E:6308 ||| NNP
)  ||| S:6308 E:6320 ||| -RRB-
for  ||| S:6320 E:6324 ||| IN
accuracy  ||| S:6324 E:6333 ||| NN
and  ||| S:6333 E:6337 ||| CC
appropriateness ||| S:6337 E:6352 ||| NN
.  ||| S:6352 E:6354 ||| .
When  ||| S:6354 E:6359 ||| WRB
a  ||| S:6359 E:6361 ||| DT
discrepancy  ||| S:6361 E:6373 ||| NN
or  ||| S:6373 E:6386 ||| CC
ambiguity  ||| S:6386 E:6396 ||| NN
was  ||| S:6396 E:6400 ||| VBD
found ||| S:6400 E:6405 ||| VBN
,  ||| S:6405 E:6407 ||| ,
the  ||| S:6407 E:6411 ||| DT
CTC  ||| S:6411 E:6415 ||| NNP
sent  ||| S:6415 E:6420 ||| VBD
a  ||| S:6420 E:6422 ||| DT
written  ||| S:6422 E:6430 ||| JJ
query  ||| S:6430 E:6436 ||| NN
to  ||| S:6436 E:6439 ||| TO
the  ||| S:6439 E:6453 ||| DT
Principal  ||| S:6453 E:6463 ||| NNP
Investigator ||| S:6463 E:6475 ||| NNP
,  ||| S:6475 E:6477 ||| ,
who  ||| S:6477 E:6481 ||| WP
retained  ||| S:6481 E:6490 ||| VBD
the  ||| S:6490 E:6494 ||| DT
final  ||| S:6494 E:6500 ||| JJ
word  ||| S:6500 E:6515 ||| NN
concerning  ||| S:6515 E:6526 ||| VBG
the  ||| S:6526 E:6530 ||| DT
diagnosis  ||| S:6530 E:6540 ||| NN
or  ||| S:6540 E:6543 ||| CC
cause  ||| S:6543 E:6549 ||| NN
of  ||| S:6549 E:6552 ||| IN
death ||| S:6552 E:6557 ||| NN
.  ||| S:6557 E:6559 ||| .
A  ||| S:6559 E:6561 ||| DT
random  ||| S:6561 E:6568 ||| JJ
10 ||| S:6568 E:6570 ||| CD
%  ||| S:6570 E:6582 ||| NN
sample  ||| S:6582 E:6589 ||| NN
of  ||| S:6589 E:6592 ||| IN
strokes ||| S:6592 E:6599 ||| NNS
,  ||| S:6599 E:6601 ||| ,
nonfatal  ||| S:6601 E:6610 ||| JJ
MIs  ||| S:6610 E:6614 ||| JJ
and  ||| S:6614 E:6618 ||| CC
CHD  ||| S:6618 E:6622 ||| NNP
deaths  ||| S:6622 E:6629 ||| NNS
was  ||| S:6629 E:6643 ||| VBD
selected  ||| S:6643 E:6652 ||| VBN
for  ||| S:6652 E:6656 ||| IN
blinded  ||| S:6656 E:6664 ||| JJ
quality  ||| S:6664 E:6672 ||| NN
control  ||| S:6672 E:6680 ||| NN
evaluation  ||| S:6680 E:6691 ||| NN
by  ||| S:6691 E:6694 ||| IN
the  ||| S:6694 E:6708 ||| DT
ALLHAT  ||| S:6708 E:6715 ||| NNP
Endpoints  ||| S:6715 E:6725 ||| NNP
Subcommittee ||| S:6725 E:6737 ||| NNP
;  ||| S:6737 E:6739 ||| :
for  ||| S:6739 E:6743 ||| IN
these  ||| S:6743 E:6749 ||| DT
cases  ||| S:6749 E:6755 ||| NNS
additional  ||| S:6755 E:6776 ||| JJ
documentation  ||| S:6776 E:6790 ||| NN
was  ||| S:6790 E:6794 ||| VBD
requested ||| S:6794 E:6803 ||| VBN
.  ||| S:6803 E:6815 ||| .
No  ||| S:6815 E:6818 ||| DT
such  ||| S:6818 E:6823 ||| JJ
routine  ||| S:6823 E:6831 ||| JJ
Endpoints  ||| S:6831 E:6841 ||| NNP
Subcommittee  ||| S:6841 E:6854 ||| NNP
quality  ||| S:6854 E:6862 ||| NN
control  ||| S:6862 E:6880 ||| NN
was  ||| S:6880 E:6884 ||| VBD
initially  ||| S:6884 E:6894 ||| RB
planned  ||| S:6894 E:6902 ||| VBN
for  ||| S:6902 E:6906 ||| IN
reported  ||| S:6906 E:6915 ||| VBN
HF ||| S:6915 E:6917 ||| NNP
.  ||| S:6917 E:6919 ||| .
However ||| S:6919 E:6926 ||| RB
,  ||| S:6926 E:6928 ||| ,
the  ||| S:6928 E:6942 ||| DT
Subcommittee  ||| S:6942 E:6955 ||| NNP
was  ||| S:6955 E:6959 ||| VBD
subsequently  ||| S:6959 E:6972 ||| RB
called  ||| S:6972 E:6979 ||| VBN
upon  ||| S:6979 E:6984 ||| RP
to  ||| S:6984 E:6987 ||| TO
evaluate  ||| S:6987 E:6996 ||| VB
a  ||| S:6996 E:7008 ||| DT
random  ||| S:7008 E:7015 ||| JJ
sample  ||| S:7015 E:7022 ||| NN
of  ||| S:7022 E:7025 ||| IN
reported  ||| S:7025 E:7034 ||| VBN
fatal  ||| S:7034 E:7040 ||| JJ
and  ||| S:7040 E:7044 ||| CC
hospitalized  ||| S:7044 E:7057 ||| VBN
nonfatal  ||| S:7057 E:7076 ||| JJ
HF  ||| S:7076 E:7079 ||| NN
events ||| S:7079 E:7085 ||| NNS
.  ||| S:7085 E:7087 ||| .
As  ||| S:7087 E:7090 ||| IN
this  ||| S:7090 E:7095 ||| DT
occurred  ||| S:7095 E:7104 ||| VBD
prior  ||| S:7104 E:7110 ||| RB
to  ||| S:7110 E:7113 ||| TO
the  ||| S:7113 E:7117 ||| DT
termination  ||| S:7117 E:7129 ||| NN
of  ||| S:7129 E:7142 ||| IN
the  ||| S:7142 E:7146 ||| DT
doxazosin  ||| S:7146 E:7156 ||| JJ
arm ||| S:7156 E:7159 ||| NN
,  ||| S:7159 E:7161 ||| ,
neither  ||| S:7161 E:7169 ||| CC
the  ||| S:7169 E:7173 ||| DT
chair  ||| S:7173 E:7179 ||| NN
nor  ||| S:7179 E:7183 ||| CC
the  ||| S:7183 E:7187 ||| DT
members  ||| S:7187 E:7195 ||| NNS
of  ||| S:7195 E:7208 ||| IN
the  ||| S:7208 E:7212 ||| DT
Subcommittee  ||| S:7212 E:7225 ||| NNP
was  ||| S:7225 E:7229 ||| VBD
informed  ||| S:7229 E:7238 ||| VBN
of  ||| S:7238 E:7241 ||| IN
the  ||| S:7241 E:7245 ||| DT
major  ||| S:7245 E:7251 ||| JJ
reason  ||| S:7251 E:7258 ||| NN
for  ||| S:7258 E:7272 ||| IN
this  ||| S:7272 E:7277 ||| DT
review ||| S:7277 E:7283 ||| NN
,  ||| S:7283 E:7285 ||| ,
namely ||| S:7285 E:7291 ||| RB
,  ||| S:7291 E:7293 ||| ,
the  ||| S:7293 E:7297 ||| DT
trend  ||| S:7297 E:7303 ||| NN
toward  ||| S:7303 E:7310 ||| IN
a  ||| S:7310 E:7312 ||| DT
higher  ||| S:7312 E:7319 ||| JJR
HF  ||| S:7319 E:7322 ||| JJ
event  ||| S:7322 E:7338 ||| NN
rate  ||| S:7338 E:7343 ||| NN
in  ||| S:7343 E:7346 ||| IN
the  ||| S:7346 E:7350 ||| DT
doxazosin  ||| S:7350 E:7360 ||| JJ
group  ||| S:7360 E:7366 ||| NN
compared  ||| S:7366 E:7375 ||| VBN
to  ||| S:7375 E:7378 ||| TO
the  ||| S:7378 E:7392 ||| DT
chlorthalidone  ||| S:7392 E:7407 ||| JJ
group ||| S:7407 E:7412 ||| NN
.  ||| S:7412 E:7414 ||| .
The  ||| S:7414 E:7418 ||| DT
Subcommittee  ||| S:7418 E:7431 ||| NNP
was  ||| S:7431 E:7435 ||| VBD
told  ||| S:7435 E:7440 ||| VBN
that  ||| S:7440 E:7445 ||| IN
the  ||| S:7445 E:7459 ||| DT
review  ||| S:7459 E:7466 ||| NN
was  ||| S:7466 E:7470 ||| VBD
undertaken  ||| S:7470 E:7481 ||| VBN
at  ||| S:7481 E:7484 ||| IN
the  ||| S:7484 E:7488 ||| DT
request  ||| S:7488 E:7496 ||| NN
of  ||| S:7496 E:7499 ||| IN
the  ||| S:7499 E:7503 ||| DT
DSMB  ||| S:7503 E:7508 ||| NNP
to  ||| S:7508 E:7521 ||| TO
address  ||| S:7521 E:7529 ||| VB
the  ||| S:7529 E:7533 ||| DT
reliability  ||| S:7533 E:7545 ||| NN
and  ||| S:7545 E:7549 ||| CC
validity  ||| S:7549 E:7558 ||| NN
of  ||| S:7558 E:7561 ||| IN
reported  ||| S:7561 E:7570 ||| VBN
HF  ||| S:7570 E:7583 ||| NNP
events ||| S:7583 E:7589 ||| NNS
.  ||| S:7589 E:7591 ||| .
This  ||| S:7591 E:7596 ||| DT
evaluation  ||| S:7596 E:7607 ||| NN
consisted  ||| S:7607 E:7617 ||| VBD
of  ||| S:7617 E:7620 ||| IN
fifty  ||| S:7620 E:7626 ||| JJ
events ||| S:7626 E:7632 ||| NNS
,  ||| S:7632 E:7634 ||| ,
evenly  ||| S:7634 E:7651 ||| RB
distributed  ||| S:7651 E:7663 ||| VBN
across  ||| S:7663 E:7670 ||| IN
the  ||| S:7670 E:7674 ||| DT
four  ||| S:7674 E:7679 ||| CD
treatment  ||| S:7679 E:7689 ||| NN
groups ||| S:7689 E:7695 ||| NNS
,  ||| S:7695 E:7697 ||| ,
reported  ||| S:7697 E:7706 ||| VBD
as  ||| S:7706 E:7719 ||| IN
fatal  ||| S:7719 E:7725 ||| JJ
or  ||| S:7725 E:7728 ||| CC
hospitalized  ||| S:7728 E:7741 ||| VBN
nonfatal  ||| S:7741 E:7750 ||| JJ
HF  ||| S:7750 E:7753 ||| NNP
and  ||| S:7753 E:7757 ||| CC
with  ||| S:7757 E:7772 ||| IN
protocol-required  ||| S:7772 E:7790 ||| JJ
documentation  ||| S:7790 E:7804 ||| NNS
( ||| S:7804 E:7805 ||| -LRB-
discharge  ||| S:7805 E:7815 ||| JJ
summary  ||| S:7815 E:7823 ||| NN
for  ||| S:7823 E:7837 ||| IN
hospitalized  ||| S:7837 E:7850 ||| JJ
events ||| S:7850 E:7856 ||| NNS
,  ||| S:7856 E:7858 ||| ,
death  ||| S:7858 E:7864 ||| NN
certificates  ||| S:7864 E:7877 ||| NNS
for  ||| S:7877 E:7881 ||| IN
deaths ||| S:7881 E:7887 ||| NNS
) ||| S:7887 E:7888 ||| -RRB-
.  ||| S:7888 E:7900 ||| .
Additional  ||| S:7900 E:7911 ||| JJ
material  ||| S:7911 E:7920 ||| NN
was  ||| S:7920 E:7924 ||| VBD
not  ||| S:7924 E:7928 ||| RB
requested ||| S:7928 E:7937 ||| VBN
,  ||| S:7937 E:7939 ||| ,
since  ||| S:7939 E:7945 ||| IN
this  ||| S:7945 E:7950 ||| DT
would  ||| S:7950 E:7966 ||| MD
have  ||| S:7966 E:7971 ||| VB
posed  ||| S:7971 E:7977 ||| VBN
an  ||| S:7977 E:7980 ||| DT
undue  ||| S:7980 E:7986 ||| JJ
burden  ||| S:7986 E:7993 ||| NN
on  ||| S:7993 E:7996 ||| IN
the  ||| S:7996 E:8000 ||| DT
clinical  ||| S:8000 E:8009 ||| JJ
site  ||| S:8009 E:8014 ||| NN
staff  ||| S:8014 E:8020 ||| NN
and  ||| S:8020 E:8034 ||| CC
would  ||| S:8034 E:8040 ||| MD
have  ||| S:8040 E:8045 ||| VB
risked  ||| S:8045 E:8052 ||| VBN
raising  ||| S:8052 E:8060 ||| VBG
questions  ||| S:8060 E:8070 ||| NNS
about  ||| S:8070 E:8076 ||| IN
emerging  ||| S:8076 E:8095 ||| VBG
differences  ||| S:8095 E:8107 ||| NNS
among  ||| S:8107 E:8113 ||| IN
treatment  ||| S:8113 E:8123 ||| NN
groups ||| S:8123 E:8129 ||| NNS
.  ||| S:8129 E:8141 ||| .
The  ||| S:8141 E:8145 ||| DT
ALLHAT  ||| S:8145 E:8152 ||| NNP
definition  ||| S:8152 E:8163 ||| NN
of  ||| S:8163 E:8166 ||| IN
HF ||| S:8166 E:8168 ||| NNP
,  ||| S:8168 E:8170 ||| ,
used  ||| S:8170 E:8175 ||| VBN
previously  ||| S:8175 E:8186 ||| RB
in  ||| S:8186 E:8189 ||| IN
the  ||| S:8189 E:8203 ||| DT
Systolic  ||| S:8203 E:8212 ||| NNP
Hypertension  ||| S:8212 E:8225 ||| NNP
in  ||| S:8225 E:8228 ||| IN
the  ||| S:8228 E:8232 ||| DT
Elderly  ||| S:8232 E:8240 ||| JJ
Program  ||| S:8240 E:8248 ||| NN
( ||| S:8248 E:8249 ||| -LRB-
SHEP ||| S:8249 E:8253 ||| NNP
)  ||| S:8253 E:8255 ||| -RRB-
[  ||| S:8255 E:8257 ||| -LRB-
5  ||| S:8257 E:8259 ||| LS
]  ||| S:8259 E:8271 ||| -RRB-
,  ||| S:8271 E:8273 ||| ,
includes  ||| S:8273 E:8282 ||| VBZ
"patients  ||| S:8282 E:8292 ||| CD
with  ||| S:8292 E:8297 ||| IN
clear-cut  ||| S:8297 E:8307 ||| JJ
signs  ||| S:8307 E:8313 ||| NNS
or  ||| S:8313 E:8316 ||| CC
symptoms  ||| S:8316 E:8325 ||| NNS
of  ||| S:8325 E:8338 ||| IN
left  ||| S:8338 E:8343 ||| VBN
or  ||| S:8343 E:8346 ||| CC
right  ||| S:8346 E:8352 ||| RB
ventricular  ||| S:8352 E:8364 ||| JJ
dysfunction  ||| S:8364 E:8376 ||| NN
that  ||| S:8376 E:8381 ||| WDT
cannot  ||| S:8381 E:8388 ||| RB
be  ||| S:8388 E:8401 ||| VB
attributed  ||| S:8401 E:8412 ||| VBN
to  ||| S:8412 E:8415 ||| TO
other  ||| S:8415 E:8421 ||| JJ
causes... ||| S:8421 E:8430 ||| NN
"  ||| S:8430 E:8432 ||| ''
The  ||| S:8432 E:8436 ||| DT
diagnosis  ||| S:8436 E:8446 ||| NN
of  ||| S:8446 E:8449 ||| IN
HF  ||| S:8449 E:8452 ||| NNP
must  ||| S:8452 E:8467 ||| MD
include  ||| S:8467 E:8475 ||| VB
at  ||| S:8475 E:8478 ||| IN
least  ||| S:8478 E:8484 ||| JJS
one  ||| S:8484 E:8488 ||| CD
of  ||| S:8488 E:8491 ||| IN
four  ||| S:8491 E:8496 ||| CD
stated  ||| S:8496 E:8503 ||| JJ
symptoms  ||| S:8503 E:8512 ||| NNS
[ ||| S:8512 E:8513 ||| -LRB-
paroxysmal  ||| S:8513 E:8534 ||| FW
nocturnal  ||| S:8534 E:8544 ||| FW
dyspnea ||| S:8544 E:8551 ||| FW
,  ||| S:8551 E:8553 ||| ,
dyspnea  ||| S:8553 E:8561 ||| VBG
at  ||| S:8561 E:8564 ||| IN
rest ||| S:8564 E:8568 ||| NN
,  ||| S:8568 E:8570 ||| ,
New  ||| S:8570 E:8574 ||| NNP
York  ||| S:8574 E:8579 ||| NNP
Heart  ||| S:8579 E:8595 ||| NNP
Classification  ||| S:8595 E:8610 ||| NNP
functional  ||| S:8610 E:8621 ||| JJ
class  ||| S:8621 E:8627 ||| NN
III  ||| S:8627 E:8631 ||| NNP
( ||| S:8631 E:8632 ||| -LRB-
for  ||| S:8632 E:8636 ||| IN
definition  ||| S:8636 E:8647 ||| NN
see  ||| S:8647 E:8661 ||| VBP
Additional  ||| S:8661 E:8672 ||| JJ
Information ||| S:8672 E:8683 ||| NNP
,  ||| S:8683 E:8685 ||| ,
Item  ||| S:8685 E:8690 ||| NNP
1 ||| S:8690 E:8691 ||| CD
) ||| S:8691 E:8692 ||| -RRB-
,  ||| S:8692 E:8694 ||| ,
or  ||| S:8694 E:8697 ||| CC
orthopnea ||| S:8697 E:8706 ||| CD
] ||| S:8706 E:8707 ||| -RRB-
,  ||| S:8707 E:8709 ||| ,
and  ||| S:8709 E:8713 ||| CC
one  ||| S:8713 E:8727 ||| CD
of  ||| S:8727 E:8730 ||| IN
seven  ||| S:8730 E:8736 ||| CD
stated  ||| S:8736 E:8743 ||| JJ
signs  ||| S:8743 E:8749 ||| NNS
( ||| S:8749 E:8750 ||| -LRB-
rales ||| S:8750 E:8755 ||| UH
,  ||| S:8755 E:8757 ||| ,
2+  ||| S:8757 E:8760 ||| NNP
or  ||| S:8760 E:8763 ||| CC
greater  ||| S:8763 E:8771 ||| JJR
ankle  ||| S:8771 E:8777 ||| JJ
edema ||| S:8777 E:8782 ||| NN
,  ||| S:8782 E:8794 ||| ,
tachycardia  ||| S:8794 E:8806 ||| NN
of  ||| S:8806 E:8809 ||| IN
120  ||| S:8809 E:8813 ||| CD
beats ||| S:8813 E:8818 ||| CD
/ ||| S:8818 E:8819 ||| CD
minute  ||| S:8819 E:8826 ||| NN
or  ||| S:8826 E:8829 ||| CC
more  ||| S:8829 E:8834 ||| JJR
after  ||| S:8834 E:8840 ||| IN
five  ||| S:8840 E:8855 ||| CD
minutes  ||| S:8855 E:8863 ||| NNS
at  ||| S:8863 E:8866 ||| IN
rest ||| S:8866 E:8870 ||| NN
,  ||| S:8870 E:8872 ||| ,
cardiomegaly  ||| S:8872 E:8885 ||| VBG
by  ||| S:8885 E:8888 ||| IN
chest  ||| S:8888 E:8894 ||| JJ
x-ray ||| S:8894 E:8899 ||| NN
,  ||| S:8899 E:8901 ||| ,
chest  ||| S:8901 E:8907 ||| JJ
x-ray  ||| S:8907 E:8923 ||| JJ
characteristic  ||| S:8923 E:8938 ||| NN
of  ||| S:8938 E:8941 ||| IN
HF ||| S:8941 E:8943 ||| NNP
,  ||| S:8943 E:8945 ||| ,
S  ||| S:8945 E:8958 ||| NNP
3  ||| S:8958 E:8960 ||| CD
gallop ||| S:8960 E:8966 ||| NN
,  ||| S:8966 E:8968 ||| ,
or  ||| S:8968 E:8971 ||| CC
jugular  ||| S:8971 E:8979 ||| FW
venous  ||| S:8979 E:8996 ||| FW
distention ||| S:8996 E:9006 ||| FW
) ||| S:9006 E:9007 ||| -RRB-
.  ||| S:9007 E:9009 ||| .
Since  ||| S:9009 E:9015 ||| IN
lower  ||| S:9015 E:9021 ||| JJR
extremity  ||| S:9021 E:9031 ||| JJ
edema  ||| S:9031 E:9037 ||| NN
or  ||| S:9037 E:9040 ||| CC
exertional  ||| S:9040 E:9061 ||| JJ
dyspnea  ||| S:9061 E:9069 ||| NN
may  ||| S:9069 E:9073 ||| MD
be  ||| S:9073 E:9076 ||| VB
due  ||| S:9076 E:9080 ||| JJ
to  ||| S:9080 E:9083 ||| TO
non-cardiac  ||| S:9083 E:9095 ||| JJ
causes ||| S:9095 E:9101 ||| NNS
,  ||| S:9101 E:9103 ||| ,
the  ||| S:9103 E:9107 ||| DT
presence  ||| S:9107 E:9116 ||| NN
of  ||| S:9116 E:9129 ||| IN
either  ||| S:9129 E:9136 ||| RB
of  ||| S:9136 E:9139 ||| IN
these  ||| S:9139 E:9145 ||| DT
alone ||| S:9145 E:9150 ||| RB
,  ||| S:9150 E:9152 ||| ,
without  ||| S:9152 E:9160 ||| IN
other  ||| S:9160 E:9166 ||| JJ
indications  ||| S:9166 E:9178 ||| NNS
of  ||| S:9178 E:9181 ||| IN
heart  ||| S:9181 E:9197 ||| NN
failure ||| S:9197 E:9204 ||| NN
,  ||| S:9204 E:9206 ||| ,
is  ||| S:9206 E:9209 ||| VBZ
not  ||| S:9209 E:9213 ||| RB
sufficient  ||| S:9213 E:9224 ||| JJ
for  ||| S:9224 E:9228 ||| IN
a  ||| S:9228 E:9230 ||| DT
diagnosis  ||| S:9230 E:9240 ||| NN
of  ||| S:9240 E:9243 ||| IN
HF ||| S:9243 E:9245 ||| NNP
.  ||| S:9245 E:9247 ||| .
Study  ||| S:9247 E:9263 ||| NN
guidelines  ||| S:9263 E:9274 ||| NNS
caution  ||| S:9274 E:9282 ||| VBP
against  ||| S:9282 E:9290 ||| IN
a  ||| S:9290 E:9292 ||| DT
hasty  ||| S:9292 E:9298 ||| JJ
HF  ||| S:9298 E:9301 ||| NNP
diagnosis  ||| S:9301 E:9311 ||| NN
in  ||| S:9311 E:9324 ||| IN
patients  ||| S:9324 E:9333 ||| NNS
with  ||| S:9333 E:9338 ||| IN
severe  ||| S:9338 E:9345 ||| JJ
pulmonary  ||| S:9345 E:9355 ||| JJ
disease ||| S:9355 E:9362 ||| NN
,  ||| S:9362 E:9364 ||| ,
including  ||| S:9364 E:9374 ||| VBG
chronic  ||| S:9374 E:9392 ||| JJ
obstructive  ||| S:9392 E:9404 ||| JJ
pulmonary  ||| S:9404 E:9414 ||| JJ
disease  ||| S:9414 E:9422 ||| NN
( ||| S:9422 E:9423 ||| -LRB-
COPD ||| S:9423 E:9427 ||| NNP
) ||| S:9427 E:9428 ||| -RRB-
,  ||| S:9428 E:9430 ||| ,
pneumonia ||| S:9430 E:9439 ||| NN
,  ||| S:9439 E:9441 ||| ,
or  ||| S:9441 E:9444 ||| CC
other  ||| S:9444 E:9460 ||| JJ
severe ||| S:9460 E:9466 ||| JJ
,  ||| S:9466 E:9468 ||| ,
documented  ||| S:9468 E:9479 ||| VBN
lung  ||| S:9479 E:9484 ||| NN
disease ||| S:9484 E:9491 ||| NN
.  ||| S:9491 E:9521 ||| .
Baseline  ||| S:9521 E:9530 ||| NNP
Characteristics  ||| S:9530 E:9546 ||| NNP
and  ||| S:9546 E:9550 ||| CC
Medical  ||| S:9550 E:9568 ||| NNP
Management  ||| S:9568 E:9589 ||| NNP
Baseline  ||| S:9589 E:9598 ||| NNP
characteristics  ||| S:9598 E:9614 ||| NNS
of  ||| S:9614 E:9617 ||| IN
chlorthalidone  ||| S:9617 E:9632 ||| NN
and  ||| S:9632 E:9646 ||| CC
doxazosin  ||| S:9646 E:9656 ||| JJ
participants  ||| S:9656 E:9669 ||| NNS
were  ||| S:9669 E:9674 ||| VBD
compared ||| S:9674 E:9682 ||| VBN
.  ||| S:9682 E:9684 ||| .
These  ||| S:9684 E:9690 ||| DT
analyses  ||| S:9690 E:9699 ||| NNS
were  ||| S:9699 E:9714 ||| VBD
stratified  ||| S:9714 E:9725 ||| VBN
by  ||| S:9725 E:9728 ||| IN
HF  ||| S:9728 E:9731 ||| NNP
outcome ||| S:9731 E:9738 ||| NN
:  ||| S:9738 E:9740 ||| :
1 ||| S:9740 E:9741 ||| LS
)  ||| S:9741 E:9743 ||| -RRB-
fatal  ||| S:9743 E:9749 ||| JJ
and  ||| S:9749 E:9753 ||| CC
hospitalized  ||| S:9753 E:9766 ||| VBN
HF ||| S:9766 E:9768 ||| NNP
;  ||| S:9768 E:9780 ||| :
2 ||| S:9780 E:9781 ||| LS
)  ||| S:9781 E:9783 ||| -RRB-
treated ||| S:9783 E:9790 ||| VBN
,  ||| S:9790 E:9792 ||| ,
non-hospitalized  ||| S:9792 E:9809 ||| NNP
HF ||| S:9809 E:9811 ||| NNP
;  ||| S:9811 E:9813 ||| :
and ||| S:9813 E:9816 ||| CC
,  ||| S:9816 E:9818 ||| ,
3 ||| S:9818 E:9819 ||| LS
)  ||| S:9819 E:9821 ||| -RRB-
no  ||| S:9821 E:9824 ||| DT
HF ||| S:9824 E:9826 ||| NNP
.  ||| S:9826 E:9838 ||| .
Post-HF  ||| S:9838 E:9846 ||| JJ
event  ||| S:9846 E:9852 ||| NN
medical  ||| S:9852 E:9860 ||| JJ
management  ||| S:9860 E:9871 ||| NN
may  ||| S:9871 E:9875 ||| MD
provide  ||| S:9875 E:9893 ||| VB
additional  ||| S:9893 E:9904 ||| JJ
evidence  ||| S:9904 E:9913 ||| NN
of  ||| S:9913 E:9916 ||| IN
the  ||| S:9916 E:9920 ||| DT
physicians ||| S:9920 E:9930 ||| NNS
'  ||| S:9930 E:9932 ||| POS
confidence  ||| S:9932 E:9943 ||| NN
in  ||| S:9943 E:9946 ||| IN
the  ||| S:9946 E:9960 ||| DT
HF  ||| S:9960 E:9963 ||| NNP
diagnosis ||| S:9963 E:9972 ||| NN
.  ||| S:9972 E:9974 ||| .
The  ||| S:9974 E:9978 ||| DT
post-event  ||| S:9978 E:9989 ||| JJ
use  ||| S:9989 E:9993 ||| NN
of  ||| S:9993 E:9996 ||| IN
open-label  ||| S:9996 E:10007 ||| JJ
diuretics ||| S:10007 E:10016 ||| NN
,  ||| S:10016 E:10028 ||| ,
ACE-inhibitors ||| S:10028 E:10042 ||| NNP
,  ||| S:10042 E:10044 ||| ,
and  ||| S:10044 E:10048 ||| CC
beta-blockers ||| S:10048 E:10061 ||| JJ
,  ||| S:10061 E:10063 ||| ,
i.e. ||| S:10063 E:10067 ||| FW
,  ||| S:10067 E:10069 ||| ,
accepted  ||| S:10069 E:10088 ||| VBD
treatments  ||| S:10088 E:10099 ||| NNS
for  ||| S:10099 E:10103 ||| IN
HF  ||| S:10103 E:10106 ||| NNP
[  ||| S:10106 E:10108 ||| -LRB-
6  ||| S:10108 E:10110 ||| CD
7  ||| S:10110 E:10112 ||| CD
8  ||| S:10112 E:10114 ||| CD
9  ||| S:10114 E:10116 ||| CD
]  ||| S:10116 E:10118 ||| -RRB-
,  ||| S:10118 E:10120 ||| ,
was  ||| S:10120 E:10124 ||| VBD
compared  ||| S:10124 E:10133 ||| VBN
between  ||| S:10133 E:10151 ||| IN
doxazosin  ||| S:10151 E:10161 ||| NN
and  ||| S:10161 E:10165 ||| CC
chlorthalidone  ||| S:10165 E:10180 ||| JJ
groups ||| S:10180 E:10186 ||| NNS
,  ||| S:10186 E:10188 ||| ,
as  ||| S:10188 E:10191 ||| RB
was  ||| S:10191 E:10195 ||| VBD
the  ||| S:10195 E:10209 ||| DT
proportion  ||| S:10209 E:10220 ||| NN
in  ||| S:10220 E:10223 ||| IN
each  ||| S:10223 E:10228 ||| DT
group  ||| S:10228 E:10234 ||| NN
of  ||| S:10234 E:10237 ||| IN
those  ||| S:10237 E:10243 ||| DT
who  ||| S:10243 E:10247 ||| WP
remained  ||| S:10247 E:10256 ||| VBD
on  ||| S:10256 E:10269 ||| IN
assigned  ||| S:10269 E:10278 ||| VBN
blinded  ||| S:10278 E:10286 ||| JJ
medication  ||| S:10286 E:10297 ||| NN
after  ||| S:10297 E:10303 ||| IN
the  ||| S:10303 E:10307 ||| DT
event ||| S:10307 E:10312 ||| NN
.  ||| S:10312 E:10314 ||| .
( ||| S:10314 E:10315 ||| -LRB-
For  ||| S:10315 E:10319 ||| IN
study  ||| S:10319 E:10335 ||| NN
guidelines  ||| S:10335 E:10346 ||| NNS
regarding  ||| S:10346 E:10356 ||| VBG
the  ||| S:10356 E:10360 ||| DT
use  ||| S:10360 E:10364 ||| NN
and  ||| S:10364 E:10368 ||| CC
reporting  ||| S:10368 E:10378 ||| VBG
of  ||| S:10378 E:10381 ||| IN
open-label  ||| S:10381 E:10402 ||| JJ
medicines  ||| S:10402 E:10412 ||| NNS
of  ||| S:10412 E:10415 ||| IN
the  ||| S:10415 E:10419 ||| DT
same  ||| S:10419 E:10424 ||| JJ
class  ||| S:10424 E:10430 ||| NN
as  ||| S:10430 E:10433 ||| IN
the  ||| S:10433 E:10437 ||| DT
blinded  ||| S:10437 E:10445 ||| JJ
drugs ||| S:10445 E:10450 ||| NNS
,  ||| S:10450 E:10452 ||| ,
see  ||| S:10452 E:10466 ||| VBP
Additional  ||| S:10466 E:10477 ||| JJ
Information ||| S:10477 E:10488 ||| NNP
,  ||| S:10488 E:10490 ||| ,
Items  ||| S:10490 E:10496 ||| NNP
2  ||| S:10496 E:10498 ||| CD
and  ||| S:10498 E:10502 ||| CC
3 ||| S:10502 E:10503 ||| CD
. ||| S:10503 E:10504 ||| .
)  ||| S:10504 E:10534 ||| -RRB-
Ejection  ||| S:10534 E:10543 ||| NNP
Fraction  ||| S:10543 E:10552 ||| NNP
Review  ||| S:10552 E:10569 ||| NNP
A  ||| S:10569 E:10571 ||| NNP
CTC  ||| S:10571 E:10575 ||| NNP
physician  ||| S:10575 E:10585 ||| NN
plus  ||| S:10585 E:10590 ||| CC
non-medical  ||| S:10590 E:10602 ||| JJ
staff  ||| S:10602 E:10608 ||| NN
reviewed  ||| S:10608 E:10617 ||| VBN
in  ||| S:10617 E:10620 ||| IN
a  ||| S:10620 E:10632 ||| DT
blinded  ||| S:10632 E:10640 ||| JJ
fashion  ||| S:10640 E:10648 ||| NN
361  ||| S:10648 E:10652 ||| CD
hospitalized  ||| S:10652 E:10665 ||| JJ
HF  ||| S:10665 E:10668 ||| NN
events  ||| S:10668 E:10675 ||| NNS
( ||| S:10675 E:10676 ||| -LRB-
representing  ||| S:10676 E:10699 ||| VBG
278  ||| S:10699 E:10703 ||| CD
participants ||| S:10703 E:10715 ||| NNS
)  ||| S:10715 E:10717 ||| -RRB-
for  ||| S:10717 E:10721 ||| IN
ejection  ||| S:10721 E:10730 ||| JJ
fraction  ||| S:10730 E:10739 ||| NN
data ||| S:10739 E:10743 ||| NNS
:  ||| S:10743 E:10745 ||| :
looking  ||| S:10745 E:10753 ||| VBG
for  ||| S:10753 E:10767 ||| IN
whether  ||| S:10767 E:10775 ||| IN
an  ||| S:10775 E:10778 ||| DT
ejection  ||| S:10778 E:10787 ||| JJ
fraction  ||| S:10787 E:10796 ||| NN
was  ||| S:10796 E:10800 ||| VBD
measured ||| S:10800 E:10808 ||| VBN
,  ||| S:10808 E:10810 ||| ,
the  ||| S:10810 E:10814 ||| DT
method  ||| S:10814 E:10831 ||| NN
utilized ||| S:10831 E:10839 ||| NN
,  ||| S:10839 E:10841 ||| ,
and  ||| S:10841 E:10845 ||| CC
the  ||| S:10845 E:10849 ||| DT
measurement ||| S:10849 E:10860 ||| NN
.  ||| S:10860 E:10862 ||| .
Results ||| S:10862 E:10869 ||| NNS
,  ||| S:10869 E:10871 ||| ,
tabulated  ||| S:10871 E:10881 ||| VBG
by  ||| S:10881 E:10894 ||| IN
randomization  ||| S:10894 E:10908 ||| JJ
groups ||| S:10908 E:10914 ||| NNS
,  ||| S:10914 E:10916 ||| ,
reflected  ||| S:10916 E:10926 ||| VBD
data  ||| S:10926 E:10931 ||| NNS
that  ||| S:10931 E:10936 ||| WDT
had  ||| S:10936 E:10940 ||| VBD
been  ||| S:10940 E:10955 ||| VBN
collected  ||| S:10955 E:10965 ||| VBN
up  ||| S:10965 E:10968 ||| RP
to  ||| S:10968 E:10971 ||| TO
July ||| S:10971 E:10975 ||| NNP
,  ||| S:10975 E:10977 ||| ,
1999 ||| S:10977 E:10981 ||| CD
,  ||| S:10981 E:10983 ||| ,
the  ||| S:10983 E:10987 ||| DT
time  ||| S:10987 E:10992 ||| NN
of  ||| S:10992 E:10995 ||| IN
the  ||| S:10995 E:10999 ||| DT
review ||| S:10999 E:11005 ||| NN
.  ||| S:11005 E:11035 ||| .
Case-Fatality  ||| S:11035 E:11049 ||| JJ
Rates  ||| S:11049 E:11055 ||| NNS
and  ||| S:11055 E:11059 ||| CC
Causes  ||| S:11059 E:11066 ||| NNP
of  ||| S:11066 E:11069 ||| IN
Death  ||| S:11069 E:11085 ||| NN
As  ||| S:11085 E:11088 ||| IN
a  ||| S:11088 E:11090 ||| DT
measure  ||| S:11090 E:11098 ||| NN
of  ||| S:11098 E:11101 ||| IN
the  ||| S:11101 E:11105 ||| DT
diagnostic  ||| S:11105 E:11116 ||| JJ
validity  ||| S:11116 E:11125 ||| NN
and  ||| S:11125 E:11129 ||| CC
severity  ||| S:11129 E:11148 ||| NN
of  ||| S:11148 E:11151 ||| IN
HF  ||| S:11151 E:11154 ||| NNP
and  ||| S:11154 E:11158 ||| CC
comparability  ||| S:11158 E:11172 ||| NN
between  ||| S:11172 E:11180 ||| IN
drug  ||| S:11180 E:11185 ||| NN
groups ||| S:11185 E:11191 ||| NNS
,  ||| S:11191 E:11203 ||| ,
time-from-event-to-death  ||| S:11203 E:11228 ||| JJ
analyses  ||| S:11228 E:11237 ||| NNS
of  ||| S:11237 E:11240 ||| IN
participants  ||| S:11240 E:11253 ||| NNS
with  ||| S:11253 E:11268 ||| IN
hospitalized  ||| S:11268 E:11281 ||| NN
or  ||| S:11281 E:11284 ||| CC
treated  ||| S:11284 E:11292 ||| VBN
HF  ||| S:11292 E:11295 ||| NNP
were  ||| S:11295 E:11300 ||| VBD
compared  ||| S:11300 E:11309 ||| VBN
between  ||| S:11309 E:11317 ||| IN
the  ||| S:11317 E:11321 ||| DT
two  ||| S:11321 E:11335 ||| CD
groups ||| S:11335 E:11341 ||| NNS
.  ||| S:11341 E:11343 ||| .
Causes  ||| S:11343 E:11350 ||| NNS
of  ||| S:11350 E:11353 ||| IN
death  ||| S:11353 E:11359 ||| NN
of  ||| S:11359 E:11362 ||| IN
such  ||| S:11362 E:11367 ||| JJ
participants  ||| S:11367 E:11380 ||| NNS
were  ||| S:11380 E:11385 ||| VBD
also  ||| S:11385 E:11400 ||| RB
compared  ||| S:11400 E:11409 ||| VBN
in  ||| S:11409 E:11412 ||| IN
the  ||| S:11412 E:11416 ||| DT
doxazosin  ||| S:11416 E:11426 ||| NN
and  ||| S:11426 E:11430 ||| CC
chlorthalidone  ||| S:11430 E:11445 ||| JJ
groups ||| S:11445 E:11451 ||| NNS
.  ||| S:11451 E:11481 ||| .
Statistical  ||| S:11481 E:11493 ||| NNP
Analyses  ||| S:11493 E:11512 ||| NNP
Data  ||| S:11512 E:11517 ||| NNP
were  ||| S:11517 E:11522 ||| VBD
analyzed  ||| S:11522 E:11531 ||| VBN
according  ||| S:11531 E:11541 ||| VBG
to  ||| S:11541 E:11544 ||| TO
participants ||| S:11544 E:11556 ||| NNS
'  ||| S:11556 E:11568 ||| POS
randomization  ||| S:11568 E:11582 ||| JJ
assignments  ||| S:11582 E:11594 ||| NN
and  ||| S:11594 E:11598 ||| CC
HF  ||| S:11598 E:11601 ||| NNP
outcome  ||| S:11601 E:11609 ||| NN
status ||| S:11609 E:11615 ||| NN
,  ||| S:11615 E:11627 ||| ,
regardless  ||| S:11627 E:11638 ||| RB
of  ||| S:11638 E:11641 ||| IN
subsequent  ||| S:11641 E:11652 ||| JJ
medication  ||| S:11652 E:11663 ||| NN
adherence ||| S:11663 E:11672 ||| NN
.  ||| S:11672 E:11674 ||| .
The  ||| S:11674 E:11688 ||| DT
Kaplan-Meier  ||| S:11688 E:11701 ||| JJ
method  ||| S:11701 E:11708 ||| NN
was  ||| S:11708 E:11712 ||| VBD
utilized  ||| S:11712 E:11721 ||| VBN
in  ||| S:11721 E:11724 ||| IN
calculating  ||| S:11724 E:11746 ||| VBG
cumulative  ||| S:11746 E:11757 ||| JJ
event  ||| S:11757 E:11763 ||| NN
rates ||| S:11763 E:11768 ||| NNS
.  ||| S:11768 E:11770 ||| .
Descriptive  ||| S:11770 E:11782 ||| JJ
statistics  ||| S:11782 E:11793 ||| NNS
by  ||| S:11793 E:11806 ||| IN
treatment  ||| S:11806 E:11816 ||| NN
groups  ||| S:11816 E:11823 ||| NNS
were  ||| S:11823 E:11828 ||| VBD
presented  ||| S:11828 E:11838 ||| VBN
for  ||| S:11838 E:11842 ||| IN
baseline  ||| S:11842 E:11861 ||| NN
characteristics ||| S:11861 E:11876 ||| NNS
,  ||| S:11876 E:11878 ||| ,
HF  ||| S:11878 E:11881 ||| NNP
ascertainment ||| S:11881 E:11894 ||| NN
,  ||| S:11894 E:11896 ||| ,
ejection  ||| S:11896 E:11905 ||| JJ
fractions  ||| S:11905 E:11915 ||| NNS
and  ||| S:11915 E:11929 ||| CC
use  ||| S:11929 E:11933 ||| NN
of  ||| S:11933 E:11936 ||| IN
HF  ||| S:11936 E:11939 ||| NNP
medications ||| S:11939 E:11950 ||| NN
.  ||| S:11950 E:11952 ||| .
Comparability  ||| S:11952 E:11966 ||| NNP
of  ||| S:11966 E:11969 ||| IN
baseline  ||| S:11969 E:11988 ||| NN
characteristics  ||| S:11988 E:12004 ||| NNS
of  ||| S:12004 E:12007 ||| IN
the  ||| S:12007 E:12011 ||| DT
treatment  ||| S:12011 E:12021 ||| NN
and  ||| S:12021 E:12025 ||| CC
HF  ||| S:12025 E:12028 ||| NNP
outcome  ||| S:12028 E:12036 ||| NN
groups  ||| S:12036 E:12053 ||| NNS
was  ||| S:12053 E:12057 ||| VBD
ascertained  ||| S:12057 E:12069 ||| VBN
by  ||| S:12069 E:12072 ||| IN
the  ||| S:12072 E:12076 ||| DT
χ  ||| S:12076 E:12078 ||| JJ
2test  ||| S:12078 E:12084 ||| NN
for  ||| S:12084 E:12088 ||| IN
categorical  ||| S:12088 E:12100 ||| JJ
variables  ||| S:12100 E:12120 ||| NNS
and  ||| S:12120 E:12124 ||| CC
standard  ||| S:12124 E:12133 ||| JJ
normal  ||| S:12133 E:12140 ||| JJ
( ||| S:12140 E:12141 ||| -LRB-
z ||| S:12141 E:12142 ||| LS
)  ||| S:12142 E:12144 ||| -RRB-
test  ||| S:12144 E:12149 ||| NN
for  ||| S:12149 E:12153 ||| IN
continuous  ||| S:12153 E:12174 ||| JJ
variables ||| S:12174 E:12183 ||| NNS
.  ||| S:12183 E:12216 ||| .
Results  ||| S:12216 E:12243 ||| NNP
Heart  ||| S:12243 E:12249 ||| NNP
Failure  ||| S:12249 E:12257 ||| NNP
Diagnostic  ||| S:12257 E:12268 ||| NNP
Criteria  ||| S:12268 E:12287 ||| NNP
The  ||| S:12287 E:12291 ||| DT
blinded  ||| S:12291 E:12299 ||| JJ
review  ||| S:12299 E:12306 ||| NN
by  ||| S:12306 E:12309 ||| IN
the  ||| S:12309 E:12313 ||| DT
Endpoints  ||| S:12313 E:12323 ||| NNP
Subcommittee  ||| S:12323 E:12336 ||| NNP
of  ||| S:12336 E:12339 ||| IN
50  ||| S:12339 E:12352 ||| CD
fatal  ||| S:12352 E:12358 ||| NNS
or  ||| S:12358 E:12361 ||| CC
hospitalized  ||| S:12361 E:12374 ||| VBN
HF  ||| S:12374 E:12377 ||| NNP
events  ||| S:12377 E:12384 ||| NNS
from  ||| S:12384 E:12389 ||| IN
the  ||| S:12389 E:12393 ||| DT
4  ||| S:12393 E:12395 ||| CD
drug  ||| S:12395 E:12400 ||| NN
groups  ||| S:12400 E:12417 ||| NNS
determined  ||| S:12417 E:12428 ||| VBD
11  ||| S:12428 E:12431 ||| CD
( ||| S:12431 E:12432 ||| -LRB-
22 ||| S:12432 E:12434 ||| CD
% ||| S:12434 E:12435 ||| NN
)  ||| S:12435 E:12437 ||| -RRB-
to  ||| S:12437 E:12440 ||| TO
have  ||| S:12440 E:12445 ||| VB
incomplete  ||| S:12445 E:12456 ||| JJ
data  ||| S:12456 E:12461 ||| NNS
for  ||| S:12461 E:12465 ||| IN
a  ||| S:12465 E:12477 ||| DT
definitive  ||| S:12477 E:12488 ||| JJ
review ||| S:12488 E:12494 ||| NN
.  ||| S:12494 E:12496 ||| .
Of  ||| S:12496 E:12499 ||| IN
the  ||| S:12499 E:12503 ||| DT
remaining  ||| S:12503 E:12513 ||| JJ
39 ||| S:12513 E:12515 ||| CD
,  ||| S:12515 E:12517 ||| ,
33  ||| S:12517 E:12520 ||| CD
( ||| S:12520 E:12521 ||| -LRB-
85 ||| S:12521 E:12523 ||| CD
% ||| S:12523 E:12524 ||| NN
)  ||| S:12524 E:12526 ||| -RRB-
were  ||| S:12526 E:12541 ||| VBD
confirmed  ||| S:12541 E:12551 ||| VBN
to  ||| S:12551 E:12554 ||| TO
have  ||| S:12554 E:12559 ||| VB
HF  ||| S:12559 E:12562 ||| NNP
by  ||| S:12562 E:12565 ||| IN
one  ||| S:12565 E:12569 ||| CD
or  ||| S:12569 E:12572 ||| CC
both  ||| S:12572 E:12577 ||| DT
reviewers ||| S:12577 E:12586 ||| NN
.  ||| S:12586 E:12588 ||| .
For  ||| S:12588 E:12592 ||| IN
both  ||| S:12592 E:12607 ||| PDT
the  ||| S:12607 E:12611 ||| DT
chlorthalidone  ||| S:12611 E:12626 ||| NN
and  ||| S:12626 E:12630 ||| CC
doxazosin  ||| S:12630 E:12640 ||| JJ
groups ||| S:12640 E:12646 ||| NNS
,  ||| S:12646 E:12648 ||| ,
the  ||| S:12648 E:12652 ||| DT
diagnosis  ||| S:12652 E:12662 ||| NN
of  ||| S:12662 E:12675 ||| IN
HF  ||| S:12675 E:12678 ||| NNP
was  ||| S:12678 E:12682 ||| VBD
confirmed  ||| S:12682 E:12692 ||| VBN
in  ||| S:12692 E:12695 ||| IN
90 ||| S:12695 E:12697 ||| CD
%  ||| S:12697 E:12699 ||| NN
( ||| S:12699 E:12700 ||| -LRB-
18 ||| S:12700 E:12702 ||| CD
/ ||| S:12702 E:12703 ||| CD
20 ||| S:12703 E:12705 ||| CD
) ||| S:12705 E:12706 ||| -RRB-
.  ||| S:12706 E:12736 ||| .
Baseline  ||| S:12736 E:12745 ||| NNP
Characteristics  ||| S:12745 E:12771 ||| NNP
Baseline  ||| S:12771 E:12780 ||| NNP
characteristics  ||| S:12780 E:12796 ||| NNS
for  ||| S:12796 E:12800 ||| IN
the  ||| S:12800 E:12804 ||| DT
doxazosin  ||| S:12804 E:12814 ||| NN
and  ||| S:12814 E:12828 ||| CC
chlorthalidone  ||| S:12828 E:12843 ||| JJ
treatment  ||| S:12843 E:12853 ||| NN
groups ||| S:12853 E:12859 ||| NNS
,  ||| S:12859 E:12861 ||| ,
stratified  ||| S:12861 E:12872 ||| VBG
for  ||| S:12872 E:12876 ||| IN
HF  ||| S:12876 E:12889 ||| NNP
status ||| S:12889 E:12895 ||| NN
,  ||| S:12895 E:12897 ||| ,
are  ||| S:12897 E:12901 ||| VBP
described  ||| S:12901 E:12911 ||| VBN
in  ||| S:12911 E:12914 ||| IN
Table  ||| S:12914 E:12920 ||| NNP
1 ||| S:12920 E:12921 ||| CD
.  ||| S:12921 E:12933 ||| .
Baseline  ||| S:12933 E:12942 ||| JJ
characteristics  ||| S:12942 E:12958 ||| NNS
of  ||| S:12958 E:12961 ||| IN
doxazosin  ||| S:12961 E:12971 ||| NN
and  ||| S:12971 E:12985 ||| CC
chlorthalidone  ||| S:12985 E:13000 ||| JJ
participants  ||| S:13000 E:13013 ||| NNS
with  ||| S:13013 E:13018 ||| IN
subsequent  ||| S:13018 E:13029 ||| JJ
hospitalized  ||| S:13029 E:13052 ||| NN
or  ||| S:13052 E:13055 ||| CC
fatal  ||| S:13055 E:13061 ||| JJ
HF  ||| S:13061 E:13064 ||| NNP
were  ||| S:13064 E:13069 ||| VBD
compared ||| S:13069 E:13077 ||| VBN
.  ||| S:13077 E:13079 ||| .
Doxazosin  ||| S:13079 E:13089 ||| JJ
participants  ||| S:13089 E:13102 ||| NNS
with  ||| S:13102 E:13117 ||| IN
hospitalized  ||| S:13117 E:13130 ||| NN
or  ||| S:13130 E:13133 ||| CC
fatal  ||| S:13133 E:13139 ||| JJ
HF  ||| S:13139 E:13142 ||| NNP
had  ||| S:13142 E:13146 ||| VBD
a  ||| S:13146 E:13148 ||| DT
higher  ||| S:13148 E:13155 ||| JJR
baseline  ||| S:13155 E:13164 ||| NN
SBP  ||| S:13164 E:13168 ||| NN
than  ||| S:13168 E:13183 ||| IN
the  ||| S:13183 E:13187 ||| DT
chlorthalidone  ||| S:13187 E:13202 ||| JJ
participants  ||| S:13202 E:13215 ||| NNS
( ||| S:13215 E:13216 ||| -LRB-
150.1  ||| S:13216 E:13222 ||| FW
vs.  ||| S:13222 E:13226 ||| FW
147.8  ||| S:13226 E:13232 ||| FW
mm  ||| S:13232 E:13235 ||| FW
Hg  ||| S:13235 E:13238 ||| NNP
at  ||| S:13238 E:13251 ||| IN
the  ||| S:13251 E:13255 ||| DT
randomization  ||| S:13255 E:13269 ||| JJ
visit ||| S:13269 E:13274 ||| NN
) ||| S:13274 E:13275 ||| -RRB-
.  ||| S:13275 E:13277 ||| .
More  ||| S:13277 E:13282 ||| RBR
doxazosin  ||| S:13282 E:13292 ||| JJ
participants  ||| S:13292 E:13305 ||| NNS
had  ||| S:13305 E:13319 ||| VBD
LVH  ||| S:13319 E:13323 ||| NNP
by  ||| S:13323 E:13326 ||| IN
ECG  ||| S:13326 E:13330 ||| NNP
( ||| S:13330 E:13331 ||| -LRB-
22.3 ||| S:13331 E:13335 ||| CD
%  ||| S:13335 E:13337 ||| NN
vs.  ||| S:13337 E:13341 ||| IN
20.5 ||| S:13341 E:13345 ||| CD
%  ||| S:13345 E:13347 ||| NN
of  ||| S:13347 E:13350 ||| IN
chlorthalidone  ||| S:13350 E:13375 ||| JJ
participants ||| S:13375 E:13387 ||| NNS
) ||| S:13387 E:13388 ||| -RRB-
;  ||| S:13388 E:13390 ||| :
slightly  ||| S:13390 E:13399 ||| RB
more  ||| S:13399 E:13404 ||| JJR
chlorthalidone  ||| S:13404 E:13419 ||| NN
than  ||| S:13419 E:13434 ||| IN
doxazosin  ||| S:13434 E:13444 ||| JJ
participants  ||| S:13444 E:13457 ||| NNS
had  ||| S:13457 E:13461 ||| VBD
LVH  ||| S:13461 E:13465 ||| NNP
by  ||| S:13465 E:13468 ||| IN
echocardiogram ||| S:13468 E:13482 ||| NN
.  ||| S:13482 E:13484 ||| .
Several  ||| S:13484 E:13502 ||| JJ
eligibility  ||| S:13502 E:13514 ||| JJ
risk  ||| S:13514 E:13519 ||| NN
factors ||| S:13519 E:13526 ||| NNS
,  ||| S:13526 E:13528 ||| ,
including  ||| S:13528 E:13538 ||| VBG
previous  ||| S:13538 E:13547 ||| JJ
MIs  ||| S:13547 E:13551 ||| JJ
or  ||| S:13551 E:13564 ||| CC
strokes ||| S:13564 E:13571 ||| NNS
,  ||| S:13571 E:13573 ||| ,
coronary  ||| S:13573 E:13582 ||| JJ
revascularization  ||| S:13582 E:13600 ||| JJ
procedures ||| S:13600 E:13610 ||| NNS
,  ||| S:13610 E:13612 ||| ,
other  ||| S:13612 E:13628 ||| JJ
atherosclerotic  ||| S:13628 E:13644 ||| JJ
cardiovascular  ||| S:13644 E:13659 ||| JJ
disease  ||| S:13659 E:13667 ||| NN
( ||| S:13667 E:13668 ||| -LRB-
ASCVD ||| S:13668 E:13673 ||| NNP
) ||| S:13673 E:13674 ||| -RRB-
,  ||| S:13674 E:13676 ||| ,
and  ||| S:13676 E:13680 ||| CC
ST-T  ||| S:13680 E:13695 ||| JJ
wave  ||| S:13695 E:13700 ||| NN
changes ||| S:13700 E:13707 ||| NNS
,  ||| S:13707 E:13709 ||| ,
were  ||| S:13709 E:13714 ||| VBD
reported  ||| S:13714 E:13723 ||| VBN
more  ||| S:13723 E:13728 ||| RBR
often  ||| S:13728 E:13734 ||| RB
in  ||| S:13734 E:13737 ||| IN
chlorthalidone  ||| S:13737 E:13762 ||| NN
than  ||| S:13762 E:13767 ||| IN
in  ||| S:13767 E:13770 ||| IN
doxazosin  ||| S:13770 E:13780 ||| JJ
participants ||| S:13780 E:13792 ||| NNS
,  ||| S:13792 E:13794 ||| ,
though  ||| S:13794 E:13801 ||| IN
the  ||| S:13801 E:13805 ||| DT
differences  ||| S:13805 E:13827 ||| NNS
were  ||| S:13827 E:13832 ||| VBD
not  ||| S:13832 E:13836 ||| RB
significant ||| S:13836 E:13847 ||| JJ
.  ||| S:13847 E:13849 ||| .
Chlorthalidone  ||| S:13849 E:13864 ||| NNP
and  ||| S:13864 E:13868 ||| CC
doxazosin  ||| S:13868 E:13888 ||| JJ
participants  ||| S:13888 E:13901 ||| NNS
with  ||| S:13901 E:13906 ||| IN
hospitalized  ||| S:13906 E:13919 ||| NN
or  ||| S:13919 E:13922 ||| CC
fatal  ||| S:13922 E:13928 ||| JJ
HF  ||| S:13928 E:13931 ||| NNP
had  ||| S:13931 E:13935 ||| VBD
similar  ||| S:13935 E:13953 ||| JJ
pre-trial  ||| S:13953 E:13963 ||| JJ
antihypertensive  ||| S:13963 E:13980 ||| JJ
treatment  ||| S:13980 E:13990 ||| NN
durations ||| S:13990 E:13999 ||| NN
.  ||| S:13999 E:14001 ||| .
None  ||| S:14001 E:14006 ||| NN
of  ||| S:14006 E:14019 ||| IN
these  ||| S:14019 E:14025 ||| DT
differences  ||| S:14025 E:14037 ||| NNS
was  ||| S:14037 E:14041 ||| VBD
significant  ||| S:14041 E:14053 ||| JJ
at  ||| S:14053 E:14067 ||| IN
P  ||| S:14067 E:14069 ||| NNP
< ||| S:14069 E:14071 ||| SYM
.05 ||| S:14071 E:14074 ||| NNP
.  ||| S:14074 E:14086 ||| .
Participants  ||| S:14086 E:14099 ||| NNS
with  ||| S:14099 E:14104 ||| IN
HF  ||| S:14104 E:14107 ||| NNP
events  ||| S:14107 E:14114 ||| NNS
displayed  ||| S:14114 E:14124 ||| VBD
higher  ||| S:14124 E:14131 ||| JJR
rates  ||| S:14131 E:14137 ||| NNS
of  ||| S:14137 E:14150 ||| IN
most  ||| S:14150 E:14155 ||| RBS
cardiovascular  ||| S:14155 E:14170 ||| JJ
risk  ||| S:14170 E:14175 ||| NN
factors  ||| S:14175 E:14183 ||| NNS
compared  ||| S:14183 E:14192 ||| VBN
to  ||| S:14192 E:14195 ||| TO
those  ||| S:14195 E:14211 ||| DT
without  ||| S:14211 E:14219 ||| IN
HF  ||| S:14219 E:14222 ||| NNP
events ||| S:14222 E:14228 ||| NNS
.  ||| S:14228 E:14230 ||| .
Approximately  ||| S:14230 E:14244 ||| RB
35-36 ||| S:14244 E:14249 ||| CD
%  ||| S:14249 E:14251 ||| NN
of  ||| S:14251 E:14254 ||| IN
chlorthalidone  ||| S:14254 E:14279 ||| NN
and  ||| S:14279 E:14283 ||| CC
doxazosin  ||| S:14283 E:14293 ||| JJ
participants  ||| S:14293 E:14306 ||| NNS
with  ||| S:14306 E:14311 ||| IN
fatal  ||| S:14311 E:14317 ||| JJ
or  ||| S:14317 E:14320 ||| CC
hospitalized  ||| S:14320 E:14333 ||| VBN
HF  ||| S:14333 E:14346 ||| NNP
had  ||| S:14346 E:14350 ||| VBD
reported  ||| S:14350 E:14359 ||| VBN
prior  ||| S:14359 E:14365 ||| JJ
MI  ||| S:14365 E:14368 ||| NNP
or  ||| S:14368 E:14371 ||| CC
stroke  ||| S:14371 E:14378 ||| NN
as  ||| S:14378 E:14381 ||| IN
baseline  ||| S:14381 E:14390 ||| JJ
eligibility  ||| S:14390 E:14412 ||| JJ
risk  ||| S:14412 E:14417 ||| NN
factors ||| S:14417 E:14424 ||| NNS
,  ||| S:14424 E:14426 ||| ,
compared  ||| S:14426 E:14435 ||| VBN
to  ||| S:14435 E:14438 ||| TO
22-23 ||| S:14438 E:14443 ||| CD
%  ||| S:14443 E:14445 ||| NN
of  ||| S:14445 E:14448 ||| IN
those  ||| S:14448 E:14454 ||| DT
without  ||| S:14454 E:14462 ||| IN
HF  ||| S:14462 E:14465 ||| NNP
(  ||| S:14465 E:14478 ||| -LRB-
P  ||| S:14478 E:14480 ||| NNP
< ||| S:14480 E:14482 ||| SYM
.001 ||| S:14482 E:14486 ||| NNP
) ||| S:14486 E:14487 ||| -RRB-
.  ||| S:14487 E:14489 ||| .
Participants  ||| S:14489 E:14502 ||| NNS
with  ||| S:14502 E:14517 ||| IN
hospitalized ||| S:14517 E:14529 ||| FW
/ ||| S:14529 E:14530 ||| FW
fatal  ||| S:14530 E:14536 ||| FW
HF  ||| S:14536 E:14539 ||| NNP
had  ||| S:14539 E:14543 ||| VBD
significantly  ||| S:14543 E:14557 ||| RB
higher  ||| S:14557 E:14564 ||| JJR
rates  ||| S:14564 E:14570 ||| NNS
of  ||| S:14570 E:14583 ||| IN
pre-randomization  ||| S:14583 E:14601 ||| FW
coronary  ||| S:14601 E:14610 ||| FW
artery  ||| S:14610 E:14617 ||| FW
bypass  ||| S:14617 E:14624 ||| FW
grafts  ||| S:14624 E:14631 ||| FW
( ||| S:14631 E:14632 ||| -LRB-
CABGs ||| S:14632 E:14637 ||| NNP
)  ||| S:14637 E:14649 ||| -RRB-
and  ||| S:14649 E:14653 ||| CC
coronary  ||| S:14653 E:14662 ||| JJ
angioplasties  ||| S:14662 E:14676 ||| NNS
( ||| S:14676 E:14677 ||| -LRB-
19-23 ||| S:14677 E:14682 ||| NNP
%  ||| S:14682 E:14684 ||| NN
of  ||| S:14684 E:14687 ||| IN
those  ||| S:14687 E:14693 ||| DT
with  ||| S:14693 E:14698 ||| IN
HF  ||| S:14698 E:14701 ||| NNP
vs.  ||| S:14701 E:14715 ||| CC
13 ||| S:14715 E:14717 ||| CD
%  ||| S:14717 E:14719 ||| NN
of  ||| S:14719 E:14722 ||| IN
those  ||| S:14722 E:14728 ||| DT
without ||| S:14728 E:14735 ||| NN
;  ||| S:14735 E:14748 ||| :
P  ||| S:14748 E:14750 ||| NNP
< ||| S:14750 E:14752 ||| SYM
.001 ||| S:14752 E:14756 ||| NNP
)  ||| S:14756 E:14758 ||| -RRB-
and  ||| S:14758 E:14762 ||| CC
other  ||| S:14762 E:14778 ||| JJ
atherosclerotic  ||| S:14778 E:14794 ||| JJ
cardiovascular  ||| S:14794 E:14809 ||| JJ
disease  ||| S:14809 E:14817 ||| NN
( ||| S:14817 E:14818 ||| -LRB-
ASCVD ||| S:14818 E:14823 ||| NNP
)  ||| S:14823 E:14825 ||| -RRB-
( ||| S:14825 E:14826 ||| -LRB-
29-33 ||| S:14826 E:14831 ||| NNP
%  ||| S:14831 E:14833 ||| NN
of  ||| S:14833 E:14846 ||| IN
those  ||| S:14846 E:14852 ||| DT
with  ||| S:14852 E:14857 ||| IN
HF  ||| S:14857 E:14860 ||| NNP
vs.  ||| S:14860 E:14864 ||| FW
23-25 ||| S:14864 E:14869 ||| FW
%  ||| S:14869 E:14871 ||| NN
of  ||| S:14871 E:14874 ||| IN
those  ||| S:14874 E:14880 ||| DT
without ||| S:14880 E:14887 ||| NN
;  ||| S:14887 E:14900 ||| :
P  ||| S:14900 E:14902 ||| NNP
< ||| S:14902 E:14904 ||| SYM
.001 ||| S:14904 E:14908 ||| NNP
) ||| S:14908 E:14909 ||| -RRB-
.  ||| S:14909 E:14911 ||| .
Diabetes  ||| S:14911 E:14920 ||| NN
as  ||| S:14920 E:14923 ||| IN
a  ||| S:14923 E:14935 ||| DT
baseline  ||| S:14935 E:14944 ||| NN
risk  ||| S:14944 E:14949 ||| NN
factor  ||| S:14949 E:14956 ||| NN
occurred  ||| S:14956 E:14965 ||| VBD
more  ||| S:14965 E:14970 ||| RBR
frequently  ||| S:14970 E:14981 ||| RB
in  ||| S:14981 E:14984 ||| IN
those  ||| S:14984 E:15000 ||| DT
with  ||| S:15000 E:15005 ||| IN
HF ||| S:15005 E:15007 ||| NNP
:  ||| S:15007 E:15009 ||| :
47-48 ||| S:15009 E:15014 ||| CD
%  ||| S:15014 E:15016 ||| NN
in  ||| S:15016 E:15019 ||| IN
those  ||| S:15019 E:15025 ||| DT
with  ||| S:15025 E:15030 ||| IN
HF ||| S:15030 E:15032 ||| NNP
,  ||| S:15032 E:15034 ||| ,
35-36 ||| S:15034 E:15039 ||| CD
%  ||| S:15039 E:15041 ||| NN
in  ||| S:15041 E:15044 ||| IN
those  ||| S:15044 E:15050 ||| DT
without  ||| S:15050 E:15068 ||| IN
(  ||| S:15068 E:15081 ||| -LRB-
P  ||| S:15081 E:15083 ||| NNP
< ||| S:15083 E:15085 ||| SYM
.001 ||| S:15085 E:15089 ||| NNP
) ||| S:15089 E:15090 ||| -RRB-
.  ||| S:15090 E:15092 ||| .
Left  ||| S:15092 E:15097 ||| VBN
ventricular  ||| S:15097 E:15119 ||| JJ
hypertrophy  ||| S:15119 E:15131 ||| NNS
( ||| S:15131 E:15132 ||| -LRB-
LVH ||| S:15132 E:15135 ||| NNP
)  ||| S:15135 E:15137 ||| -RRB-
by  ||| S:15137 E:15140 ||| IN
ECG  ||| S:15140 E:15144 ||| NNP
was  ||| S:15144 E:15148 ||| VBD
a  ||| S:15148 E:15150 ||| DT
risk  ||| S:15150 E:15155 ||| NN
factor  ||| S:15155 E:15162 ||| NN
in  ||| S:15162 E:15165 ||| IN
21-22 ||| S:15165 E:15170 ||| CD
%  ||| S:15170 E:15172 ||| NN
of  ||| S:15172 E:15185 ||| IN
those  ||| S:15185 E:15191 ||| DT
who  ||| S:15191 E:15195 ||| WP
later  ||| S:15195 E:15201 ||| RB
developed  ||| S:15201 E:15211 ||| VBN
HF ||| S:15211 E:15213 ||| NNP
,  ||| S:15213 E:15215 ||| ,
compared  ||| S:15215 E:15224 ||| VBN
with  ||| S:15224 E:15229 ||| IN
16 ||| S:15229 E:15231 ||| CD
%  ||| S:15231 E:15233 ||| NN
of  ||| S:15233 E:15236 ||| IN
those  ||| S:15236 E:15252 ||| DT
in  ||| S:15252 E:15255 ||| IN
each  ||| S:15255 E:15260 ||| DT
group  ||| S:15260 E:15266 ||| NN
who  ||| S:15266 E:15270 ||| WP
did  ||| S:15270 E:15274 ||| VBD
not  ||| S:15274 E:15278 ||| RB
develop  ||| S:15278 E:15286 ||| VB
HF  ||| S:15286 E:15289 ||| NNP
(  ||| S:15289 E:15302 ||| -LRB-
P  ||| S:15302 E:15304 ||| NNP
< ||| S:15304 E:15306 ||| SYM
.001 ||| S:15306 E:15310 ||| NNP
) ||| S:15310 E:15311 ||| -RRB-
.  ||| S:15311 E:15323 ||| .
Baseline  ||| S:15323 E:15332 ||| JJ
pulse  ||| S:15332 E:15338 ||| NN
pressure  ||| S:15338 E:15347 ||| NN
( ||| S:15347 E:15348 ||| -LRB-
PP ||| S:15348 E:15350 ||| NNP
)  ||| S:15350 E:15352 ||| -RRB-
showed  ||| S:15352 E:15359 ||| VBD
some  ||| S:15359 E:15364 ||| DT
variation  ||| S:15364 E:15384 ||| NN
between  ||| S:15384 E:15392 ||| IN
participants  ||| S:15392 E:15405 ||| NNS
who  ||| S:15405 E:15409 ||| WP
did  ||| S:15409 E:15413 ||| VBD
and  ||| S:15413 E:15417 ||| CC
did  ||| S:15417 E:15421 ||| VBD
not  ||| S:15421 E:15425 ||| RB
develop  ||| S:15425 E:15433 ||| VB
HF ||| S:15433 E:15435 ||| NNP
.  ||| S:15435 E:15437 ||| .
For  ||| S:15437 E:15451 ||| IN
participants  ||| S:15451 E:15464 ||| NNS
with  ||| S:15464 E:15469 ||| IN
subsequent  ||| S:15469 E:15480 ||| JJ
hospitalization  ||| S:15480 E:15496 ||| NN
or  ||| S:15496 E:15499 ||| CC
death  ||| S:15499 E:15515 ||| NN
from  ||| S:15515 E:15520 ||| IN
HF ||| S:15520 E:15522 ||| NNP
,  ||| S:15522 E:15524 ||| ,
PP  ||| S:15524 E:15527 ||| NNP
was  ||| S:15527 E:15531 ||| VBD
67  ||| S:15531 E:15534 ||| CD
and  ||| S:15534 E:15538 ||| CC
68  ||| S:15538 E:15541 ||| CD
mm  ||| S:15541 E:15544 ||| CD
Hg  ||| S:15544 E:15547 ||| NNS
for  ||| S:15547 E:15551 ||| IN
the  ||| S:15551 E:15555 ||| DT
chlorthalidone  ||| S:15555 E:15580 ||| NN
and  ||| S:15580 E:15584 ||| CC
doxazosin  ||| S:15584 E:15594 ||| JJ
groups ||| S:15594 E:15600 ||| NNS
,  ||| S:15600 E:15602 ||| ,
respectively ||| S:15602 E:15614 ||| RB
.  ||| S:15614 E:15616 ||| .
Treated ||| S:15616 E:15623 ||| NNP
,  ||| S:15623 E:15635 ||| ,
non-hospitalized  ||| S:15635 E:15652 ||| JJ
participants  ||| S:15652 E:15665 ||| NNS
showed  ||| S:15665 E:15672 ||| VBD
a  ||| S:15672 E:15674 ||| DT
lower  ||| S:15674 E:15680 ||| JJR
mean  ||| S:15680 E:15695 ||| JJ
baseline  ||| S:15695 E:15704 ||| NN
PP  ||| S:15704 E:15707 ||| NN
of  ||| S:15707 E:15710 ||| IN
65  ||| S:15710 E:15713 ||| CD
( ||| S:15713 E:15714 ||| -LRB-
chlorthalidone  ||| S:15714 E:15729 ||| JJ
group ||| S:15729 E:15734 ||| NN
)  ||| S:15734 E:15736 ||| -RRB-
and  ||| S:15736 E:15740 ||| CC
64  ||| S:15740 E:15743 ||| CD
mm  ||| S:15743 E:15746 ||| JJ
Hg  ||| S:15746 E:15759 ||| NNP
( ||| S:15759 E:15760 ||| -LRB-
doxazosin  ||| S:15760 E:15770 ||| JJ
group ||| S:15770 E:15775 ||| NN
) ||| S:15775 E:15776 ||| -RRB-
,  ||| S:15776 E:15778 ||| ,
and  ||| S:15778 E:15782 ||| CC
an  ||| S:15782 E:15785 ||| DT
even  ||| S:15785 E:15790 ||| RB
lower  ||| S:15790 E:15796 ||| RBR
mean  ||| S:15796 E:15801 ||| JJ
PP  ||| S:15801 E:15804 ||| NN
in  ||| S:15804 E:15807 ||| IN
those  ||| S:15807 E:15823 ||| DT
without  ||| S:15823 E:15831 ||| IN
HF  ||| S:15831 E:15834 ||| NNP
( ||| S:15834 E:15835 ||| -LRB-
62  ||| S:15835 E:15838 ||| CD
mm  ||| S:15838 E:15841 ||| CD
Hg  ||| S:15841 E:15844 ||| NNS
in  ||| S:15844 E:15847 ||| IN
each  ||| S:15847 E:15852 ||| DT
group ||| S:15852 E:15857 ||| NN
) ||| S:15857 E:15858 ||| -RRB-
.  ||| S:15858 E:15888 ||| .
Medical  ||| S:15888 E:15896 ||| NNP
Management  ||| S:15896 E:15917 ||| NNP
Table  ||| S:15917 E:15923 ||| NNP
2presents  ||| S:15923 E:15933 ||| NNP
post-event  ||| S:15933 E:15944 ||| JJ
pharmacologic  ||| S:15944 E:15958 ||| JJ
treatment  ||| S:15958 E:15968 ||| NN
of  ||| S:15968 E:15981 ||| IN
participants  ||| S:15981 E:15994 ||| NNS
with  ||| S:15994 E:15999 ||| IN
HF  ||| S:15999 E:16002 ||| NNP
and  ||| S:16002 E:16006 ||| CC
antihypertensive  ||| S:16006 E:16023 ||| JJ
treatment  ||| S:16023 E:16033 ||| NN
of  ||| S:16033 E:16046 ||| IN
participants  ||| S:16046 E:16059 ||| NNS
without  ||| S:16059 E:16067 ||| IN
HF ||| S:16067 E:16069 ||| NNP
.  ||| S:16069 E:16071 ||| .
Following  ||| S:16071 E:16081 ||| VBG
hospitalization  ||| S:16081 E:16097 ||| NN
for  ||| S:16097 E:16111 ||| IN
HF ||| S:16111 E:16113 ||| NNP
,  ||| S:16113 E:16115 ||| ,
36 ||| S:16115 E:16117 ||| CD
%  ||| S:16117 E:16119 ||| NN
( ||| S:16119 E:16120 ||| -LRB-
83 ||| S:16120 E:16122 ||| CD
/ ||| S:16122 E:16123 ||| CD
232 ||| S:16123 E:16126 ||| CD
)  ||| S:16126 E:16128 ||| -RRB-
of  ||| S:16128 E:16131 ||| IN
chlorthalidone  ||| S:16131 E:16146 ||| JJ
participants  ||| S:16146 E:16159 ||| NNS
and  ||| S:16159 E:16163 ||| CC
45 ||| S:16163 E:16165 ||| CD
%  ||| S:16165 E:16177 ||| NN
( ||| S:16177 E:16178 ||| -LRB-
126 ||| S:16178 E:16181 ||| CD
/ ||| S:16181 E:16182 ||| CD
281 ||| S:16182 E:16185 ||| CD
)  ||| S:16185 E:16187 ||| -RRB-
of  ||| S:16187 E:16190 ||| IN
doxazosin  ||| S:16190 E:16200 ||| JJ
participants  ||| S:16200 E:16213 ||| NNS
remained  ||| S:16213 E:16222 ||| VBD
on  ||| S:16222 E:16225 ||| IN
their  ||| S:16225 E:16241 ||| PRP$
blinded  ||| S:16241 E:16249 ||| JJ
medications ||| S:16249 E:16260 ||| NN
.  ||| S:16260 E:16262 ||| .
Percentages  ||| S:16262 E:16274 ||| NNS
of  ||| S:16274 E:16277 ||| IN
participants  ||| S:16277 E:16290 ||| NNS
on  ||| S:16290 E:16303 ||| IN
open-label  ||| S:16303 E:16314 ||| JJ
diuretics  ||| S:16314 E:16324 ||| NN
and  ||| S:16324 E:16328 ||| CC
ACE-inhibitors  ||| S:16328 E:16343 ||| NNP
were  ||| S:16343 E:16348 ||| VBD
similar  ||| S:16348 E:16366 ||| JJ
following  ||| S:16366 E:16376 ||| VBG
the  ||| S:16376 E:16380 ||| DT
event ||| S:16380 E:16385 ||| NN
:  ||| S:16385 E:16387 ||| :
58 ||| S:16387 E:16389 ||| CD
%  ||| S:16389 E:16391 ||| NN
( ||| S:16391 E:16392 ||| -LRB-
135 ||| S:16392 E:16395 ||| CD
/ ||| S:16395 E:16396 ||| CD
232 ||| S:16396 E:16399 ||| CD
)  ||| S:16399 E:16401 ||| -RRB-
of  ||| S:16401 E:16404 ||| IN
chlorthalidone  ||| S:16404 E:16429 ||| JJ
participants  ||| S:16429 E:16442 ||| NNS
and  ||| S:16442 E:16446 ||| CC
64 ||| S:16446 E:16448 ||| CD
%  ||| S:16448 E:16450 ||| NN
( ||| S:16450 E:16451 ||| -LRB-
180 ||| S:16451 E:16454 ||| CD
/ ||| S:16454 E:16455 ||| CD
281 ||| S:16455 E:16458 ||| CD
)  ||| S:16458 E:16460 ||| -RRB-
of  ||| S:16460 E:16463 ||| IN
doxazosin  ||| S:16463 E:16473 ||| JJ
participants  ||| S:16473 E:16496 ||| NNS
were  ||| S:16496 E:16501 ||| VBD
prescribed  ||| S:16501 E:16512 ||| VBN
open-label  ||| S:16512 E:16523 ||| JJ
diuretics ||| S:16523 E:16532 ||| NN
;  ||| S:16532 E:16534 ||| :
39 ||| S:16534 E:16536 ||| CD
%  ||| S:16536 E:16538 ||| NN
( ||| S:16538 E:16539 ||| -LRB-
90 ||| S:16539 E:16541 ||| CD
/ ||| S:16541 E:16542 ||| CD
232 ||| S:16542 E:16545 ||| CD
)  ||| S:16545 E:16547 ||| -RRB-
of  ||| S:16547 E:16560 ||| IN
chlorthalidone  ||| S:16560 E:16575 ||| JJ
participants  ||| S:16575 E:16588 ||| NNS
and  ||| S:16588 E:16592 ||| CC
41 ||| S:16592 E:16594 ||| CD
%  ||| S:16594 E:16596 ||| NN
( ||| S:16596 E:16597 ||| -LRB-
114 ||| S:16597 E:16600 ||| CD
/ ||| S:16600 E:16601 ||| CD
281 ||| S:16601 E:16604 ||| CD
)  ||| S:16604 E:16606 ||| -RRB-
of  ||| S:16606 E:16619 ||| IN
doxazosin  ||| S:16619 E:16629 ||| JJ
participants  ||| S:16629 E:16642 ||| NNS
were  ||| S:16642 E:16647 ||| VBD
prescribed  ||| S:16647 E:16658 ||| VBN
open-label  ||| S:16658 E:16679 ||| JJ
ACE-inhibitors ||| S:16679 E:16693 ||| NN
.  ||| S:16693 E:16695 ||| .
Beta-blockers  ||| S:16695 E:16709 ||| NNP
were  ||| S:16709 E:16714 ||| VBD
prescribed  ||| S:16714 E:16725 ||| VBN
for  ||| S:16725 E:16729 ||| IN
14 ||| S:16729 E:16731 ||| CD
%  ||| S:16731 E:16733 ||| NN
of  ||| S:16733 E:16746 ||| IN
each  ||| S:16746 E:16751 ||| DT
group  ||| S:16751 E:16757 ||| NN
following  ||| S:16757 E:16767 ||| VBG
the  ||| S:16767 E:16771 ||| DT
event ||| S:16771 E:16776 ||| NN
,  ||| S:16776 E:16778 ||| ,
which  ||| S:16778 E:16784 ||| WDT
was  ||| S:16784 E:16788 ||| VBD
actually  ||| S:16788 E:16807 ||| RB
somewhat  ||| S:16807 E:16816 ||| RB
less  ||| S:16816 E:16821 ||| JJR
than  ||| S:16821 E:16826 ||| IN
for  ||| S:16826 E:16830 ||| IN
participants  ||| S:16830 E:16843 ||| NNS
who  ||| S:16843 E:16847 ||| WP
did  ||| S:16847 E:16851 ||| VBD
not  ||| S:16851 E:16855 ||| RB
develop  ||| S:16855 E:16873 ||| VB
HF ||| S:16873 E:16875 ||| NNP
.  ||| S:16875 E:16877 ||| .
Three-quarters  ||| S:16877 E:16892 ||| NNS
of  ||| S:16892 E:16895 ||| IN
hospitalized  ||| S:16895 E:16908 ||| JJ
HF  ||| S:16908 E:16911 ||| NN
participants  ||| S:16911 E:16924 ||| NNS
in  ||| S:16924 E:16937 ||| IN
each  ||| S:16937 E:16942 ||| DT
group  ||| S:16942 E:16948 ||| NN
( ||| S:16948 E:16949 ||| -LRB-
169 ||| S:16949 E:16952 ||| CD
/ ||| S:16952 E:16953 ||| CD
232  ||| S:16953 E:16957 ||| CD
in  ||| S:16957 E:16960 ||| IN
chlorthalidone  ||| S:16960 E:16975 ||| JJ
group ||| S:16975 E:16980 ||| NN
,  ||| S:16980 E:16982 ||| ,
210 ||| S:16982 E:16985 ||| CD
/ ||| S:16985 E:16986 ||| CD
281  ||| S:16986 E:16990 ||| CD
in  ||| S:16990 E:17003 ||| IN
doxazosin  ||| S:17003 E:17013 ||| JJ
group ||| S:17013 E:17018 ||| NN
)  ||| S:17018 E:17020 ||| -RRB-
received  ||| S:17020 E:17029 ||| VBD
at  ||| S:17029 E:17032 ||| IN
least  ||| S:17032 E:17038 ||| JJS
one  ||| S:17038 E:17042 ||| CD
of  ||| S:17042 E:17045 ||| IN
the  ||| S:17045 E:17049 ||| DT
three  ||| S:17049 E:17065 ||| CD
medications  ||| S:17065 E:17077 ||| NNS
( ||| S:17077 E:17078 ||| -LRB-
diuretic ||| S:17078 E:17086 ||| UH
,  ||| S:17086 E:17088 ||| ,
ACE-inhibitor ||| S:17088 E:17101 ||| NNP
,  ||| S:17101 E:17103 ||| ,
or  ||| S:17103 E:17106 ||| CC
beta-blocker ||| S:17106 E:17118 ||| NN
)  ||| S:17118 E:17130 ||| -RRB-
post-hospitalization ||| S:17130 E:17150 ||| JJ
.  ||| S:17150 E:17162 ||| .
Among  ||| S:17162 E:17168 ||| IN
participants  ||| S:17168 E:17181 ||| NNS
treated  ||| S:17181 E:17189 ||| VBN
but  ||| S:17189 E:17193 ||| CC
not  ||| S:17193 E:17197 ||| RB
hospitalized  ||| S:17197 E:17210 ||| VBN
for  ||| S:17210 E:17224 ||| IN
HF ||| S:17224 E:17226 ||| NNP
,  ||| S:17226 E:17228 ||| ,
58 ||| S:17228 E:17230 ||| CD
%  ||| S:17230 E:17232 ||| NN
( ||| S:17232 E:17233 ||| -LRB-
54 ||| S:17233 E:17235 ||| CD
/ ||| S:17235 E:17236 ||| CD
93 ||| S:17236 E:17238 ||| CD
)  ||| S:17238 E:17240 ||| -RRB-
of  ||| S:17240 E:17243 ||| IN
the  ||| S:17243 E:17247 ||| DT
chlorthalidone  ||| S:17247 E:17262 ||| JJ
group  ||| S:17262 E:17268 ||| NN
and  ||| S:17268 E:17272 ||| CC
64 ||| S:17272 E:17274 ||| CD
%  ||| S:17274 E:17286 ||| NN
( ||| S:17286 E:17287 ||| -LRB-
93 ||| S:17287 E:17289 ||| CD
/ ||| S:17289 E:17290 ||| CD
145 ||| S:17290 E:17293 ||| CD
)  ||| S:17293 E:17295 ||| -RRB-
of  ||| S:17295 E:17298 ||| IN
the  ||| S:17298 E:17302 ||| DT
doxazosin  ||| S:17302 E:17312 ||| JJ
group  ||| S:17312 E:17318 ||| NN
remained  ||| S:17318 E:17327 ||| VBD
on  ||| S:17327 E:17330 ||| IN
their  ||| S:17330 E:17336 ||| PRP$
blinded  ||| S:17336 E:17354 ||| JJ
medication ||| S:17354 E:17364 ||| NN
.  ||| S:17364 E:17366 ||| .
Over  ||| S:17366 E:17371 ||| IN
60 ||| S:17371 E:17373 ||| CD
%  ||| S:17373 E:17375 ||| NN
of  ||| S:17375 E:17378 ||| IN
participants  ||| S:17378 E:17391 ||| NNS
in  ||| S:17391 E:17394 ||| IN
each  ||| S:17394 E:17399 ||| DT
group  ||| S:17399 E:17405 ||| NN
were  ||| S:17405 E:17420 ||| VBD
prescribed  ||| S:17420 E:17431 ||| VBN
open-label  ||| S:17431 E:17442 ||| JJ
diuretics  ||| S:17442 E:17452 ||| NN
and  ||| S:17452 E:17456 ||| CC
over  ||| S:17456 E:17461 ||| IN
30 ||| S:17461 E:17463 ||| CD
%  ||| S:17463 E:17465 ||| NN
received  ||| S:17465 E:17484 ||| VBD
ACE-inhibitors ||| S:17484 E:17498 ||| JJ
.  ||| S:17498 E:17500 ||| .
Open-label  ||| S:17500 E:17511 ||| JJ
beta-blocker  ||| S:17511 E:17524 ||| NN
use  ||| S:17524 E:17528 ||| NN
post-event  ||| S:17528 E:17549 ||| NN
occurred  ||| S:17549 E:17558 ||| VBD
in  ||| S:17558 E:17561 ||| IN
19 ||| S:17561 E:17563 ||| CD
%  ||| S:17563 E:17565 ||| NN
( ||| S:17565 E:17566 ||| -LRB-
18 ||| S:17566 E:17568 ||| CD
/ ||| S:17568 E:17569 ||| CD
93 ||| S:17569 E:17571 ||| CD
)  ||| S:17571 E:17573 ||| -RRB-
of  ||| S:17573 E:17576 ||| IN
the  ||| S:17576 E:17580 ||| DT
chlorthalidone  ||| S:17580 E:17595 ||| JJ
group  ||| S:17595 E:17601 ||| NN
and  ||| S:17601 E:17615 ||| CC
22 ||| S:17615 E:17617 ||| CD
%  ||| S:17617 E:17619 ||| NN
( ||| S:17619 E:17620 ||| -LRB-
32 ||| S:17620 E:17622 ||| CD
/ ||| S:17622 E:17623 ||| CD
145 ||| S:17623 E:17626 ||| CD
)  ||| S:17626 E:17628 ||| -RRB-
of  ||| S:17628 E:17631 ||| IN
the  ||| S:17631 E:17635 ||| DT
doxazosin  ||| S:17635 E:17645 ||| JJ
group ||| S:17645 E:17650 ||| NN
,  ||| S:17650 E:17652 ||| ,
approximately  ||| S:17652 E:17666 ||| RB
the  ||| S:17666 E:17680 ||| DT
same  ||| S:17680 E:17685 ||| JJ
frequency  ||| S:17685 E:17695 ||| NN
as  ||| S:17695 E:17698 ||| IN
in  ||| S:17698 E:17701 ||| IN
participants  ||| S:17701 E:17714 ||| NNS
without  ||| S:17714 E:17722 ||| IN
HF ||| S:17722 E:17724 ||| NNP
.  ||| S:17724 E:17726 ||| .
In  ||| S:17726 E:17729 ||| IN
both  ||| S:17729 E:17744 ||| DT
treatment  ||| S:17744 E:17754 ||| NN
groups ||| S:17754 E:17760 ||| NNS
,  ||| S:17760 E:17762 ||| ,
a  ||| S:17762 E:17764 ||| DT
diuretic ||| S:17764 E:17772 ||| NN
,  ||| S:17772 E:17774 ||| ,
ACE-inhibitor  ||| S:17774 E:17788 ||| JJ
or  ||| S:17788 E:17801 ||| CC
beta-blocker  ||| S:17801 E:17814 ||| NN
was  ||| S:17814 E:17818 ||| VBD
prescribed  ||| S:17818 E:17829 ||| VBN
for  ||| S:17829 E:17833 ||| IN
over  ||| S:17833 E:17838 ||| IN
75 ||| S:17838 E:17840 ||| CD
%  ||| S:17840 E:17842 ||| NN
of  ||| S:17842 E:17845 ||| IN
these  ||| S:17845 E:17861 ||| DT
participants  ||| S:17861 E:17874 ||| NNS
( ||| S:17874 E:17875 ||| -LRB-
72 ||| S:17875 E:17877 ||| CD
/ ||| S:17877 E:17878 ||| CD
93  ||| S:17878 E:17881 ||| CD
in  ||| S:17881 E:17884 ||| IN
chlorthalidone  ||| S:17884 E:17899 ||| JJ
group ||| S:17899 E:17904 ||| NN
,  ||| S:17904 E:17906 ||| ,
119 ||| S:17906 E:17909 ||| CD
/ ||| S:17909 E:17910 ||| CD
145  ||| S:17910 E:17914 ||| CD
in  ||| S:17914 E:17927 ||| IN
doxazosin  ||| S:17927 E:17937 ||| JJ
group ||| S:17937 E:17942 ||| NN
) ||| S:17942 E:17943 ||| -RRB-
.  ||| S:17943 E:17973 ||| .
Ejection  ||| S:17973 E:17982 ||| NNP
Fraction  ||| S:17982 E:17991 ||| NNP
Review  ||| S:17991 E:18008 ||| NNP
Table  ||| S:18008 E:18014 ||| NNP
3displays  ||| S:18014 E:18024 ||| CD
the  ||| S:18024 E:18028 ||| DT
ejection  ||| S:18028 E:18037 ||| JJ
fraction  ||| S:18037 E:18046 ||| NN
data ||| S:18046 E:18050 ||| NNS
.  ||| S:18050 E:18052 ||| .
About  ||| S:18052 E:18058 ||| IN
half  ||| S:18058 E:18073 ||| NN
( ||| S:18073 E:18074 ||| -LRB-
178 ||| S:18074 E:18077 ||| CD
/ ||| S:18077 E:18078 ||| CD
361 ||| S:18078 E:18081 ||| CD
)  ||| S:18081 E:18083 ||| -RRB-
of  ||| S:18083 E:18086 ||| IN
reviewed  ||| S:18086 E:18095 ||| FW
discharge  ||| S:18095 E:18105 ||| FW
summaries  ||| S:18105 E:18115 ||| FW
mentioned  ||| S:18115 E:18135 ||| FW
ejection  ||| S:18135 E:18144 ||| FW
fractions  ||| S:18144 E:18154 ||| FW
measured  ||| S:18154 E:18163 ||| VBN
during  ||| S:18163 E:18170 ||| IN
hospitalization ||| S:18170 E:18185 ||| NN
,  ||| S:18185 E:18197 ||| ,
two-thirds  ||| S:18197 E:18208 ||| NNS
( ||| S:18208 E:18209 ||| -LRB-
116 ||| S:18209 E:18212 ||| CD
/ ||| S:18212 E:18213 ||| CD
169 ||| S:18213 E:18216 ||| CD
)  ||| S:18216 E:18218 ||| -RRB-
of  ||| S:18218 E:18221 ||| IN
which  ||| S:18221 E:18227 ||| WDT
had  ||| S:18227 E:18231 ||| VBD
quantitative  ||| S:18231 E:18254 ||| JJ
measurements  ||| S:18254 E:18267 ||| NNS
reported  ||| S:18267 E:18276 ||| VBD
in  ||| S:18276 E:18279 ||| IN
the  ||| S:18279 E:18283 ||| DT
discharge  ||| S:18283 E:18293 ||| NN
summaries  ||| S:18293 E:18303 ||| NNS
( ||| S:18303 E:18304 ||| -LRB-
data  ||| S:18304 E:18319 ||| NNS
not  ||| S:18319 E:18323 ||| RB
given ||| S:18323 E:18328 ||| VBN
) ||| S:18328 E:18329 ||| -RRB-
.  ||| S:18329 E:18331 ||| .
Considering  ||| S:18331 E:18343 ||| VBG
only  ||| S:18343 E:18348 ||| RB
the  ||| S:18348 E:18352 ||| DT
earliest  ||| S:18352 E:18361 ||| JJS
ejection  ||| S:18361 E:18380 ||| JJ
fraction  ||| S:18380 E:18389 ||| NN
information  ||| S:18389 E:18401 ||| NN
ascertained  ||| S:18401 E:18413 ||| NN
for  ||| S:18413 E:18417 ||| IN
each  ||| S:18417 E:18422 ||| DT
HF  ||| S:18422 E:18425 ||| NNP
participant ||| S:18425 E:18436 ||| NN
,  ||| S:18436 E:18448 ||| ,
63 ||| S:18448 E:18450 ||| CD
%  ||| S:18450 E:18452 ||| NN
( ||| S:18452 E:18453 ||| -LRB-
29 ||| S:18453 E:18455 ||| CD
/ ||| S:18455 E:18456 ||| CD
46 ||| S:18456 E:18458 ||| CD
)  ||| S:18458 E:18460 ||| -RRB-
of  ||| S:18460 E:18463 ||| IN
the  ||| S:18463 E:18467 ||| DT
chlorthalidone  ||| S:18467 E:18482 ||| NN
and  ||| S:18482 E:18486 ||| CC
70 ||| S:18486 E:18488 ||| CD
%  ||| S:18488 E:18490 ||| NN
( ||| S:18490 E:18491 ||| -LRB-
41 ||| S:18491 E:18493 ||| CD
/ ||| S:18493 E:18494 ||| CD
59 ||| S:18494 E:18496 ||| CD
)  ||| S:18496 E:18498 ||| -RRB-
of  ||| S:18498 E:18501 ||| IN
the  ||| S:18501 E:18515 ||| DT
doxazosin  ||| S:18515 E:18525 ||| JJ
participants  ||| S:18525 E:18538 ||| NNS
had  ||| S:18538 E:18542 ||| VBD
ejection  ||| S:18542 E:18551 ||| JJ
fractions  ||| S:18551 E:18561 ||| NNS
at  ||| S:18561 E:18564 ||| IN
or  ||| S:18564 E:18567 ||| CC
below  ||| S:18567 E:18583 ||| IN
40 ||| S:18583 E:18585 ||| CD
% ||| S:18585 E:18586 ||| NN
.  ||| S:18586 E:18588 ||| .
Just  ||| S:18588 E:18593 ||| RB
under  ||| S:18593 E:18599 ||| IN
half  ||| S:18599 E:18604 ||| NN
( ||| S:18604 E:18605 ||| -LRB-
27 ||| S:18605 E:18607 ||| CD
/ ||| S:18607 E:18608 ||| CD
59 ||| S:18608 E:18610 ||| CD
)  ||| S:18610 E:18612 ||| -RRB-
of  ||| S:18612 E:18615 ||| IN
the  ||| S:18615 E:18619 ||| DT
ejection  ||| S:18619 E:18628 ||| JJ
fractions  ||| S:18628 E:18648 ||| NNS
reported  ||| S:18648 E:18657 ||| VBD
in  ||| S:18657 E:18660 ||| IN
the  ||| S:18660 E:18664 ||| DT
doxazosin  ||| S:18664 E:18674 ||| JJ
group  ||| S:18674 E:18680 ||| NN
were  ||| S:18680 E:18685 ||| VBD
at  ||| S:18685 E:18688 ||| IN
or  ||| S:18688 E:18691 ||| CC
below  ||| S:18691 E:18697 ||| IN
30 ||| S:18697 E:18699 ||| CD
% ||| S:18699 E:18700 ||| NN
,  ||| S:18700 E:18712 ||| ,
compared  ||| S:18712 E:18721 ||| VBN
with  ||| S:18721 E:18726 ||| IN
one  ||| S:18726 E:18730 ||| CD
third  ||| S:18730 E:18736 ||| JJ
( ||| S:18736 E:18737 ||| -LRB-
15 ||| S:18737 E:18739 ||| CD
/ ||| S:18739 E:18740 ||| CD
46 ||| S:18740 E:18742 ||| CD
)  ||| S:18742 E:18744 ||| -RRB-
in  ||| S:18744 E:18747 ||| IN
the  ||| S:18747 E:18751 ||| DT
chlorthalidone  ||| S:18751 E:18776 ||| JJ
group ||| S:18776 E:18781 ||| NN
.  ||| S:18781 E:18783 ||| .
Two-thirds  ||| S:18783 E:18794 ||| NNS
of  ||| S:18794 E:18797 ||| IN
ejection  ||| S:18797 E:18806 ||| JJ
fractions  ||| S:18806 E:18816 ||| NNS
were  ||| S:18816 E:18821 ||| VBD
obtained  ||| S:18821 E:18830 ||| VBN
by  ||| S:18830 E:18843 ||| IN
echocardiograms ||| S:18843 E:18858 ||| NN
,  ||| S:18858 E:18860 ||| ,
though  ||| S:18860 E:18867 ||| IN
catheterizations  ||| S:18867 E:18884 ||| NN
accounted  ||| S:18884 E:18894 ||| VBD
for  ||| S:18894 E:18898 ||| IN
a  ||| S:18898 E:18910 ||| DT
larger  ||| S:18910 E:18917 ||| JJR
percentage  ||| S:18917 E:18928 ||| NN
of  ||| S:18928 E:18931 ||| IN
results  ||| S:18931 E:18939 ||| NNS
in  ||| S:18939 E:18942 ||| IN
the  ||| S:18942 E:18946 ||| DT
doxazosin  ||| S:18946 E:18956 ||| JJ
group  ||| S:18956 E:18962 ||| NN
than  ||| S:18962 E:18977 ||| IN
in  ||| S:18977 E:18980 ||| IN
the  ||| S:18980 E:18984 ||| DT
chlorthalidone  ||| S:18984 E:18999 ||| JJ
group  ||| S:18999 E:19005 ||| NN
( ||| S:19005 E:19006 ||| -LRB-
36 ||| S:19006 E:19008 ||| CD
%  ||| S:19008 E:19010 ||| NN
vs.  ||| S:19010 E:19014 ||| IN
24 ||| S:19014 E:19016 ||| CD
% ||| S:19016 E:19017 ||| NN
) ||| S:19017 E:19018 ||| -RRB-
.  ||| S:19018 E:19048 ||| .
Causes  ||| S:19048 E:19055 ||| NNS
of  ||| S:19055 E:19058 ||| IN
Death  ||| S:19058 E:19064 ||| NNP
and  ||| S:19064 E:19068 ||| CC
2-Year  ||| S:19068 E:19075 ||| NNP
Case-Fatality  ||| S:19075 E:19099 ||| NNP
Causes  ||| S:19099 E:19106 ||| NNP
of  ||| S:19106 E:19109 ||| IN
death  ||| S:19109 E:19115 ||| NN
of  ||| S:19115 E:19118 ||| IN
participants  ||| S:19118 E:19131 ||| NNS
with  ||| S:19131 E:19136 ||| IN
previous  ||| S:19136 E:19145 ||| JJ
HF  ||| S:19145 E:19158 ||| NNP
hospitalization  ||| S:19158 E:19174 ||| NN
were  ||| S:19174 E:19179 ||| VBD
distributed  ||| S:19179 E:19191 ||| VBN
similarly  ||| S:19191 E:19201 ||| RB
in  ||| S:19201 E:19204 ||| IN
the  ||| S:19204 E:19208 ||| DT
two  ||| S:19208 E:19222 ||| CD
groups ||| S:19222 E:19228 ||| NNS
,  ||| S:19228 E:19230 ||| ,
with  ||| S:19230 E:19235 ||| IN
slight  ||| S:19235 E:19242 ||| JJ
variations ||| S:19242 E:19252 ||| NNS
.  ||| S:19252 E:19254 ||| .
HF  ||| S:19254 E:19257 ||| NNP
accounted  ||| S:19257 E:19267 ||| VBD
for  ||| S:19267 E:19271 ||| IN
21.2 ||| S:19271 E:19275 ||| CD
%  ||| S:19275 E:19287 ||| NN
( ||| S:19287 E:19288 ||| -LRB-
11 ||| S:19288 E:19290 ||| CD
/ ||| S:19290 E:19291 ||| CD
52 ||| S:19291 E:19293 ||| CD
)  ||| S:19293 E:19295 ||| -RRB-
of  ||| S:19295 E:19298 ||| IN
the  ||| S:19298 E:19302 ||| DT
deaths  ||| S:19302 E:19309 ||| NNS
among  ||| S:19309 E:19315 ||| IN
chlorthalidone  ||| S:19315 E:19330 ||| JJ
participants  ||| S:19330 E:19353 ||| NNS
and  ||| S:19353 E:19357 ||| CC
17.1 ||| S:19357 E:19361 ||| CD
%  ||| S:19361 E:19363 ||| NN
( ||| S:19363 E:19364 ||| -LRB-
12 ||| S:19364 E:19366 ||| CD
/ ||| S:19366 E:19367 ||| CD
70 ||| S:19367 E:19369 ||| CD
)  ||| S:19369 E:19371 ||| -RRB-
of  ||| S:19371 E:19374 ||| IN
the  ||| S:19374 E:19378 ||| DT
deaths  ||| S:19378 E:19385 ||| NNS
among  ||| S:19385 E:19391 ||| IN
doxazosin  ||| S:19391 E:19411 ||| JJ
participants ||| S:19411 E:19423 ||| NNS
.  ||| S:19423 E:19425 ||| .
Over  ||| S:19425 E:19430 ||| IN
half  ||| S:19430 E:19435 ||| NN
of  ||| S:19435 E:19438 ||| IN
the  ||| S:19438 E:19442 ||| DT
deaths  ||| S:19442 E:19449 ||| NNS
in  ||| S:19449 E:19452 ||| IN
each  ||| S:19452 E:19457 ||| DT
group  ||| S:19457 E:19473 ||| NN
( ||| S:19473 E:19474 ||| -LRB-
29 ||| S:19474 E:19476 ||| CD
/ ||| S:19476 E:19477 ||| CD
52  ||| S:19477 E:19480 ||| CD
in  ||| S:19480 E:19483 ||| IN
the  ||| S:19483 E:19487 ||| DT
chlorthalidone  ||| S:19487 E:19502 ||| JJ
group ||| S:19502 E:19507 ||| NN
;  ||| S:19507 E:19509 ||| :
43 ||| S:19509 E:19511 ||| CD
/ ||| S:19511 E:19512 ||| CD
70  ||| S:19512 E:19515 ||| CD
in  ||| S:19515 E:19518 ||| IN
the  ||| S:19518 E:19532 ||| DT
doxazosin  ||| S:19532 E:19542 ||| JJ
group ||| S:19542 E:19547 ||| NN
)  ||| S:19547 E:19549 ||| -RRB-
were  ||| S:19549 E:19554 ||| VBD
due  ||| S:19554 E:19558 ||| JJ
to  ||| S:19558 E:19561 ||| TO
cardiovascular  ||| S:19561 E:19576 ||| JJ
events ||| S:19576 E:19582 ||| NNS
.  ||| S:19582 E:19594 ||| .
Fifteen  ||| S:19594 E:19602 ||| JJ
percent  ||| S:19602 E:19610 ||| NN
( ||| S:19610 E:19611 ||| -LRB-
8 ||| S:19611 E:19612 ||| CD
/ ||| S:19612 E:19613 ||| CD
52 ||| S:19613 E:19615 ||| CD
)  ||| S:19615 E:19617 ||| -RRB-
of  ||| S:19617 E:19620 ||| IN
deaths  ||| S:19620 E:19627 ||| NNS
in  ||| S:19627 E:19630 ||| IN
the  ||| S:19630 E:19634 ||| DT
chlorthalidone  ||| S:19634 E:19659 ||| JJ
group  ||| S:19659 E:19665 ||| NN
were  ||| S:19665 E:19670 ||| VBD
attributed  ||| S:19670 E:19681 ||| VBN
to  ||| S:19681 E:19684 ||| TO
cancer ||| S:19684 E:19690 ||| NN
,  ||| S:19690 E:19692 ||| ,
compared  ||| S:19692 E:19701 ||| VBN
to  ||| S:19701 E:19704 ||| TO
9 ||| S:19704 E:19705 ||| CD
%  ||| S:19705 E:19707 ||| NN
( ||| S:19707 E:19708 ||| -LRB-
6 ||| S:19708 E:19709 ||| CD
/ ||| S:19709 E:19710 ||| CD
70 ||| S:19710 E:19712 ||| CD
)  ||| S:19712 E:19714 ||| -RRB-
in  ||| S:19714 E:19727 ||| IN
the  ||| S:19727 E:19731 ||| DT
doxazosin  ||| S:19731 E:19741 ||| JJ
group  ||| S:19741 E:19747 ||| NN
( ||| S:19747 E:19748 ||| -LRB-
Table  ||| S:19748 E:19754 ||| NNP
4 ||| S:19754 E:19755 ||| CD
) ||| S:19755 E:19756 ||| -RRB-
.  ||| S:19756 E:19768 ||| .
Case-fatality  ||| S:19768 E:19782 ||| JJ
for  ||| S:19782 E:19786 ||| IN
participants  ||| S:19786 E:19799 ||| NNS
with  ||| S:19799 E:19804 ||| IN
hospitalized  ||| S:19804 E:19817 ||| JJ
HF  ||| S:19817 E:19830 ||| NN
events  ||| S:19830 E:19837 ||| NNS
showed  ||| S:19837 E:19844 ||| VBD
no  ||| S:19844 E:19847 ||| DT
significant  ||| S:19847 E:19859 ||| JJ
differences  ||| S:19859 E:19871 ||| NNS
( ||| S:19871 E:19872 ||| -LRB-
RR  ||| S:19872 E:19875 ||| NNP
0.96 ||| S:19875 E:19879 ||| NNP
,  ||| S:19879 E:19881 ||| ,
95 ||| S:19881 E:19883 ||| CD
%  ||| S:19883 E:19895 ||| NN
CI ||| S:19895 E:19897 ||| NNP
,  ||| S:19897 E:19899 ||| ,
0.67-1.38 ||| S:19899 E:19908 ||| NNP
,  ||| S:19908 E:19921 ||| ,
P  ||| S:19921 E:19923 ||| NN
=  ||| S:19923 E:19925 ||| SYM
0.83 ||| S:19925 E:19929 ||| CD
)  ||| S:19929 E:19931 ||| -RRB-
between  ||| S:19931 E:19939 ||| IN
the  ||| S:19939 E:19943 ||| DT
two  ||| S:19943 E:19947 ||| CD
treatment  ||| S:19947 E:19967 ||| NN
groups  ||| S:19967 E:19974 ||| NNS
( ||| S:19974 E:19975 ||| -LRB-
Figure  ||| S:19975 E:19982 ||| NNP
1 ||| S:19982 E:19983 ||| CD
) ||| S:19983 E:19984 ||| -RRB-
.  ||| S:19984 E:19986 ||| .
Among  ||| S:19986 E:19992 ||| IN
participants  ||| S:19992 E:20005 ||| NNS
in  ||| S:20005 E:20008 ||| IN
the  ||| S:20008 E:20012 ||| DT
doxazosin  ||| S:20012 E:20032 ||| JJ
treatment  ||| S:20032 E:20042 ||| NN
group  ||| S:20042 E:20048 ||| NN
who  ||| S:20048 E:20052 ||| WP
had  ||| S:20052 E:20056 ||| VBD
been  ||| S:20056 E:20061 ||| VBN
previously  ||| S:20061 E:20072 ||| RB
hospitalized  ||| S:20072 E:20085 ||| VBN
for  ||| S:20085 E:20099 ||| IN
HF ||| S:20099 E:20101 ||| NNP
,  ||| S:20101 E:20103 ||| ,
22.1 ||| S:20103 E:20107 ||| CD
%  ||| S:20107 E:20109 ||| NN
( ||| S:20109 E:20110 ||| -LRB-
70 ||| S:20110 E:20112 ||| CD
/ ||| S:20112 E:20113 ||| CD
317 ||| S:20113 E:20116 ||| CD
)  ||| S:20116 E:20118 ||| -RRB-
subsequently  ||| S:20118 E:20131 ||| RB
died ||| S:20131 E:20135 ||| VBD
,  ||| S:20135 E:20137 ||| ,
compared  ||| S:20137 E:20146 ||| VBN
to  ||| S:20146 E:20149 ||| TO
18.6 ||| S:20149 E:20153 ||| CD
%  ||| S:20153 E:20165 ||| NN
( ||| S:20165 E:20166 ||| -LRB-
52 ||| S:20166 E:20168 ||| CD
/ ||| S:20168 E:20169 ||| CD
280 ||| S:20169 E:20172 ||| CD
)  ||| S:20172 E:20174 ||| -RRB-
of  ||| S:20174 E:20177 ||| IN
those  ||| S:20177 E:20183 ||| DT
in  ||| S:20183 E:20186 ||| IN
the  ||| S:20186 E:20190 ||| DT
chlorthalidone  ||| S:20190 E:20205 ||| JJ
group  ||| S:20205 E:20211 ||| NN
( ||| S:20211 E:20212 ||| -LRB-
Table  ||| S:20212 E:20218 ||| NNP
4 ||| S:20218 E:20219 ||| CD
) ||| S:20219 E:20220 ||| -RRB-
.  ||| S:20220 E:20232 ||| .
As  ||| S:20232 E:20235 ||| RB
previously  ||| S:20235 E:20246 ||| RB
reported ||| S:20246 E:20254 ||| VBN
,  ||| S:20254 E:20256 ||| ,
all-cause  ||| S:20256 E:20266 ||| JJ
mortality  ||| S:20266 E:20276 ||| NN
did  ||| S:20276 E:20280 ||| VBD
not  ||| S:20280 E:20294 ||| RB
significantly  ||| S:20294 E:20308 ||| RB
differ  ||| S:20308 E:20315 ||| VB
in  ||| S:20315 E:20318 ||| IN
the  ||| S:20318 E:20322 ||| DT
two  ||| S:20322 E:20326 ||| CD
treatment  ||| S:20326 E:20336 ||| NN
groups  ||| S:20336 E:20343 ||| NNS
( ||| S:20343 E:20344 ||| -LRB-
RR  ||| S:20344 E:20357 ||| NNP
1.03 ||| S:20357 E:20361 ||| CD
,  ||| S:20361 E:20363 ||| ,
95 ||| S:20363 E:20365 ||| CD
%  ||| S:20365 E:20367 ||| NN
CI  ||| S:20367 E:20370 ||| NNP
0.90-1.15 ||| S:20370 E:20379 ||| NNP
,  ||| S:20379 E:20392 ||| ,
P  ||| S:20392 E:20394 ||| NN
=  ||| S:20394 E:20396 ||| SYM
0.56 ||| S:20396 E:20400 ||| CD
)  ||| S:20400 E:20402 ||| -RRB-
[  ||| S:20402 E:20404 ||| -LRB-
2  ||| S:20404 E:20406 ||| LS
]  ||| S:20406 E:20408 ||| -RRB-
.  ||| S:20408 E:20441 ||| .
Discussion  ||| S:20441 E:20460 ||| NN
The  ||| S:20460 E:20464 ||| DT
finding  ||| S:20464 E:20472 ||| NN
of  ||| S:20472 E:20475 ||| IN
significantly  ||| S:20475 E:20489 ||| RB
increased  ||| S:20489 E:20499 ||| VBN
HF  ||| S:20499 E:20502 ||| NNP
events  ||| S:20502 E:20509 ||| NNS
in  ||| S:20509 E:20512 ||| IN
the  ||| S:20512 E:20524 ||| DT
doxazosin  ||| S:20524 E:20534 ||| JJ
group  ||| S:20534 E:20540 ||| NN
compared  ||| S:20540 E:20549 ||| VBN
with  ||| S:20549 E:20554 ||| IN
the  ||| S:20554 E:20558 ||| DT
chlorthalidone  ||| S:20558 E:20573 ||| JJ
group  ||| S:20573 E:20587 ||| NN
created  ||| S:20587 E:20595 ||| VBD
a  ||| S:20595 E:20597 ||| DT
dilemma  ||| S:20597 E:20605 ||| NN
for  ||| S:20605 E:20609 ||| IN
ALLHAT ||| S:20609 E:20615 ||| NNP
.  ||| S:20615 E:20617 ||| .
Since  ||| S:20617 E:20623 ||| IN
the  ||| S:20623 E:20627 ||| DT
trial  ||| S:20627 E:20633 ||| NN
was  ||| S:20633 E:20637 ||| VBD
not  ||| S:20637 E:20649 ||| RB
designed  ||| S:20649 E:20658 ||| VBN
to  ||| S:20658 E:20661 ||| TO
focus  ||| S:20661 E:20667 ||| VB
on  ||| S:20667 E:20670 ||| IN
HF ||| S:20670 E:20672 ||| NNP
,  ||| S:20672 E:20674 ||| ,
a  ||| S:20674 E:20676 ||| DT
component  ||| S:20676 E:20686 ||| NN
of  ||| S:20686 E:20689 ||| IN
a  ||| S:20689 E:20691 ||| DT
secondary  ||| S:20691 E:20709 ||| JJ
endpoint ||| S:20709 E:20717 ||| NN
,  ||| S:20717 E:20719 ||| ,
the  ||| S:20719 E:20723 ||| DT
validity  ||| S:20723 E:20732 ||| NN
of  ||| S:20732 E:20735 ||| IN
reported  ||| S:20735 E:20744 ||| VBN
HF  ||| S:20744 E:20747 ||| NNP
events  ||| S:20747 E:20754 ||| NNS
became  ||| S:20754 E:20761 ||| VBD
an  ||| S:20761 E:20772 ||| DT
issue ||| S:20772 E:20777 ||| NN
.  ||| S:20777 E:20779 ||| .
In  ||| S:20779 E:20782 ||| IN
this  ||| S:20782 E:20787 ||| DT
paper ||| S:20787 E:20792 ||| NN
,  ||| S:20792 E:20794 ||| ,
we  ||| S:20794 E:20797 ||| PRP
have  ||| S:20797 E:20802 ||| VBP
described  ||| S:20802 E:20812 ||| VBN
several  ||| S:20812 E:20820 ||| JJ
analyses  ||| S:20820 E:20829 ||| NNS
to  ||| S:20829 E:20840 ||| TO
address  ||| S:20840 E:20848 ||| VB
this  ||| S:20848 E:20853 ||| DT
concern ||| S:20853 E:20860 ||| NN
.  ||| S:20860 E:20870 ||| .
As  ||| S:20870 E:20873 ||| RB
previously  ||| S:20873 E:20884 ||| RB
reported ||| S:20884 E:20892 ||| VBN
,  ||| S:20892 E:20894 ||| ,
lost-to-follow-up  ||| S:20894 E:20912 ||| JJ
and  ||| S:20912 E:20916 ||| CC
event  ||| S:20916 E:20930 ||| NN
documentation  ||| S:20930 E:20944 ||| NN
were  ||| S:20944 E:20949 ||| VBD
similar  ||| S:20949 E:20957 ||| JJ
in  ||| S:20957 E:20960 ||| IN
the  ||| S:20960 E:20964 ||| DT
two  ||| S:20964 E:20968 ||| CD
treatment  ||| S:20968 E:20978 ||| NN
groups  ||| S:20978 E:20985 ||| NNS
[  ||| S:20985 E:20987 ||| -LRB-
2  ||| S:20987 E:20997 ||| LS
]  ||| S:20997 E:20999 ||| -RRB-
.  ||| S:20999 E:21001 ||| .
Steps  ||| S:21001 E:21007 ||| NNS
employed  ||| S:21007 E:21016 ||| VBN
to  ||| S:21016 E:21019 ||| TO
validate  ||| S:21019 E:21028 ||| VB
the  ||| S:21028 E:21032 ||| DT
HF  ||| S:21032 E:21035 ||| NNP
outcome  ||| S:21035 E:21043 ||| NN
in  ||| S:21043 E:21046 ||| IN
these  ||| S:21046 E:21060 ||| DT
treatment  ||| S:21060 E:21070 ||| NN
groups  ||| S:21070 E:21077 ||| NNS
confirmed  ||| S:21077 E:21087 ||| VBD
the  ||| S:21087 E:21091 ||| DT
consistency  ||| S:21091 E:21103 ||| NN
of  ||| S:21103 E:21106 ||| IN
HF  ||| S:21106 E:21109 ||| NNP
event  ||| S:21109 E:21123 ||| NN
reporting ||| S:21123 E:21132 ||| NN
.  ||| S:21132 E:21134 ||| .
Participants  ||| S:21134 E:21147 ||| NNS
in  ||| S:21147 E:21150 ||| IN
the  ||| S:21150 E:21154 ||| DT
two  ||| S:21154 E:21158 ||| CD
drug  ||| S:21158 E:21163 ||| NN
groups  ||| S:21163 E:21170 ||| NNS
had  ||| S:21170 E:21174 ||| VBD
similar  ||| S:21174 E:21190 ||| JJ
baseline  ||| S:21190 E:21199 ||| NN
characteristics  ||| S:21199 E:21215 ||| NNS
when  ||| S:21215 E:21220 ||| WRB
stratified  ||| S:21220 E:21231 ||| NNS
by  ||| S:21231 E:21234 ||| IN
HF  ||| S:21234 E:21237 ||| NNP
status ||| S:21237 E:21243 ||| NN
.  ||| S:21243 E:21245 ||| .
The  ||| S:21245 E:21257 ||| DT
differences  ||| S:21257 E:21269 ||| NNS
in  ||| S:21269 E:21272 ||| IN
eligibility  ||| S:21272 E:21284 ||| JJ
risk  ||| S:21284 E:21289 ||| NN
factors  ||| S:21289 E:21297 ||| NNS
between  ||| S:21297 E:21305 ||| IN
those  ||| S:21305 E:21319 ||| DT
participants  ||| S:21319 E:21332 ||| NNS
with  ||| S:21332 E:21337 ||| IN
HF  ||| S:21337 E:21340 ||| NNP
and  ||| S:21340 E:21344 ||| CC
those  ||| S:21344 E:21350 ||| DT
without  ||| S:21350 E:21358 ||| NN
is  ||| S:21358 E:21361 ||| VBZ
not  ||| S:21361 E:21365 ||| RB
surprising ||| S:21365 E:21375 ||| JJ
:  ||| S:21375 E:21385 ||| :
larger  ||| S:21385 E:21392 ||| JJR
percentages  ||| S:21392 E:21404 ||| NNS
of  ||| S:21404 E:21407 ||| IN
those  ||| S:21407 E:21413 ||| DT
with  ||| S:21413 E:21418 ||| IN
HF  ||| S:21418 E:21421 ||| NNP
had  ||| S:21421 E:21425 ||| VBD
a  ||| S:21425 E:21427 ||| DT
history  ||| S:21427 E:21435 ||| NN
of  ||| S:21435 E:21438 ||| IN
MI ||| S:21438 E:21440 ||| NNP
,  ||| S:21440 E:21450 ||| ,
stroke ||| S:21450 E:21456 ||| NN
,  ||| S:21456 E:21458 ||| ,
CABG ||| S:21458 E:21462 ||| NNP
,  ||| S:21462 E:21464 ||| ,
angioplasty ||| S:21464 E:21475 ||| NN
,  ||| S:21475 E:21477 ||| ,
other  ||| S:21477 E:21483 ||| JJ
atherosclerotic  ||| S:21483 E:21507 ||| JJ
cardiovascular  ||| S:21507 E:21522 ||| JJ
disease  ||| S:21522 E:21530 ||| NN
( ||| S:21530 E:21531 ||| -LRB-
ASCVD ||| S:21531 E:21536 ||| NNP
) ||| S:21536 E:21537 ||| -RRB-
,  ||| S:21537 E:21539 ||| ,
diabetes ||| S:21539 E:21547 ||| NN
,  ||| S:21547 E:21549 ||| ,
low  ||| S:21549 E:21553 ||| JJ
HDL  ||| S:21553 E:21557 ||| NN
levels  ||| S:21557 E:21572 ||| NNS
and  ||| S:21572 E:21576 ||| CC
ECG  ||| S:21576 E:21580 ||| NNP
abnormalities ||| S:21580 E:21593 ||| NN
.  ||| S:21593 E:21595 ||| .
Nonetheless ||| S:21595 E:21606 ||| RB
,  ||| S:21606 E:21608 ||| ,
these  ||| S:21608 E:21614 ||| DT
eligibility  ||| S:21614 E:21634 ||| JJ
factors  ||| S:21634 E:21642 ||| NNS
were  ||| S:21642 E:21647 ||| VBD
not  ||| S:21647 E:21651 ||| RB
substantially  ||| S:21651 E:21665 ||| RB
different  ||| S:21665 E:21675 ||| JJ
between  ||| S:21675 E:21691 ||| IN
chlorthalidone  ||| S:21691 E:21706 ||| NN
and  ||| S:21706 E:21710 ||| CC
doxazosin  ||| S:21710 E:21720 ||| JJ
participants  ||| S:21720 E:21733 ||| NNS
with  ||| S:21733 E:21738 ||| IN
HF ||| S:21738 E:21740 ||| NNP
.  ||| S:21740 E:21750 ||| .
Post-diagnosis  ||| S:21750 E:21765 ||| JJ
pharmacologic  ||| S:21765 E:21779 ||| JJ
management  ||| S:21779 E:21790 ||| NN
of  ||| S:21790 E:21793 ||| IN
patients  ||| S:21793 E:21802 ||| NNS
is  ||| S:21802 E:21813 ||| VBZ
one  ||| S:21813 E:21817 ||| CD
measure  ||| S:21817 E:21825 ||| NN
of  ||| S:21825 E:21828 ||| IN
the  ||| S:21828 E:21832 ||| DT
strength  ||| S:21832 E:21841 ||| NN
of  ||| S:21841 E:21844 ||| IN
physicians ||| S:21844 E:21854 ||| NNS
'  ||| S:21854 E:21856 ||| POS
confidence  ||| S:21856 E:21867 ||| NN
in  ||| S:21867 E:21878 ||| IN
the  ||| S:21878 E:21882 ||| DT
HF  ||| S:21882 E:21885 ||| NNP
diagnoses ||| S:21885 E:21894 ||| NN
.  ||| S:21894 E:21896 ||| .
Open-label  ||| S:21896 E:21907 ||| JJ
diuretics ||| S:21907 E:21916 ||| NN
,  ||| S:21916 E:21918 ||| ,
ACE-inhibitors  ||| S:21918 E:21933 ||| JJ
and  ||| S:21933 E:21945 ||| CC
beta-blockers ||| S:21945 E:21958 ||| JJ
,  ||| S:21958 E:21960 ||| ,
all  ||| S:21960 E:21964 ||| DT
recognized  ||| S:21964 E:21975 ||| JJ
treatments  ||| S:21975 E:21986 ||| NNS
for  ||| S:21986 E:21990 ||| IN
HF ||| S:21990 E:21992 ||| NNP
,  ||| S:21992 E:21994 ||| ,
were  ||| S:21994 E:22007 ||| VBD
prescribed  ||| S:22007 E:22018 ||| VBN
similarly  ||| S:22018 E:22028 ||| RB
for  ||| S:22028 E:22032 ||| IN
the  ||| S:22032 E:22036 ||| DT
chlorthalidone  ||| S:22036 E:22051 ||| NN
and  ||| S:22051 E:22055 ||| CC
doxazosin  ||| S:22055 E:22073 ||| JJ
groups ||| S:22073 E:22079 ||| NNS
,  ||| S:22079 E:22081 ||| ,
suggesting  ||| S:22081 E:22092 ||| VBG
similar  ||| S:22092 E:22100 ||| JJ
assessment  ||| S:22100 E:22111 ||| NN
of  ||| S:22111 E:22114 ||| IN
these  ||| S:22114 E:22120 ||| DT
events  ||| S:22120 E:22127 ||| NNS
in  ||| S:22127 E:22138 ||| IN
the  ||| S:22138 E:22142 ||| DT
two  ||| S:22142 E:22146 ||| CD
treatment  ||| S:22146 E:22156 ||| NN
groups ||| S:22156 E:22162 ||| NNS
.  ||| S:22162 E:22172 ||| .
ALLHAT  ||| S:22172 E:22179 ||| NNP
criteria  ||| S:22179 E:22188 ||| NNS
for  ||| S:22188 E:22192 ||| IN
HF  ||| S:22192 E:22195 ||| NNP
were  ||| S:22195 E:22200 ||| VBD
equivalently  ||| S:22200 E:22213 ||| VBN
met  ||| S:22213 E:22217 ||| VBN
in  ||| S:22217 E:22220 ||| IN
the  ||| S:22220 E:22224 ||| DT
two  ||| S:22224 E:22236 ||| CD
groups ||| S:22236 E:22242 ||| NNS
.  ||| S:22242 E:22244 ||| .
While  ||| S:22244 E:22250 ||| IN
the  ||| S:22250 E:22254 ||| DT
sample  ||| S:22254 E:22261 ||| NN
( ||| S:22261 E:22262 ||| -LRB-
n  ||| S:22262 E:22264 ||| CD
=  ||| S:22264 E:22266 ||| SYM
50 ||| S:22266 E:22268 ||| CD
)  ||| S:22268 E:22270 ||| -RRB-
of  ||| S:22270 E:22273 ||| IN
hospitalized  ||| S:22273 E:22286 ||| NN
or  ||| S:22286 E:22289 ||| CC
fatal  ||| S:22289 E:22303 ||| JJ
HF  ||| S:22303 E:22306 ||| NNP
reports  ||| S:22306 E:22314 ||| VBZ
reviewed  ||| S:22314 E:22323 ||| VBN
by  ||| S:22323 E:22326 ||| IN
the  ||| S:22326 E:22330 ||| DT
ALLHAT  ||| S:22330 E:22337 ||| NNP
Endpoints  ||| S:22337 E:22347 ||| NNP
Subcommittee  ||| S:22347 E:22368 ||| NNP
was  ||| S:22368 E:22372 ||| VBD
limited  ||| S:22372 E:22380 ||| VBN
in  ||| S:22380 E:22383 ||| IN
number  ||| S:22383 E:22390 ||| NN
and  ||| S:22390 E:22394 ||| CC
in  ||| S:22394 E:22397 ||| IN
adequacy  ||| S:22397 E:22406 ||| NN
of  ||| S:22406 E:22409 ||| IN
corroborating  ||| S:22409 E:22431 ||| JJ
documentation ||| S:22431 E:22444 ||| NN
,  ||| S:22444 E:22446 ||| ,
the  ||| S:22446 E:22450 ||| DT
review  ||| S:22450 E:22457 ||| NN
nonetheless  ||| S:22457 E:22469 ||| RB
showed  ||| S:22469 E:22476 ||| VBD
adherence  ||| S:22476 E:22486 ||| VBN
to  ||| S:22486 E:22497 ||| TO
study  ||| S:22497 E:22503 ||| VB
criteria  ||| S:22503 E:22512 ||| NNS
for  ||| S:22512 E:22516 ||| IN
the  ||| S:22516 E:22520 ||| DT
majority  ||| S:22520 E:22529 ||| NN
( ||| S:22529 E:22530 ||| -LRB-
85 ||| S:22530 E:22532 ||| CD
% ||| S:22532 E:22533 ||| NN
)  ||| S:22533 E:22535 ||| -RRB-
of  ||| S:22535 E:22538 ||| IN
the  ||| S:22538 E:22542 ||| DT
event  ||| S:22542 E:22548 ||| NN
reports ||| S:22548 E:22555 ||| NNS
.  ||| S:22555 E:22565 ||| .
The  ||| S:22565 E:22569 ||| DT
sometimes-discrepant  ||| S:22569 E:22590 ||| JJ
results  ||| S:22590 E:22598 ||| NNS
between  ||| S:22598 E:22606 ||| IN
reviewers  ||| S:22606 E:22624 ||| JJ
pertained  ||| S:22624 E:22634 ||| NN
more  ||| S:22634 E:22639 ||| RBR
often  ||| S:22639 E:22645 ||| RB
to  ||| S:22645 E:22648 ||| TO
incomplete  ||| S:22648 E:22659 ||| JJ
data  ||| S:22659 E:22664 ||| NNS
than  ||| S:22664 E:22669 ||| IN
to  ||| S:22669 E:22672 ||| TO
rejection  ||| S:22672 E:22690 ||| NN
of  ||| S:22690 E:22693 ||| IN
a  ||| S:22693 E:22695 ||| DT
HF  ||| S:22695 E:22698 ||| NNP
diagnosis ||| S:22698 E:22707 ||| NN
.  ||| S:22707 E:22717 ||| .
Clinical  ||| S:22717 E:22726 ||| JJ
use  ||| S:22726 E:22730 ||| NN
of  ||| S:22730 E:22733 ||| IN
more  ||| S:22733 E:22738 ||| JJR
objective  ||| S:22738 E:22748 ||| NN
measures ||| S:22748 E:22756 ||| NNS
,  ||| S:22756 E:22758 ||| ,
including  ||| S:22758 E:22776 ||| VBG
noninvasive  ||| S:22776 E:22788 ||| NNS
and ||| S:22788 E:22791 ||| CC
/ ||| S:22791 E:22792 ||| NNP
or  ||| S:22792 E:22795 ||| CC
invasive  ||| S:22795 E:22804 ||| JJ
tools  ||| S:22804 E:22810 ||| NNS
for  ||| S:22810 E:22814 ||| IN
the  ||| S:22814 E:22818 ||| DT
measurement  ||| S:22818 E:22830 ||| NN
of  ||| S:22830 E:22841 ||| IN
left  ||| S:22841 E:22846 ||| VBN
ventricular  ||| S:22846 E:22858 ||| JJ
function ||| S:22858 E:22866 ||| NN
,  ||| S:22866 E:22868 ||| ,
offers  ||| S:22868 E:22875 ||| VBZ
a  ||| S:22875 E:22877 ||| DT
means  ||| S:22877 E:22883 ||| NNS
of  ||| S:22883 E:22886 ||| IN
establishing  ||| S:22886 E:22907 ||| VBG
and  ||| S:22907 E:22911 ||| CC
quantifying  ||| S:22911 E:22923 ||| JJ
systolic  ||| S:22923 E:22932 ||| JJ
failure  ||| S:22932 E:22940 ||| NN
in  ||| S:22940 E:22943 ||| IN
cases  ||| S:22943 E:22949 ||| NNS
clinically  ||| S:22949 E:22968 ||| VBP
suggestive  ||| S:22968 E:22979 ||| VBN
of  ||| S:22979 E:22982 ||| IN
HF  ||| S:22982 E:22985 ||| NNP
[  ||| S:22985 E:22987 ||| -LRB-
7  ||| S:22987 E:22989 ||| CD
10  ||| S:22989 E:22992 ||| CD
]  ||| S:22992 E:22994 ||| -RRB-
.  ||| S:22994 E:22996 ||| .
Among  ||| S:22996 E:23002 ||| IN
the  ||| S:23002 E:23006 ||| DT
ejection  ||| S:23006 E:23015 ||| JJ
fractions  ||| S:23015 E:23033 ||| NNS
reported  ||| S:23033 E:23042 ||| VBD
in  ||| S:23042 E:23045 ||| IN
the  ||| S:23045 E:23049 ||| DT
ALLHAT  ||| S:23049 E:23056 ||| NNP
events  ||| S:23056 E:23063 ||| NNS
that  ||| S:23063 E:23068 ||| WDT
were  ||| S:23068 E:23073 ||| VBD
reviewed ||| S:23073 E:23081 ||| VBN
,  ||| S:23081 E:23083 ||| ,
the  ||| S:23083 E:23095 ||| DT
majority  ||| S:23095 E:23104 ||| NN
fell  ||| S:23104 E:23109 ||| VBD
at  ||| S:23109 E:23112 ||| IN
or  ||| S:23112 E:23115 ||| CC
below  ||| S:23115 E:23121 ||| IN
40 ||| S:23121 E:23123 ||| CD
% ||| S:23123 E:23124 ||| NN
,  ||| S:23124 E:23126 ||| ,
indicating  ||| S:23126 E:23137 ||| VBG
some  ||| S:23137 E:23142 ||| DT
degree  ||| S:23142 E:23149 ||| NN
of  ||| S:23149 E:23160 ||| IN
systolic  ||| S:23160 E:23169 ||| JJ
dysfunction ||| S:23169 E:23180 ||| NN
.  ||| S:23180 E:23182 ||| .
However ||| S:23182 E:23189 ||| RB
,  ||| S:23189 E:23191 ||| ,
HF  ||| S:23191 E:23194 ||| NNP
is  ||| S:23194 E:23197 ||| VBZ
a  ||| S:23197 E:23199 ||| DT
clinical  ||| S:23199 E:23208 ||| JJ
diagnosis  ||| S:23208 E:23226 ||| NN
that  ||| S:23226 E:23231 ||| WDT
does  ||| S:23231 E:23236 ||| VBZ
not  ||| S:23236 E:23240 ||| RB
necessarily  ||| S:23240 E:23252 ||| RB
exclude  ||| S:23252 E:23260 ||| VB
those  ||| S:23260 E:23266 ||| DT
with  ||| S:23266 E:23271 ||| IN
intact  ||| S:23271 E:23278 ||| JJ
left  ||| S:23278 E:23291 ||| JJ
ventricular  ||| S:23291 E:23303 ||| JJ
systolic  ||| S:23303 E:23312 ||| JJ
function  ||| S:23312 E:23321 ||| NN
[  ||| S:23321 E:23323 ||| -LRB-
11  ||| S:23323 E:23326 ||| CD
]  ||| S:23326 E:23328 ||| -RRB-
.  ||| S:23328 E:23330 ||| .
Hypertension  ||| S:23330 E:23343 ||| NNP
is  ||| S:23343 E:23346 ||| VBZ
a  ||| S:23346 E:23356 ||| DT
major  ||| S:23356 E:23362 ||| JJ
risk  ||| S:23362 E:23367 ||| NN
factor  ||| S:23367 E:23374 ||| NN
for  ||| S:23374 E:23378 ||| IN
diastolic  ||| S:23378 E:23388 ||| JJ
HF ||| S:23388 E:23390 ||| NNP
;  ||| S:23390 E:23392 ||| :
as  ||| S:23392 E:23395 ||| IN
many  ||| S:23395 E:23400 ||| JJ
as  ||| S:23400 E:23403 ||| IN
25 ||| S:23403 E:23405 ||| CD
%  ||| S:23405 E:23407 ||| NN
of  ||| S:23407 E:23418 ||| IN
asymptomatic  ||| S:23418 E:23431 ||| JJ
hypertensives  ||| S:23431 E:23445 ||| NN
with  ||| S:23445 E:23450 ||| IN
left  ||| S:23450 E:23455 ||| VBN
ventricular  ||| S:23455 E:23475 ||| JJ
hypertrophy  ||| S:23475 E:23487 ||| NNS
have  ||| S:23487 E:23492 ||| VBP
diastolic  ||| S:23492 E:23502 ||| JJ
dysfunction ||| S:23502 E:23513 ||| NN
.  ||| S:23513 E:23515 ||| .
Additionally ||| S:23515 E:23527 ||| RB
,  ||| S:23527 E:23529 ||| ,
90 ||| S:23529 E:23531 ||| CD
%  ||| S:23531 E:23541 ||| NN
of  ||| S:23541 E:23544 ||| IN
patients  ||| S:23544 E:23553 ||| NNS
with  ||| S:23553 E:23558 ||| IN
coronary  ||| S:23558 E:23567 ||| JJ
artery  ||| S:23567 E:23574 ||| NN
disease  ||| S:23574 E:23582 ||| NN
may  ||| S:23582 E:23586 ||| MD
have  ||| S:23586 E:23591 ||| VB
some  ||| S:23591 E:23604 ||| DT
degree  ||| S:23604 E:23611 ||| NN
of  ||| S:23611 E:23614 ||| IN
diastolic  ||| S:23614 E:23624 ||| JJ
dysfunction  ||| S:23624 E:23636 ||| NNS
[  ||| S:23636 E:23638 ||| -LRB-
12  ||| S:23638 E:23641 ||| CD
]  ||| S:23641 E:23643 ||| -RRB-
.  ||| S:23643 E:23653 ||| .
The  ||| S:23653 E:23657 ||| DT
two-fold  ||| S:23657 E:23666 ||| JJ
increased  ||| S:23666 E:23676 ||| JJ
relative  ||| S:23676 E:23685 ||| JJ
risk  ||| S:23685 E:23690 ||| NN
of  ||| S:23690 E:23693 ||| IN
HF  ||| S:23693 E:23696 ||| NNP
in  ||| S:23696 E:23699 ||| IN
the  ||| S:23699 E:23711 ||| DT
doxazosin  ||| S:23711 E:23721 ||| JJ
group  ||| S:23721 E:23727 ||| NN
compared  ||| S:23727 E:23736 ||| VBN
to  ||| S:23736 E:23739 ||| TO
the  ||| S:23739 E:23743 ||| DT
chlorthalidone  ||| S:23743 E:23758 ||| JJ
group  ||| S:23758 E:23772 ||| NN
changed  ||| S:23772 E:23780 ||| VBD
little  ||| S:23780 E:23787 ||| RB
when  ||| S:23787 E:23792 ||| WRB
confined  ||| S:23792 E:23801 ||| VBN
to  ||| S:23801 E:23804 ||| TO
hospitalized  ||| S:23804 E:23817 ||| VB
and  ||| S:23817 E:23821 ||| CC
fatal  ||| S:23821 E:23835 ||| JJ
events ||| S:23835 E:23841 ||| NNS
.  ||| S:23841 E:23843 ||| .
Further ||| S:23843 E:23850 ||| RB
,  ||| S:23850 E:23852 ||| ,
HF  ||| S:23852 E:23855 ||| NNP
patients  ||| S:23855 E:23864 ||| NNS
in  ||| S:23864 E:23867 ||| IN
both  ||| S:23867 E:23872 ||| PDT
the  ||| S:23872 E:23876 ||| DT
doxazosin  ||| S:23876 E:23886 ||| NN
and  ||| S:23886 E:23898 ||| CC
chlorthalidone  ||| S:23898 E:23913 ||| JJ
treatment  ||| S:23913 E:23923 ||| NN
groups  ||| S:23923 E:23930 ||| NNS
showed  ||| S:23930 E:23937 ||| VBD
a  ||| S:23937 E:23939 ||| DT
rather  ||| S:23939 E:23946 ||| RB
high  ||| S:23946 E:23951 ||| JJ
20 ||| S:23951 E:23953 ||| CD
%  ||| S:23953 E:23963 ||| NN
case-fatality  ||| S:23963 E:23977 ||| JJ
rate  ||| S:23977 E:23982 ||| NN
over  ||| S:23982 E:23987 ||| IN
two  ||| S:23987 E:23991 ||| CD
years ||| S:23991 E:23996 ||| NNS
,  ||| S:23996 E:23998 ||| ,
as  ||| S:23998 E:24001 ||| RB
expected  ||| S:24001 E:24010 ||| VBN
in  ||| S:24010 E:24013 ||| IN
HF  ||| S:24013 E:24024 ||| NNP
patients  ||| S:24024 E:24033 ||| NNS
[  ||| S:24033 E:24035 ||| -LRB-
11  ||| S:24035 E:24038 ||| CD
13  ||| S:24038 E:24041 ||| CD
14  ||| S:24041 E:24044 ||| CD
]  ||| S:24044 E:24046 ||| -RRB-
,  ||| S:24046 E:24048 ||| ,
further  ||| S:24048 E:24056 ||| RB
supporting  ||| S:24056 E:24067 ||| VBG
the  ||| S:24067 E:24071 ||| DT
validity  ||| S:24071 E:24080 ||| NN
of  ||| S:24080 E:24091 ||| IN
the  ||| S:24091 E:24095 ||| DT
diagnoses  ||| S:24095 E:24105 ||| NN
in  ||| S:24105 E:24108 ||| IN
the  ||| S:24108 E:24112 ||| DT
two  ||| S:24112 E:24116 ||| CD
groups ||| S:24116 E:24122 ||| NNS
.  ||| S:24122 E:24124 ||| .
Among  ||| S:24124 E:24130 ||| IN
participants  ||| S:24130 E:24151 ||| NNS
hospitalized  ||| S:24151 E:24164 ||| VBN
for  ||| S:24164 E:24168 ||| IN
HF  ||| S:24168 E:24171 ||| NNP
who  ||| S:24171 E:24175 ||| WP
subsequently  ||| S:24175 E:24188 ||| RB
died ||| S:24188 E:24192 ||| VBD
,  ||| S:24192 E:24194 ||| ,
over  ||| S:24194 E:24199 ||| IN
half  ||| S:24199 E:24204 ||| NN
of  ||| S:24204 E:24207 ||| IN
the  ||| S:24207 E:24219 ||| DT
deaths  ||| S:24219 E:24226 ||| NNS
in  ||| S:24226 E:24229 ||| IN
each  ||| S:24229 E:24234 ||| DT
drug  ||| S:24234 E:24239 ||| NN
group  ||| S:24239 E:24245 ||| NN
were  ||| S:24245 E:24250 ||| VBD
attributed  ||| S:24250 E:24261 ||| VBN
to  ||| S:24261 E:24264 ||| TO
cardiovascular  ||| S:24264 E:24287 ||| JJ
causes ||| S:24287 E:24293 ||| NNS
.  ||| S:24293 E:24303 ||| .
Treatment  ||| S:24303 E:24313 ||| NN
group  ||| S:24313 E:24319 ||| NN
differences  ||| S:24319 E:24331 ||| NNS
in  ||| S:24331 E:24334 ||| IN
mortality  ||| S:24334 E:24344 ||| NN
attributed  ||| S:24344 E:24355 ||| VBD
to  ||| S:24355 E:24366 ||| TO
HF  ||| S:24366 E:24369 ||| NNP
may  ||| S:24369 E:24373 ||| MD
take  ||| S:24373 E:24378 ||| VB
time  ||| S:24378 E:24383 ||| NN
to  ||| S:24383 E:24386 ||| TO
be  ||| S:24386 E:24389 ||| VB
recognized ||| S:24389 E:24399 ||| VBN
.  ||| S:24399 E:24401 ||| .
Patients  ||| S:24401 E:24410 ||| NNS
with  ||| S:24410 E:24415 ||| IN
HF  ||| S:24415 E:24418 ||| NNP
are  ||| S:24418 E:24422 ||| VBP
at  ||| S:24422 E:24433 ||| IN
risk  ||| S:24433 E:24438 ||| NN
for  ||| S:24438 E:24442 ||| IN
other  ||| S:24442 E:24448 ||| JJ
competing  ||| S:24448 E:24458 ||| VBG
causes  ||| S:24458 E:24465 ||| NNS
of  ||| S:24465 E:24468 ||| IN
death ||| S:24468 E:24473 ||| NN
.  ||| S:24473 E:24475 ||| .
Accordingly ||| S:24475 E:24486 ||| RB
,  ||| S:24486 E:24488 ||| ,
it  ||| S:24488 E:24499 ||| PRP
may  ||| S:24499 E:24503 ||| MD
be  ||| S:24503 E:24506 ||| VB
too  ||| S:24506 E:24510 ||| RB
early  ||| S:24510 E:24516 ||| JJ
to  ||| S:24516 E:24519 ||| TO
determine  ||| S:24519 E:24529 ||| VB
if  ||| S:24529 E:24532 ||| IN
a  ||| S:24532 E:24534 ||| DT
higher  ||| S:24534 E:24541 ||| JJR
rate  ||| S:24541 E:24546 ||| NN
of  ||| S:24546 E:24549 ||| IN
HF  ||| S:24549 E:24552 ||| NNP
in  ||| S:24552 E:24555 ||| IN
the  ||| S:24555 E:24567 ||| DT
doxazosin  ||| S:24567 E:24577 ||| JJ
group  ||| S:24577 E:24583 ||| NN
translates  ||| S:24583 E:24594 ||| NN
into  ||| S:24594 E:24599 ||| IN
a  ||| S:24599 E:24601 ||| DT
higher  ||| S:24601 E:24608 ||| JJR
overall  ||| S:24608 E:24616 ||| JJ
mortality  ||| S:24616 E:24634 ||| NN
rate ||| S:24634 E:24638 ||| NN
.  ||| S:24638 E:24640 ||| .
A  ||| S:24640 E:24642 ||| DT
20 ||| S:24642 E:24644 ||| CD
%  ||| S:24644 E:24646 ||| NN
2-year  ||| S:24646 E:24653 ||| CD
case-fatality  ||| S:24653 E:24667 ||| JJ
rate  ||| S:24667 E:24672 ||| NN
with  ||| S:24672 E:24677 ||| IN
a  ||| S:24677 E:24679 ||| DT
4 ||| S:24679 E:24680 ||| CD
%  ||| S:24680 E:24682 ||| NN
difference  ||| S:24682 E:24701 ||| NN
in  ||| S:24701 E:24704 ||| IN
HF  ||| S:24704 E:24707 ||| NNP
incidence  ||| S:24707 E:24717 ||| NN
rate  ||| S:24717 E:24722 ||| NN
translates  ||| S:24722 E:24733 ||| NN
into  ||| S:24733 E:24738 ||| IN
a  ||| S:24738 E:24740 ||| DT
0.8 ||| S:24740 E:24743 ||| CD
%  ||| S:24743 E:24745 ||| NN
potential  ||| S:24745 E:24763 ||| JJ
difference  ||| S:24763 E:24774 ||| NN
in  ||| S:24774 E:24777 ||| IN
total  ||| S:24777 E:24783 ||| JJ
mortality  ||| S:24783 E:24793 ||| NN
without  ||| S:24793 E:24801 ||| IN
any  ||| S:24801 E:24805 ||| DT
competing  ||| S:24805 E:24815 ||| JJ
causes  ||| S:24815 E:24830 ||| NNS
of  ||| S:24830 E:24833 ||| IN
death ||| S:24833 E:24838 ||| NN
.  ||| S:24838 E:24840 ||| .
With  ||| S:24840 E:24845 ||| IN
competing  ||| S:24845 E:24855 ||| VBG
causes ||| S:24855 E:24861 ||| NNS
,  ||| S:24861 E:24863 ||| ,
the  ||| S:24863 E:24867 ||| DT
difference  ||| S:24867 E:24878 ||| NN
would  ||| S:24878 E:24884 ||| MD
be  ||| S:24884 E:24895 ||| VB
smaller  ||| S:24895 E:24903 ||| JJR
and  ||| S:24903 E:24907 ||| CC
difficult  ||| S:24907 E:24917 ||| JJ
to  ||| S:24917 E:24920 ||| TO
detect  ||| S:24920 E:24927 ||| VB
even  ||| S:24927 E:24932 ||| RB
in  ||| S:24932 E:24935 ||| IN
a  ||| S:24935 E:24937 ||| DT
trial  ||| S:24937 E:24943 ||| NN
of  ||| S:24943 E:24946 ||| IN
ALLHAT ||| S:24946 E:24952 ||| NNP
's  ||| S:24952 E:24963 ||| POS
size ||| S:24963 E:24967 ||| NN
.  ||| S:24967 E:24977 ||| .
The  ||| S:24977 E:24981 ||| DT
diagnosis  ||| S:24981 E:24991 ||| NN
of  ||| S:24991 E:24994 ||| IN
HF  ||| S:24994 E:24997 ||| NNP
is  ||| S:24997 E:25000 ||| VBZ
generally  ||| S:25000 E:25010 ||| RB
made  ||| S:25010 E:25015 ||| VBN
on  ||| S:25015 E:25018 ||| IN
the  ||| S:25018 E:25022 ||| DT
basis  ||| S:25022 E:25028 ||| NN
of  ||| S:25028 E:25039 ||| IN
signs  ||| S:25039 E:25045 ||| NNS
and  ||| S:25045 E:25049 ||| CC
symptoms  ||| S:25049 E:25058 ||| NNS
that  ||| S:25058 E:25063 ||| WDT
may  ||| S:25063 E:25067 ||| MD
overlap  ||| S:25067 E:25075 ||| VB
with  ||| S:25075 E:25080 ||| IN
those  ||| S:25080 E:25086 ||| DT
of  ||| S:25086 E:25089 ||| IN
other  ||| S:25089 E:25103 ||| JJ
cardiovascular  ||| S:25103 E:25118 ||| NN
and  ||| S:25118 E:25122 ||| CC
pulmonary  ||| S:25122 E:25132 ||| JJ
pathologies ||| S:25132 E:25143 ||| NN
.  ||| S:25143 E:25145 ||| .
Moreover ||| S:25145 E:25153 ||| RB
,  ||| S:25153 E:25155 ||| ,
the  ||| S:25155 E:25167 ||| DT
clinical  ||| S:25167 E:25176 ||| JJ
picture  ||| S:25176 E:25184 ||| NN
may  ||| S:25184 E:25188 ||| MD
be  ||| S:25188 E:25191 ||| VB
further  ||| S:25191 E:25199 ||| RB
complicated  ||| S:25199 E:25211 ||| VBN
for  ||| S:25211 E:25215 ||| IN
patients  ||| S:25215 E:25232 ||| NNS
taking  ||| S:25232 E:25239 ||| VBG
doxazosin ||| S:25239 E:25248 ||| NN
,  ||| S:25248 E:25250 ||| ,
side  ||| S:25250 E:25255 ||| NN
effects  ||| S:25255 E:25263 ||| NNS
of  ||| S:25263 E:25266 ||| IN
which  ||| S:25266 E:25272 ||| WDT
( ||| S:25272 E:25273 ||| -LRB-
edema ||| S:25273 E:25278 ||| UH
,  ||| S:25278 E:25280 ||| ,
dyspnea ||| S:25280 E:25287 ||| NN
,  ||| S:25287 E:25297 ||| ,
and  ||| S:25297 E:25301 ||| CC
tachycardia ||| S:25301 E:25312 ||| CD
)  ||| S:25312 E:25314 ||| -RRB-
[  ||| S:25314 E:25316 ||| -LRB-
15  ||| S:25316 E:25319 ||| CD
]  ||| S:25319 E:25321 ||| -RRB-
may  ||| S:25321 E:25325 ||| MD
be  ||| S:25325 E:25328 ||| VB
misinterpreted  ||| S:25328 E:25343 ||| VBN
as  ||| S:25343 E:25354 ||| IN
manifestations  ||| S:25354 E:25369 ||| NNS
of  ||| S:25369 E:25372 ||| IN
HF ||| S:25372 E:25374 ||| NNP
.  ||| S:25374 E:25384 ||| .
The  ||| S:25384 E:25388 ||| DT
capture  ||| S:25388 E:25396 ||| NN
of  ||| S:25396 E:25399 ||| IN
events  ||| S:25399 E:25406 ||| NNS
in  ||| S:25406 E:25409 ||| IN
a  ||| S:25409 E:25411 ||| DT
"large  ||| S:25411 E:25418 ||| NNP
and  ||| S:25418 E:25422 ||| CC
simple  ||| S:25422 E:25429 ||| JJ
trial ||| S:25429 E:25434 ||| NN
"  ||| S:25434 E:25436 ||| ``
such  ||| S:25436 E:25449 ||| JJ
as  ||| S:25449 E:25452 ||| IN
ALLHAT  ||| S:25452 E:25459 ||| NNP
has  ||| S:25459 E:25463 ||| VBZ
potential  ||| S:25463 E:25473 ||| JJ
limitations ||| S:25473 E:25484 ||| NNS
.  ||| S:25484 E:25486 ||| .
Built  ||| S:25486 E:25492 ||| VBN
into  ||| S:25492 E:25497 ||| IN
a  ||| S:25497 E:25499 ||| DT
structure  ||| S:25499 E:25517 ||| NN
composed  ||| S:25517 E:25526 ||| VBN
largely  ||| S:25526 E:25534 ||| RB
of  ||| S:25534 E:25537 ||| IN
community-based  ||| S:25537 E:25553 ||| JJ
physicians  ||| S:25553 E:25564 ||| NNS
is  ||| S:25564 E:25567 ||| VBZ
the  ||| S:25567 E:25579 ||| DT
assumption  ||| S:25579 E:25590 ||| NN
that  ||| S:25590 E:25595 ||| IN
their  ||| S:25595 E:25601 ||| PRP$
characterization  ||| S:25601 E:25618 ||| NN
of  ||| S:25618 E:25621 ||| IN
clinical  ||| S:25621 E:25630 ||| JJ
events  ||| S:25630 E:25645 ||| NNS
reflects  ||| S:25645 E:25654 ||| VBZ
diagnostic  ||| S:25654 E:25665 ||| JJ
standards  ||| S:25665 E:25675 ||| NNS
of  ||| S:25675 E:25678 ||| IN
the  ||| S:25678 E:25682 ||| DT
medical  ||| S:25682 E:25690 ||| JJ
community ||| S:25690 E:25699 ||| NN
,  ||| S:25699 E:25709 ||| ,
and ||| S:25709 E:25712 ||| CC
,  ||| S:25712 E:25714 ||| ,
as  ||| S:25714 E:25717 ||| IN
such ||| S:25717 E:25721 ||| JJ
,  ||| S:25721 E:25723 ||| ,
meets  ||| S:25723 E:25729 ||| VBZ
study  ||| S:25729 E:25735 ||| NN
criteria ||| S:25735 E:25743 ||| NNS
.  ||| S:25743 E:25745 ||| .
However ||| S:25745 E:25752 ||| RB
,  ||| S:25752 E:25754 ||| ,
with  ||| S:25754 E:25759 ||| IN
its  ||| S:25759 E:25763 ||| PRP$
large  ||| S:25763 E:25777 ||| JJ
number  ||| S:25777 E:25784 ||| NN
of  ||| S:25784 E:25787 ||| IN
endpoints ||| S:25787 E:25796 ||| NN
,  ||| S:25796 E:25798 ||| ,
resources  ||| S:25798 E:25808 ||| NNS
available  ||| S:25808 E:25818 ||| JJ
to  ||| S:25818 E:25821 ||| TO
ALLHAT  ||| S:25821 E:25836 ||| NNP
precluded  ||| S:25836 E:25846 ||| VBD
more  ||| S:25846 E:25851 ||| JJR
than  ||| S:25851 E:25856 ||| IN
modest  ||| S:25856 E:25863 ||| JJ
confirmatory  ||| S:25863 E:25876 ||| JJ
event  ||| S:25876 E:25890 ||| NN
documentation ||| S:25890 E:25903 ||| NN
.  ||| S:25903 E:25905 ||| .
Resources  ||| S:25905 E:25915 ||| NNP
were  ||| S:25915 E:25920 ||| VBD
allocated  ||| S:25920 E:25930 ||| VBN
for  ||| S:25930 E:25934 ||| IN
additional  ||| S:25934 E:25953 ||| JJ
documentation  ||| S:25953 E:25967 ||| NN
for  ||| S:25967 E:25971 ||| IN
quality  ||| S:25971 E:25979 ||| NN
control  ||| S:25979 E:25987 ||| NN
validation  ||| S:25987 E:25998 ||| VBZ
only  ||| S:25998 E:26003 ||| RB
for  ||| S:26003 E:26007 ||| IN
a  ||| S:26007 E:26017 ||| DT
sample  ||| S:26017 E:26024 ||| NN
of  ||| S:26024 E:26027 ||| IN
the  ||| S:26027 E:26031 ||| DT
primary  ||| S:26031 E:26039 ||| JJ
endpoint  ||| S:26039 E:26048 ||| NNS
( ||| S:26048 E:26049 ||| -LRB-
MIs  ||| S:26049 E:26053 ||| NNP
and  ||| S:26053 E:26057 ||| CC
fatal  ||| S:26057 E:26063 ||| JJ
CHD ||| S:26063 E:26066 ||| NNP
)  ||| S:26066 E:26068 ||| -RRB-
and  ||| S:26068 E:26072 ||| CC
for  ||| S:26072 E:26084 ||| IN
strokes ||| S:26084 E:26091 ||| NNS
.  ||| S:26091 E:26093 ||| .
While  ||| S:26093 E:26099 ||| IN
all  ||| S:26099 E:26103 ||| DT
reported  ||| S:26103 E:26112 ||| JJ
events  ||| S:26112 E:26119 ||| NNS
are  ||| S:26119 E:26123 ||| VBP
reviewed  ||| S:26123 E:26132 ||| VBN
at  ||| S:26132 E:26135 ||| IN
the  ||| S:26135 E:26139 ||| DT
CTC ||| S:26139 E:26142 ||| NNP
,  ||| S:26142 E:26152 ||| ,
the  ||| S:26152 E:26156 ||| DT
sometimes  ||| S:26156 E:26166 ||| RB
incomplete  ||| S:26166 E:26177 ||| JJ
supporting  ||| S:26177 E:26188 ||| JJ
details  ||| S:26188 E:26196 ||| NNS
in  ||| S:26196 E:26207 ||| IN
documentation  ||| S:26207 E:26221 ||| NN
may  ||| S:26221 E:26225 ||| MD
not  ||| S:26225 E:26229 ||| RB
allow  ||| S:26229 E:26235 ||| VB
for  ||| S:26235 E:26239 ||| IN
validation  ||| S:26239 E:26250 ||| NN
of  ||| S:26250 E:26253 ||| IN
all  ||| S:26253 E:26257 ||| DT
events  ||| S:26257 E:26272 ||| NNS
according  ||| S:26272 E:26282 ||| VBG
to  ||| S:26282 E:26285 ||| TO
ALLHAT  ||| S:26285 E:26292 ||| NNP
criteria ||| S:26292 E:26300 ||| NNS
.  ||| S:26300 E:26302 ||| .
Some  ||| S:26302 E:26307 ||| DT
discharge  ||| S:26307 E:26317 ||| NN
summaries  ||| S:26317 E:26327 ||| NNS
and  ||| S:26327 E:26339 ||| CC
death  ||| S:26339 E:26345 ||| NN
certificates  ||| S:26345 E:26358 ||| NNS
may  ||| S:26358 E:26362 ||| MD
lack  ||| S:26362 E:26367 ||| VB
sufficient  ||| S:26367 E:26378 ||| JJ
descriptive  ||| S:26378 E:26398 ||| JJ
information  ||| S:26398 E:26410 ||| NN
needed  ||| S:26410 E:26417 ||| VBN
to  ||| S:26417 E:26420 ||| TO
confirm  ||| S:26420 E:26428 ||| VB
the  ||| S:26428 E:26432 ||| DT
clinical  ||| S:26432 E:26441 ||| JJ
diagnoses ||| S:26441 E:26450 ||| NN
.  ||| S:26450 E:26460 ||| .
Clinic  ||| S:26460 E:26467 ||| NNP
staff  ||| S:26467 E:26473 ||| NN
are  ||| S:26473 E:26477 ||| VBP
unable  ||| S:26477 E:26484 ||| JJ
to  ||| S:26484 E:26487 ||| TO
provide  ||| S:26487 E:26495 ||| VB
corroborating  ||| S:26495 E:26517 ||| JJ
documentation  ||| S:26517 E:26531 ||| NN
for  ||| S:26531 E:26535 ||| IN
2 ||| S:26535 E:26536 ||| CD
%  ||| S:26536 E:26538 ||| NN
of  ||| S:26538 E:26541 ||| IN
ALLHAT  ||| S:26541 E:26548 ||| NNP
event  ||| S:26548 E:26554 ||| NN
reports ||| S:26554 E:26561 ||| NNS
.  ||| S:26561 E:26571 ||| .
Efforts  ||| S:26571 E:26579 ||| NNS
to  ||| S:26579 E:26582 ||| TO
authenticate  ||| S:26582 E:26595 ||| VB
the  ||| S:26595 E:26599 ||| DT
HF  ||| S:26599 E:26602 ||| NNP
events  ||| S:26602 E:26609 ||| NNS
in  ||| S:26609 E:26612 ||| IN
the  ||| S:26612 E:26616 ||| DT
doxazosin  ||| S:26616 E:26634 ||| NN
and  ||| S:26634 E:26638 ||| CC
chlorthalidone  ||| S:26638 E:26653 ||| JJ
treatment  ||| S:26653 E:26663 ||| NN
groups  ||| S:26663 E:26670 ||| NNS
represented  ||| S:26670 E:26682 ||| VBD
a  ||| S:26682 E:26684 ||| DT
desirable  ||| S:26684 E:26702 ||| JJ
step  ||| S:26702 E:26707 ||| NN
in  ||| S:26707 E:26710 ||| IN
the  ||| S:26710 E:26714 ||| DT
examination  ||| S:26714 E:26726 ||| NN
of  ||| S:26726 E:26729 ||| IN
the  ||| S:26729 E:26733 ||| DT
increased  ||| S:26733 E:26743 ||| JJ
rate  ||| S:26743 E:26748 ||| NN
of  ||| S:26748 E:26751 ||| IN
HR  ||| S:26751 E:26754 ||| NNP
in  ||| S:26754 E:26757 ||| IN
the  ||| S:26757 E:26769 ||| DT
doxazosin  ||| S:26769 E:26779 ||| JJ
group ||| S:26779 E:26784 ||| NN
.  ||| S:26784 E:26786 ||| .
All  ||| S:26786 E:26790 ||| DT
methods  ||| S:26790 E:26798 ||| NNS
employed  ||| S:26798 E:26807 ||| VBN
provided  ||| S:26807 E:26816 ||| VBN
confirmatory  ||| S:26816 E:26837 ||| JJ
evidence  ||| S:26837 E:26846 ||| NN
that  ||| S:26846 E:26851 ||| IN
both  ||| S:26851 E:26856 ||| PDT
the  ||| S:26856 E:26860 ||| DT
HF  ||| S:26860 E:26863 ||| NNP
diagnosis  ||| S:26863 E:26873 ||| NN
and  ||| S:26873 E:26877 ||| CC
the  ||| S:26877 E:26881 ||| DT
difference  ||| S:26881 E:26892 ||| NN
in  ||| S:26892 E:26903 ||| IN
HF  ||| S:26903 E:26906 ||| NNP
rates  ||| S:26906 E:26912 ||| NNS
noted  ||| S:26912 E:26918 ||| VBD
between  ||| S:26918 E:26926 ||| IN
the  ||| S:26926 E:26930 ||| DT
doxazosin  ||| S:26930 E:26940 ||| NN
and  ||| S:26940 E:26944 ||| CC
chlorthalidone  ||| S:26944 E:26967 ||| JJ
groups  ||| S:26967 E:26974 ||| NNS
were  ||| S:26974 E:26979 ||| VBD
valid ||| S:26979 E:26984 ||| JJ
.  ||| S:26984 E:26986 ||| .
Results  ||| S:26986 E:26994 ||| NNS
of  ||| S:26994 E:26997 ||| IN
this  ||| S:26997 E:27002 ||| DT
exploratory  ||| S:27002 E:27022 ||| JJ
investigation  ||| S:27022 E:27036 ||| NN
support  ||| S:27036 E:27044 ||| NN
the  ||| S:27044 E:27048 ||| DT
event  ||| S:27048 E:27054 ||| NN
ascertainment  ||| S:27054 E:27068 ||| NN
methods  ||| S:27068 E:27084 ||| NNS
developed  ||| S:27084 E:27094 ||| VBN
for  ||| S:27094 E:27098 ||| IN
ALLHAT ||| S:27098 E:27104 ||| NNP
,  ||| S:27104 E:27106 ||| ,
specifically  ||| S:27106 E:27119 ||| RB
for  ||| S:27119 E:27123 ||| IN
HF  ||| S:27123 E:27126 ||| NNP
events ||| S:27126 E:27132 ||| NNS
.  ||| S:27132 E:27134 ||| .
This  ||| S:27134 E:27147 ||| DT
validation  ||| S:27147 E:27158 ||| JJ
exercise  ||| S:27158 E:27167 ||| NN
further  ||| S:27167 E:27175 ||| RB
illustrates  ||| S:27175 E:27187 ||| VBZ
the  ||| S:27187 E:27191 ||| DT
ability  ||| S:27191 E:27199 ||| NN
of  ||| S:27199 E:27210 ||| IN
large ||| S:27210 E:27215 ||| JJ
,  ||| S:27215 E:27217 ||| ,
simple  ||| S:27217 E:27224 ||| JJ
trials  ||| S:27224 E:27231 ||| NNS
to  ||| S:27231 E:27234 ||| TO
answer  ||| S:27234 E:27241 ||| VB
important  ||| S:27241 E:27251 ||| JJ
public  ||| S:27251 E:27258 ||| JJ
health  ||| S:27258 E:27273 ||| NN
questions  ||| S:27273 E:27283 ||| NNS
requiring  ||| S:27283 E:27293 ||| VBG
large  ||| S:27293 E:27299 ||| JJ
sample  ||| S:27299 E:27306 ||| NN
sizes  ||| S:27306 E:27312 ||| NNS
and  ||| S:27312 E:27316 ||| CC
to  ||| S:27316 E:27319 ||| TO
grapple  ||| S:27319 E:27327 ||| VB
with  ||| S:27327 E:27340 ||| IN
unexpected  ||| S:27340 E:27351 ||| JJ
results  ||| S:27351 E:27359 ||| NNS
in  ||| S:27359 E:27362 ||| IN
a  ||| S:27362 E:27364 ||| DT
responsible  ||| S:27364 E:27376 ||| JJ
and  ||| S:27376 E:27380 ||| CC
meaningful  ||| S:27380 E:27399 ||| JJ
manner ||| S:27399 E:27405 ||| NN
.  ||| S:27405 E:27429 ||| .
Competing  ||| S:27429 E:27439 ||| VBG
Interests  ||| S:27439 E:27457 ||| NNP
The  ||| S:27457 E:27461 ||| DT
authors  ||| S:27461 E:27469 ||| NNS
of  ||| S:27469 E:27472 ||| IN
this  ||| S:27472 E:27477 ||| DT
paper  ||| S:27477 E:27483 ||| NN
disclose  ||| S:27483 E:27492 ||| VB
their  ||| S:27492 E:27498 ||| PRP$
affiliations  ||| S:27498 E:27519 ||| NN
with  ||| S:27519 E:27524 ||| IN
Aventis  ||| S:27524 E:27532 ||| NNP
( ||| S:27532 E:27533 ||| -LRB-
A ||| S:27533 E:27534 ||| NNP
) ||| S:27534 E:27535 ||| -RRB-
,  ||| S:27535 E:27537 ||| ,
Abbott  ||| S:27537 E:27544 ||| NNP
( ||| S:27544 E:27545 ||| -LRB-
AB ||| S:27545 E:27547 ||| NNP
) ||| S:27547 E:27548 ||| -RRB-
,  ||| S:27548 E:27550 ||| ,
AstraZeneca  ||| S:27550 E:27562 ||| NNP
( ||| S:27562 E:27563 ||| -LRB-
AZ ||| S:27563 E:27565 ||| NNP
) ||| S:27565 E:27566 ||| -RRB-
,  ||| S:27566 E:27568 ||| ,
Bayer  ||| S:27568 E:27574 ||| NNP
( ||| S:27574 E:27575 ||| -LRB-
B ||| S:27575 E:27576 ||| NNP
) ||| S:27576 E:27577 ||| -RRB-
,  ||| S:27577 E:27587 ||| ,
Biovail  ||| S:27587 E:27595 ||| NNP
( ||| S:27595 E:27596 ||| -LRB-
BV ||| S:27596 E:27598 ||| NNP
) ||| S:27598 E:27599 ||| -RRB-
,  ||| S:27599 E:27601 ||| ,
Bristol-Myers  ||| S:27601 E:27615 ||| NNP
Squibb  ||| S:27615 E:27622 ||| NNP
( ||| S:27622 E:27623 ||| -LRB-
BMS ||| S:27623 E:27626 ||| NNP
) ||| S:27626 E:27627 ||| -RRB-
,  ||| S:27627 E:27629 ||| ,
Forest  ||| S:27629 E:27636 ||| NNP
( ||| S:27636 E:27637 ||| -LRB-
F ||| S:27637 E:27638 ||| NNP
) ||| S:27638 E:27639 ||| -RRB-
,  ||| S:27639 E:27649 ||| ,
Glaxo-SmithKline ||| S:27649 E:27665 ||| NNP
/ ||| S:27665 E:27666 ||| NNP
SmithKline  ||| S:27666 E:27677 ||| NNP
Beecham  ||| S:27677 E:27685 ||| NNP
( ||| S:27685 E:27686 ||| -LRB-
GSK ||| S:27686 E:27689 ||| NNP
/ ||| S:27689 E:27690 ||| NNP
SKB ||| S:27690 E:27693 ||| NNP
) ||| S:27693 E:27694 ||| -RRB-
,  ||| S:27694 E:27696 ||| ,
King  ||| S:27696 E:27709 ||| NNP
Pharmaceuticals ||| S:27709 E:27724 ||| NNP
/ ||| S:27724 E:27725 ||| NNP
Monarch  ||| S:27725 E:27733 ||| NNP
( ||| S:27733 E:27734 ||| -LRB-
KM ||| S:27734 E:27736 ||| NNP
) ||| S:27736 E:27737 ||| -RRB-
,  ||| S:27737 E:27739 ||| ,
Merck  ||| S:27739 E:27745 ||| NNP
( ||| S:27745 E:27746 ||| -LRB-
M ||| S:27746 E:27747 ||| NNP
) ||| S:27747 E:27748 ||| -RRB-
,  ||| S:27748 E:27750 ||| ,
Novartis  ||| S:27750 E:27759 ||| NNP
( ||| S:27759 E:27760 ||| -LRB-
N ||| S:27760 E:27761 ||| NNP
) ||| S:27761 E:27762 ||| -RRB-
,  ||| S:27762 E:27772 ||| ,
Nu-Pharm  ||| S:27772 E:27781 ||| NNP
( ||| S:27781 E:27782 ||| -LRB-
NP ||| S:27782 E:27784 ||| NNP
) ||| S:27784 E:27785 ||| -RRB-
,  ||| S:27785 E:27787 ||| ,
Pharmacia ||| S:27787 E:27796 ||| NNP
/ ||| S:27796 E:27797 ||| NNP
Upjohn  ||| S:27797 E:27804 ||| NNP
( ||| S:27804 E:27805 ||| -LRB-
PHU ||| S:27805 E:27808 ||| NNP
) ||| S:27808 E:27809 ||| -RRB-
,  ||| S:27809 E:27811 ||| ,
Pfizer ||| S:27811 E:27817 ||| NNP
,  ||| S:27817 E:27819 ||| ,
Inc.  ||| S:27819 E:27824 ||| NNP
( ||| S:27824 E:27825 ||| -LRB-
P ||| S:27825 E:27826 ||| NN
) ||| S:27826 E:27827 ||| -RRB-
,  ||| S:27827 E:27837 ||| ,
Sankyo  ||| S:27837 E:27844 ||| NNP
( ||| S:27844 E:27845 ||| -LRB-
SY ||| S:27845 E:27847 ||| NNP
) ||| S:27847 E:27848 ||| -RRB-
,  ||| S:27848 E:27850 ||| ,
Searle  ||| S:27850 E:27857 ||| NNP
( ||| S:27857 E:27858 ||| -LRB-
SE ||| S:27858 E:27860 ||| NNP
) ||| S:27860 E:27861 ||| -RRB-
,  ||| S:27861 E:27863 ||| ,
Solvay  ||| S:27863 E:27870 ||| NNP
( ||| S:27870 E:27871 ||| -LRB-
SV ||| S:27871 E:27873 ||| NNP
) ||| S:27873 E:27874 ||| -RRB-
,  ||| S:27874 E:27876 ||| ,
Takeda  ||| S:27876 E:27883 ||| NNP
( ||| S:27883 E:27884 ||| -LRB-
T ||| S:27884 E:27885 ||| NN
) ||| S:27885 E:27886 ||| -RRB-
.  ||| S:27886 E:27888 ||| .
These  ||| S:27888 E:27902 ||| DT
relate  ||| S:27902 E:27909 ||| NN
to  ||| S:27909 E:27912 ||| TO
personal  ||| S:27912 E:27921 ||| JJ
or  ||| S:27921 E:27924 ||| CC
institutional-affiliated  ||| S:27924 E:27949 ||| JJ
receipt  ||| S:27949 E:27957 ||| NN
of  ||| S:27957 E:27968 ||| IN
income  ||| S:27968 E:27975 ||| NN
in  ||| S:27975 E:27978 ||| IN
the  ||| S:27978 E:27982 ||| DT
areas  ||| S:27982 E:27988 ||| NNS
of  ||| S:27988 E:27991 ||| IN
research  ||| S:27991 E:28000 ||| NN
grants ||| S:28000 E:28006 ||| NNS
,  ||| S:28006 E:28008 ||| ,
consultant  ||| S:28008 E:28019 ||| NN
fees ||| S:28019 E:28023 ||| NNS
,  ||| S:28023 E:28025 ||| ,
or  ||| S:28025 E:28036 ||| CC
other  ||| S:28036 E:28042 ||| JJ
compensation ||| S:28042 E:28054 ||| NN
:  ||| S:28054 E:28056 ||| :
BRD  ||| S:28056 E:28060 ||| NNP
( ||| S:28060 E:28061 ||| -LRB-
AB ||| S:28061 E:28063 ||| NNP
, ||| S:28063 E:28064 ||| ,
BMS ||| S:28064 E:28067 ||| NNP
, ||| S:28067 E:28068 ||| ,
F ||| S:28068 E:28069 ||| NNP
, ||| S:28069 E:28070 ||| ,
M ||| S:28070 E:28071 ||| NNP
, ||| S:28071 E:28072 ||| ,
P ||| S:28072 E:28073 ||| NN
, ||| S:28073 E:28074 ||| ,
PHU ||| S:28074 E:28077 ||| NNP
, ||| S:28077 E:28078 ||| ,
GSK ||| S:28078 E:28081 ||| NNP
/ ||| S:28081 E:28082 ||| NNP
SKB ||| S:28082 E:28085 ||| NNP
) ||| S:28085 E:28086 ||| -RRB-
,  ||| S:28086 E:28088 ||| ,
WCC  ||| S:28088 E:28100 ||| NNP
( ||| S:28100 E:28101 ||| -LRB-
AZ ||| S:28101 E:28103 ||| NNP
, ||| S:28103 E:28104 ||| ,
BMS ||| S:28104 E:28107 ||| NNP
, ||| S:28107 E:28108 ||| ,
F ||| S:28108 E:28109 ||| NNP
, ||| S:28109 E:28110 ||| ,
M ||| S:28110 E:28111 ||| NNP
, ||| S:28111 E:28112 ||| ,
P ||| S:28112 E:28113 ||| NN
, ||| S:28113 E:28114 ||| ,
PHU ||| S:28114 E:28117 ||| NNP
, ||| S:28117 E:28118 ||| ,
SY ||| S:28118 E:28120 ||| NNP
, ||| S:28120 E:28121 ||| ,
SE ||| S:28121 E:28123 ||| NNP
, ||| S:28123 E:28124 ||| ,
SV ||| S:28124 E:28126 ||| NNP
, ||| S:28126 E:28127 ||| ,
T ||| S:28127 E:28128 ||| NN
) ||| S:28128 E:28129 ||| -RRB-
,  ||| S:28129 E:28131 ||| ,
JTW  ||| S:28131 E:28135 ||| NNP
( ||| S:28135 E:28136 ||| -LRB-
A ||| S:28136 E:28137 ||| NNP
, ||| S:28137 E:28138 ||| ,
B ||| S:28138 E:28139 ||| NNP
, ||| S:28139 E:28140 ||| ,
BMS ||| S:28140 E:28143 ||| NNP
, ||| S:28143 E:28144 ||| ,
F ||| S:28144 E:28145 ||| NNP
, ||| S:28145 E:28146 ||| ,
KM ||| S:28146 E:28148 ||| NNP
,  ||| S:28148 E:28150 ||| ,
M ||| S:28150 E:28151 ||| NNP
, ||| S:28151 E:28152 ||| ,
N ||| S:28152 E:28153 ||| NNP
, ||| S:28153 E:28154 ||| ,
P ||| S:28154 E:28155 ||| NN
) ||| S:28155 E:28156 ||| -RRB-
,  ||| S:28156 E:28166 ||| ,
FHHL  ||| S:28166 E:28171 ||| NNP
( ||| S:28171 E:28172 ||| -LRB-
AZ ||| S:28172 E:28174 ||| NNP
, ||| S:28174 E:28175 ||| ,
B ||| S:28175 E:28176 ||| NNP
, ||| S:28176 E:28177 ||| ,
BMS ||| S:28177 E:28180 ||| NNP
, ||| S:28180 E:28181 ||| ,
M ||| S:28181 E:28182 ||| NNP
, ||| S:28182 E:28183 ||| ,
NP ||| S:28183 E:28185 ||| NNP
, ||| S:28185 E:28186 ||| ,
P ||| S:28186 E:28187 ||| NN
, ||| S:28187 E:28188 ||| ,
PHU ||| S:28188 E:28191 ||| NNP
) ||| S:28191 E:28192 ||| -RRB-
,  ||| S:28192 E:28194 ||| ,
LJH  ||| S:28194 E:28198 ||| NNP
( ||| S:28198 E:28199 ||| -LRB-
PHU ||| S:28199 E:28202 ||| NNP
) ||| S:28202 E:28203 ||| -RRB-
;  ||| S:28203 E:28205 ||| :
the  ||| S:28205 E:28209 ||| DT
other  ||| S:28209 E:28215 ||| JJ
authors  ||| S:28215 E:28231 ||| NNS
report  ||| S:28231 E:28238 ||| VBP
no  ||| S:28238 E:28241 ||| RB
competing  ||| S:28241 E:28251 ||| VBG
interests ||| S:28251 E:28260 ||| NNS
.  ||| S:28260 E:28284 ||| .
Additional  ||| S:28284 E:28295 ||| JJ
Information  ||| S:28295 E:28315 ||| NNP
1 ||| S:28315 E:28316 ||| CD
)  ||| S:28316 E:28318 ||| -RRB-
New  ||| S:28318 E:28322 ||| NNP
York  ||| S:28322 E:28327 ||| NNP
Heart  ||| S:28327 E:28333 ||| NNP
Classification  ||| S:28333 E:28348 ||| NNP
functional  ||| S:28348 E:28359 ||| JJ
class  ||| S:28359 E:28365 ||| NN
III ||| S:28365 E:28368 ||| NNP
:  ||| S:28368 E:28378 ||| :
"Patients  ||| S:28378 E:28388 ||| CD
with  ||| S:28388 E:28393 ||| IN
cardiac  ||| S:28393 E:28401 ||| JJ
disease  ||| S:28401 E:28409 ||| NN
resulting  ||| S:28409 E:28419 ||| VBG
in  ||| S:28419 E:28422 ||| IN
marked  ||| S:28422 E:28437 ||| JJ
limitation  ||| S:28437 E:28448 ||| NN
of  ||| S:28448 E:28451 ||| IN
physical  ||| S:28451 E:28460 ||| JJ
activity ||| S:28460 E:28468 ||| NN
.  ||| S:28468 E:28470 ||| .
They  ||| S:28470 E:28475 ||| PRP
are  ||| S:28475 E:28479 ||| VBP
comfortable  ||| S:28479 E:28491 ||| JJ
at  ||| S:28491 E:28502 ||| IN
rest ||| S:28502 E:28506 ||| NN
.  ||| S:28506 E:28508 ||| .
Less  ||| S:28508 E:28513 ||| RBR
than  ||| S:28513 E:28518 ||| IN
ordinary  ||| S:28518 E:28527 ||| JJ
physical  ||| S:28527 E:28536 ||| JJ
activity  ||| S:28536 E:28545 ||| NN
causes  ||| S:28545 E:28552 ||| VBZ
fatigue ||| S:28552 E:28559 ||| VBN
,  ||| S:28559 E:28569 ||| ,
palpitation ||| S:28569 E:28580 ||| NN
,  ||| S:28580 E:28582 ||| ,
dyspnea ||| S:28582 E:28589 ||| NN
,  ||| S:28589 E:28591 ||| ,
or  ||| S:28591 E:28594 ||| CC
anginal  ||| S:28594 E:28602 ||| JJ
pain. ||| S:28602 E:28607 ||| NN
"  ||| S:28607 E:28609 ||| ''
1994  ||| S:28609 E:28614 ||| CD
Revisions  ||| S:28614 E:28624 ||| NNS
to  ||| S:28624 E:28635 ||| TO
Classification  ||| S:28635 E:28650 ||| NNP
of  ||| S:28650 E:28653 ||| IN
Functional  ||| S:28653 E:28664 ||| NNP
Capacity  ||| S:28664 E:28673 ||| NNP
and  ||| S:28673 E:28677 ||| CC
Objective  ||| S:28677 E:28695 ||| NNP
Assessment  ||| S:28695 E:28706 ||| NNP
of  ||| S:28706 E:28709 ||| IN
Patients  ||| S:28709 E:28718 ||| NNS
with  ||| S:28718 E:28723 ||| IN
Diseases  ||| S:28723 E:28732 ||| NNP
of  ||| S:28732 E:28735 ||| IN
the  ||| S:28735 E:28739 ||| DT
Heart ||| S:28739 E:28744 ||| NNP
:  ||| S:28744 E:28746 ||| :
AHA  ||| S:28746 E:28758 ||| NNP
Medical ||| S:28758 E:28765 ||| NNP
/ ||| S:28765 E:28766 ||| NNP
Scientific  ||| S:28766 E:28777 ||| NNP
Statement.  ||| S:28777 E:28796 ||| CD
2 ||| S:28796 E:28797 ||| CD
)  ||| S:28797 E:28799 ||| -RRB-
The  ||| S:28799 E:28803 ||| DT
ALLHAT  ||| S:28803 E:28810 ||| NNP
Manual  ||| S:28810 E:28817 ||| NNP
of  ||| S:28817 E:28820 ||| IN
Operations  ||| S:28820 E:28831 ||| NNP
provides  ||| S:28831 E:28840 ||| VBZ
for  ||| S:28840 E:28852 ||| IN
prescription  ||| S:28852 E:28865 ||| NN
of  ||| S:28865 E:28868 ||| IN
open-label  ||| S:28868 E:28879 ||| JJ
medicines  ||| S:28879 E:28889 ||| NNS
of  ||| S:28889 E:28892 ||| IN
the  ||| S:28892 E:28896 ||| DT
same  ||| S:28896 E:28901 ||| JJ
class  ||| S:28901 E:28907 ||| NN
as  ||| S:28907 E:28918 ||| IN
the  ||| S:28918 E:28922 ||| DT
blinded  ||| S:28922 E:28930 ||| JJ
medications ||| S:28930 E:28941 ||| NN
,  ||| S:28941 E:28943 ||| ,
when  ||| S:28943 E:28948 ||| WRB
a  ||| S:28948 E:28950 ||| DT
compelling  ||| S:28950 E:28961 ||| JJ
indication  ||| S:28961 E:28980 ||| NN
exists ||| S:28980 E:28986 ||| VBZ
,  ||| S:28986 E:28988 ||| ,
such  ||| S:28988 E:28993 ||| JJ
that  ||| S:28993 E:28998 ||| IN
the  ||| S:28998 E:29002 ||| DT
total  ||| S:29002 E:29008 ||| JJ
dose  ||| S:29008 E:29013 ||| NN
of  ||| S:29013 E:29016 ||| IN
the  ||| S:29016 E:29020 ||| DT
added  ||| S:29020 E:29026 ||| JJ
open-label  ||| S:29026 E:29045 ||| JJ
drug  ||| S:29045 E:29050 ||| NN
should  ||| S:29050 E:29057 ||| MD
not  ||| S:29057 E:29061 ||| RB
exceed  ||| S:29061 E:29068 ||| VB
1 ||| S:29068 E:29069 ||| CD
/ ||| S:29069 E:29070 ||| CD
2  ||| S:29070 E:29072 ||| CD
of  ||| S:29072 E:29075 ||| IN
the  ||| S:29075 E:29079 ||| DT
maximum  ||| S:29079 E:29087 ||| JJ
dose  ||| S:29087 E:29092 ||| NN
as  ||| S:29092 E:29103 ||| IN
recommended  ||| S:29103 E:29115 ||| VBN
in  ||| S:29115 E:29118 ||| IN
the  ||| S:29118 E:29122 ||| DT
Sixth  ||| S:29122 E:29128 ||| NNP
Report  ||| S:29128 E:29135 ||| NNP
of  ||| S:29135 E:29138 ||| IN
the  ||| S:29138 E:29142 ||| DT
Joint  ||| S:29142 E:29148 ||| NNP
National  ||| S:29148 E:29165 ||| NNP
Committee  ||| S:29165 E:29175 ||| NNP
on  ||| S:29175 E:29178 ||| IN
Detection ||| S:29178 E:29187 ||| NNP
,  ||| S:29187 E:29189 ||| ,
Evaluation  ||| S:29189 E:29200 ||| NNP
and  ||| S:29200 E:29204 ||| CC
Treatment  ||| S:29204 E:29214 ||| NNP
of  ||| S:29214 E:29217 ||| IN
High  ||| S:29217 E:29230 ||| NNP
Blood  ||| S:29230 E:29236 ||| NNP
Pressure  ||| S:29236 E:29245 ||| NNP
( ||| S:29245 E:29246 ||| -LRB-
JNC  ||| S:29246 E:29250 ||| NNP
VI ||| S:29250 E:29252 ||| NNP
) ||| S:29252 E:29253 ||| -RRB-
.  ||| S:29253 E:29255 ||| .
If  ||| S:29255 E:29258 ||| IN
a  ||| S:29258 E:29260 ||| DT
compelling  ||| S:29260 E:29271 ||| JJ
reason  ||| S:29271 E:29278 ||| NN
requires  ||| S:29278 E:29287 ||| VBZ
a  ||| S:29287 E:29297 ||| DT
higher  ||| S:29297 E:29304 ||| JJR
dose ||| S:29304 E:29308 ||| NN
,  ||| S:29308 E:29310 ||| ,
it  ||| S:29310 E:29313 ||| PRP
is  ||| S:29313 E:29316 ||| VBZ
permitted.  ||| S:29316 E:29335 ||| CD
3 ||| S:29335 E:29336 ||| CD
)  ||| S:29336 E:29338 ||| -RRB-
The  ||| S:29338 E:29342 ||| DT
ALLHAT  ||| S:29342 E:29349 ||| NNP
follow-up  ||| S:29349 E:29359 ||| JJ
form  ||| S:29359 E:29364 ||| NN
allows  ||| S:29364 E:29371 ||| VBZ
for  ||| S:29371 E:29375 ||| IN
reporting  ||| S:29375 E:29385 ||| VBG
of  ||| S:29385 E:29396 ||| IN
open-label  ||| S:29396 E:29407 ||| JJ
ACE-inhibitors  ||| S:29407 E:29422 ||| JJ
and  ||| S:29422 E:29426 ||| CC
diuretics ||| S:29426 E:29435 ||| NNS
;  ||| S:29435 E:29437 ||| :
among  ||| S:29437 E:29451 ||| IN
beta-blockers ||| S:29451 E:29464 ||| NNP
,  ||| S:29464 E:29466 ||| ,
only  ||| S:29466 E:29471 ||| JJ
atenolol  ||| S:29471 E:29480 ||| NN
is  ||| S:29480 E:29483 ||| VBZ
reported ||| S:29483 E:29491 ||| VBN
.  ||| S:29491 E:29493 ||| .
The  ||| S:29493 E:29497 ||| DT
use  ||| S:29497 E:29501 ||| NN
of  ||| S:29501 E:29504 ||| IN
other  ||| S:29504 E:29518 ||| JJ
beta-blockers  ||| S:29518 E:29532 ||| JJ
cannot  ||| S:29532 E:29539 ||| NNS
be  ||| S:29539 E:29542 ||| VB
ascertained  ||| S:29542 E:29554 ||| VBN
from  ||| S:29554 E:29559 ||| IN
the  ||| S:29559 E:29563 ||| DT
data ||| S:29563 E:29567 ||| NNS
.  ||| S:29567 E:29584 ||| .
